Chronic Kidney Disease

On this page

Quick Reference

RxDrug of choiceQuadruple therapy: RAAS inhibitor (ACEi/ARB) + SGLT2 inhibitor (dapagliflozin 10 mg or empagliflozin 10 mg) + nonsteroidal MRA (finerenone 10-20 mg) + GLP-1 receptor agonist (semaglutide 1.0 mg weekly) in appropriate populations

AltAlternativesARB if ACEi-intolerant; canagliflozin 100 mg as alternative SGLT2i; patiromer for hyperkalemia; roxadustat for anemia if injectables declined

⊘AvoidNSAIDs (all stages of CKD); non-dihydropyridine CCBs (diltiazem, verapamil) in CKD with heart failure; metformin if eGFR <30; nitrofurantoin if eGFR <30; high-dose rosuvastatin (>10 mg) if eGFR <30

DxTest of choiceSerum creatinine for eGFR (CKD-EPI 2021, race-free) + spot urine albumin-to-creatinine ratio; confirmatory cystatin C if eGFRcr 45-59 with A1

ScKey scoreKidney Failure Risk Equation (KFRE) - 5-year risk of ESKD; also KDIGO CGA heat map for baseline risk stratification

→When to refereGFR <30 mL/min/1.73 m², UACR >300 mg/g, rapidly progressive disease (≥50% eGFR decline over months), diagnostic uncertainty, severe complications (hyperkalemia, anemia, CKD-MBD, resistant hypertension)

CKD is common and deadly but highly treatable with contemporary quadruple therapy; early detection via eGFR+UACR screening and prompt initiation of guideline-directed medical therapy can slow progression, reduce cardiovascular mortality, and delay RRT by years.

Chronic kidney disease (CKD) affects an estimated 850 million people worldwide and is a leading cause of death, driven largely by cardiovascular disease. The condition is frequently asymptomatic until advanced stages, making early detection through eGFR and UACR screening critical. Modern guideline-directed therapy, including RAAS inhibitors, SGLT2 inhibitors, nonsteroidal mineralocorticoid receptor antagonists, and GLP-1 receptor agonists, can substantially slow progression, reduce cardiovascular events, and delay or prevent kidney failure. Management centers on risk stratification, addressing electrolyte and metabolic complications, and timely preparation for renal replacement therapy when indicated.

Overview and Recommendations

Background

•CKD is defined by KDIGO as abnormalities of kidney structure or function present for >3 months, staged by cause, GFR (G1-G5), and albuminuria (A1-A3). It affects ~10-14% of the global adult population and was the cause of 1.2 million deaths in 2017, with projections to become the fifth leading cause of death by 2050. The condition was historically termed chronic renal failure; end-stage renal disease is now often replaced by the term kidney failure.
•The final common pathway is kidney fibrosis, driven by TGF-β signaling through Smad2/3, metabolic reprogramming (PFKFB3-driven histone lactylation), and hemodynamic stress from single-nephron hyperfiltration. RAAS and sympathetic activation amplify injury, while maladaptive autophagy, cellular senescence, and necroinflammation create self-propagating cycles of tubular damage and interstitial fibrosis.
•Diabetes and hypertension account for the majority of cases globally. Other etiologies include glomerular disease (e.g., IgA nephropathy, FSGS), tubulointerstitial disease, vascular disease (hypertensive nephrosclerosis), and cystic/congenital disorders (ADPKD). APOL1 risk variants in African-ancestry populations confer a substantially elevated lifetime risk. Acute kidney injury is a powerful independent risk factor, with a pooled adjusted HR of 8.8 for subsequent CKD.
•Landmark trials have reshaped therapy: PARADIGM-HF and DAPA-HF established SGLT2i benefits; DAPA-CKD and EMPA-KIDNEY proved nephroprotection in non-diabetic CKD; FIDELIO-DKD and FIGARO-DKD confirmed finerenone's cardiorenal effects; FLOW demonstrated GLP-1 RA benefit. The paradigm has shifted from RAASi monotherapy to quadruple therapy, achieving additive albuminuria reductions of 30-50%.
•Untreated or suboptimally managed CKD carries high mortality, 5-year mortality for a 65-year-old with stage 4 CKD approaches 45%, mostly from cardiovascular causes. Albuminuria (UACR ≥30 mg/g) and eGFR <60 mL/min/1.73 m² are multiplicative risk factors, with no threshold for albuminuria. Early detection and combination therapy can now delay kidney failure by >6 years and make remission (eGFR slope <1 mL/min/1.73 m²/yr) an increasingly attainable goal.

Evaluation

•Suspect CKD in any patient with exertional dyspnea, unexplained fatigue, nocturia, foamy urine, or dependent edema, though most early-stage patients are asymptomatic and detected incidentally on lab testing.
•Ask about long-standing diabetes, hypertension, family history of kidney disease, prior episodes of AKI, use of nephrotoxins (NSAIDs, herbal remedies, aristolochic acid), hematuria, flank pain, and systemic symptoms suggesting glomerulonephritis (sore throat, rash, arthritis, sinusitis).
•Examine blood pressure (volume-dependent hypertension is common), jugular venous pressure, presence of peripheral edema or pulmonary crackles, pallor (anemia when eGFR <30), fundoscopic changes (hypertensive/diabetic retinopathy), abdominal bruits, and signs of uremia (pericardial rub, asterixis, peripheral neuropathy, cognitive impairment).
•Order serum creatinine for eGFR using the CKD-EPI 2021 equation (without race) and spot urine albumin-to-creatinine ratio (UACR). Persistent eGFR <60 mL/min/1.73 m² for >3 months or UACR ≥30 mg/g establishes the diagnosis of CKD.
•If eGFRcr is 45-59 mL/min/1.73 m² without albuminuria (A1), obtain serum cystatin C. An eGFRcys <60 mL/min/1.73 m² confirms CKD; if eGFRcys ≥60, measured GFR (iohexol or inulin clearance) may be needed, up to 17% of this group do not have true CKD.
•Additional laboratories include serum electrolytes (K+, Na+, Cl-), bicarbonate, BUN, calcium, phosphate, intact PTH, CBC with differential, and serologies if active sediment or systemic disease is suspected (ANA, ANCA, anti-GBM, complements, hepatitis B/C, HIV, serum protein electrophoresis).
•Perform renal ultrasound as first-line imaging: assess kidney size (<9 cm suggests chronic scarring), cortical thickness, echogenicity, and exclude obstruction or cystic disease. Asymmetric kidneys suggest renovascular disease; larger kidneys with cysts suggest ADPKD.
•Consider native kidney biopsy when the cause remains uncertain after noninvasive workup and there is active urinary sediment (dysmorphic RBCs, RBC casts), nephrotic-range proteinuria (>3.5 g/day or UACR >3000 mg/g), rapidly progressive glomerulonephritis, or suspected systemic disease with renal involvement. Major complication rate is low (bleeding needing transfusion in 1.6%).
•Stage and risk stratify using the KDIGO CGA heat map: combine GFR category (G1-G5) and albuminuria category (A1-A3) to assign low, moderate, high, or very high risk for progression and cardiovascular mortality.
•Calculate the 5-year Kidney Failure Risk Equation (KFRE) using age, sex, eGFR, and UACR to estimate risk of ESKD and guide timing of nephrology referral and RRT planning (referral recommended when risk >3-5%).
•Assess for complications at every visit: anemia (Hb <10 g/dL), metabolic acidosis (serum bicarbonate <22 mmol/L), hyperkalemia (K+ >5.0 mmol/L, especially with RAASi), mineral bone disease (hyperphosphatemia, hypocalcemia, elevated PTH), and malnutrition (low albumin, muscle wasting, unintentional weight loss).
•Consider genetic testing in young-onset CKD (<40 years), strong family history, extrarenal features (e.g., hearing loss, cysts, hypomagnesemia), or when cause is unknown despite thorough evaluation. Monogenic causes are identified in 11-37% of such cases.

Management

•Initiate an ACE inhibitor or ARB at maximally tolerated dose for all patients with CKD and UACR ≥30 mg/g or hypertension. Lisinopril start 5-10 mg daily, target 40 mg daily; losartan start 25-50 mg daily, target 100 mg daily. A network meta-analysis showed ACEi reduces kidney failure by 39% (OR 0.61). Do not discontinue RAASi in advanced CKD, the STOP ACEi trial showed no benefit and a trend toward more ESKD events with discontinuation.
•Add an SGLT2 inhibitor (dapagliflozin 10 mg, empagliflozin 10 mg, or canagliflozin 100 mg daily) for CKD with eGFR ≥20-25 mL/min/1.73 m² and UACR ≥200 mg/g, irrespective of diabetes status. DAPA-CKD reported a 39% reduction in the primary composite (≥50% eGFR decline, ESKD, or renal/CV death; NNT 19). An early eGFR dip >10% is benign and predicts slower long-term decline. Continue until eGFR <20 mL/min/1.73 m² or dialysis initiation.
•Add finerenone 10-20 mg daily (10 mg if eGFR ≥60, 20 mg if eGFR <60) for CKD with type 2 diabetes and albuminuria (UACR ≥30 mg/g, eGFR ≥25). In FIDELIO-DKD the kidney composite was reduced by 18% (HR 0.82); in FIGARO-DKD the CV composite was reduced by 13% (HR 0.87). Hyperkalemia >5.5 mmol/L occurs in 21.4% vs 9.2% but rarely leads to discontinuation (2.3% vs 0.9%). Consider combining with an SGLT2i for additive albuminuria reduction (CONFIDENCE trial: 29% greater UACR reduction vs finerenone alone).
•Consider semaglutide 1.0 mg subcutaneously weekly for CKD with type 2 diabetes and albuminuria. The FLOW trial showed a 24% reduction in major kidney disease events (HR 0.76) and a 20% reduction in all-cause mortality. Tirzepatide is emerging as an alternative with similar renal benefits. GLP-1 RA benefits appear additive to SGLT2i.
•Target systolic BP <120 mmHg in patients with CKD and hypertension based on SPRINT (HR 0.72 for all-cause death). Achieve with RAASi plus calcium channel blockers or thiazide-like diuretics as needed. Dietary sodium restriction to <2 g/day is essential.
•Manage hyperkalemia to preserve RAASi and nsMRA therapy: use sodium zirconium cyclosilicate 5 g PO TID for 48 hours then 5 mg once daily, or patiromer 4.2 g BID (titrate to max 8.4 g BID). SGLT2i also reduce hyperkalemia risk (HR 0.74 vs DPP-4i). Do not discontinue RAASi for mild hyperkalemia, this increases mortality (HR 1.47).
•Correct metabolic acidosis (serum bicarbonate <22 mmol/L) with oral sodium bicarbonate 0.5-1.0 mEq/kg/day (e.g., 650 mg tabs, 1-3 tabs TID). A meta-analysis of 14 RCTs showed improved eGFR slope and reduced hospitalizations (OR 0.37). Avoid overcorrection; monitor for volume overload and hypertension.
•Treat anemia of CKD when Hb <10 g/dL with erythropoiesis-stimulating agents (target Hb 10-12 g/dL) plus intravenous iron to maintain ferritin 400-600 μg/L. Consider roxadustat 70 mg thrice weekly as an oral alternative, it raised Hb by 1.75 g/dL and reduced transfusion risk by 63%.
•Manage CKD-mineral bone disease: restrict dietary phosphate (to <800-1000 mg/day), use phosphate binders (calcium acetate, sevelamer, or lanthanum) when serum phosphate is elevated. Use active vitamin D analogs (calcitriol or paricalcitol) and calcimimetics (cinacalcet) to control secondary hyperparathyroidism. Target PTH 2-9 times the upper limit of normal.
•Recommend a plant-dominant, low-sodium diet (increased vegetables, fruits, legumes, whole grains), regular exercise (≥150 minutes/week of moderate activity), smoking cessation, and avoidance of nephrotoxins (NSAIDs, aminoglycosides, aristolochic acid, high-dose PPIs). Weight management is important in obesity.
•For disease-specific therapy: in IgA nephropathy, add SGLT2i and consider sparsentan 200-400 mg daily or nefecon 16 mg daily for high-risk patients. In ADPKD, start tolvaptan when eGFR >25 and rapid progression is documented. In lupus nephritis or ANCA vasculitis, use immunosuppression (cyclophosphamide, rituximab, mycophenolate) per KDIGO guidelines.
•Refer to nephrology when eGFR <30 mL/min/1.73 m², persistent UACR >300 mg/g, rapidly progressive disease, diagnostic uncertainty, or complications requiring specialist management (resistant hypertension, refractory hyperkalemia, severe anemia, CKD-MBD).
•Prepare for renal replacement therapy when eGFR declines to 15-20 mL/min/1.73 m² with symptoms, not based on a fixed eGFR threshold (IDEAL trial). Discuss modalities: hemodialysis, peritoneal dialysis, and preemptive kidney transplantation. Create a KDOQI Life-Plan for vascular access, AVF is preferred but individualize based on maturation probability.
•What NOT to do: avoid NSAIDs in any stage of CKD; do not discontinue RAASi for hyperkalemia without trying potassium binders first; do not target Hb >12 g/dL with ESAs (increases stroke risk); do not initiate statin therapy de novo in dialysis-dependent CKD; do not use race in eGFR equations.
•For hyperkalemia emergencies: first give calcium gluconate 1 g IV over 2-5 minutes for cardiac protection if K+ >6.5 or ECG changes, then regular insulin 10 units IV plus D50W 25 g IV, plus albuterol 10-20 mg nebulized. For sustained removal: SZC or patiromer. Escalate to emergent hemodialysis if K+ >6.5 mmol/L despite medical therapy (AEIOU criteria).

Board Review — High Yield

•KDIGO CGA staging - Classify every CKD patient by cause, GFR (G1-G5), and albuminuria (A1-A3); the combination predicts risk of progression and mortality.
•Albuminuria (UACR ≥30 mg/g) - An independent, log-linear predictor of cardiovascular and all-cause mortality with no threshold; as important as eGFR for risk stratification.
•SGLT2 inhibitors - Reduce kidney disease progression by 37% and cardiovascular death in CKD regardless of diabetes; continue until eGFR <20 or dialysis.
•Finerenone (nonsteroidal MRA) - Reduces CKD progression and CV events in T2DM with albuminuria; additive albuminuria reduction when combined with SGLT2i.
•Hyperkalemia management - Do NOT stop RAASi/nsMRA for hyperkalemia; instead use potassium binders (SZC or patiromer) to maintain cardiorenal protection.
•Cystatin C confirmatory testing - Order in patients with eGFRcr 45-59 and no albuminuria; up to 17% will reclassify as having no CKD.
•AKI-to-CKD transition - Even mild AKI (stage 1, <3 days) increases future CKD risk (HR 8.8); mandates structured follow-up including eGFR and UACR.
•Metabolic acidosis correction - Serum bicarbonate <22 mmol/L accelerates progression; treat with oral sodium bicarbonate to preserve eGFR and reduce hospitalizations.
•Anemia target - Treat when Hb <10 g/dL, target 10-12 g/dL; higher targets increase stroke risk without CV benefit.
•Remission paradigm - Aim for eGFR slope <1 mL/min/1.73 m²/yr or normalized albuminuria with preserved eGFR; increasingly achievable with early quadruple therapy.

Deep Dive — Evidence Details

Definition, Classification and Nomenclature

▸CKD is defined by KDIGO as kidney abnormalities lasting >3 months with health implications, classified by cause, GFR category, and albuminuria category (CGA system).
▸The fixed eGFR threshold of 60 mL/min/1.73 m² remains the diagnostic cutoff, but risk interpretation should be age-adapted; the absolute mortality risk is highest in older adults even though the relative risk is lower compared with younger individuals.
▸CKD is a multifactorial, systemic disease; up to 20% of cases may have no identified cause (CKDx), with a substantial fraction due to monogenic mutations identifiable by genetic testing.

Dx Diagnostic Essentials: The 3‑month duration requirement is essential to distinguish CKD from acute kidney disease (AKD); a single abnormal eGFR or urine albumin without persistence does not establish the diagnosis [14].

Chronic kidney disease (CKD) is a type of long-term kidney disease, defined by the sustained presence of abnormal kidney function and/or abnormal kidney structure. To meet the criteria for CKD, the abnormalities must be — Chronic kidney disease — Chronic kidney disease (CKD) is a type of long-term kidney disease, defined by the sustained presence of abnormal kidney function and/or abnormal kidn...Wikipedia ↗

Chronic kidney disease (CKD) is defined by Kidney Disease: Improving Global Outcomes (KDIGO) as abnormalities of kidney structure or function present for more than 3 months that have implications for health ^[3]^D5^[52]^D5. The condition was historically termed chronic renal failure or chronic renal disease; the term end‑stage renal disease (ESRD) is being progressively replaced by kidney failure ^[17]^D5.

Staging Framework

The KDIGO classification stratifies CKD along three axes: cause (C), glomerular filtration rate (G), and albuminuria (A), the CGA system ^[3]^D5^[10]^B2a. eGFR categories are defined as G1 (≥90 mL/min/1.73 m²), G2 (60-89), G3a (45-59), G3b (30-44), G4 (15-29), and G5 (<15), the last termed kidney failure ^[10]^B2a. Albuminuria is graded as A1 (<30 mg/g), A2 (30-300 mg/g), and A3 (>300 mg/g) ^[10]^B2a. The combination of eGFR and albuminuria categories identifies the risk of progression, cardiovascular mortality, and kidney failure; at an eGFR of 45 mL/min/1.73 m² the hazard ratio for all‑cause mortality is 1.57 (95% CI 1.39-1.78) compared with 95 mL/min/1.73 m² ^[10]^B2a.

Classification by Cause

CKD is etiologically classified into glomerular (e.g., , glomerulonephritis), tubulointerstitial (e.g., autosomal dominant tubulointerstitial kidney disease, drug‑induced), vascular (e.g., hypertensive nephrosclerosis, ), and cystic/congenital (e.g., autosomal dominant polycystic kidney disease) categories ^[52]^D5^[60]^A1c^[71]^D5. Many patients have multifactorial disease, with diabetes and as the dominant drivers worldwide ^[52]^D5^[71]^D5. In patients with no identifiable cause after thorough evaluation, the term CKD of unknown cause (CKDx) is applied; genetic testing identifies a monogenic etiology in 11% to over 30% of such cases ^[60]^A1c.

Clinical Significance

CKD affects an estimated 10-14% of the global adult population ^[30]^A1a^[52]^D5 and is among the leading causes of death, largely through cardiovascular disease ^[54]^D5. In a Taiwanese cohort of 462 293 individuals, CKD conferred an 83% higher all‑cause mortality (HR 1.83) and 100% higher cardiovascular mortality ^[11]^B2b. Premature death is more common than progression to kidney failure, especially in older adults ^[32]^D5^[59]^D5.

Controversies and Guideline Disagreement

A key debate concerns whether the fixed eGFR threshold of 60 mL/min/1.73 m² overdiagnoses CKD in older adults, in whom GFR declines physiologically and mortality risk does not clearly increase until eGFR <45 mL/min/1.73 m² ^[32]^D5. The KDIGO position retains the 60 mL/min threshold but recommends interpreting it in the context of albuminuria, age, and clinical context ^[3]^D5.

Pearl: Always document the KDIGO CGA triad (cause, GFR, albuminuria) for every patient with CKD; the albuminuria category is as critical as the eGFR for risk stratification.

CKD Classification by Cause

Category	Examples	Key Features
Glomerular	Diabetic kidney disease, glomerulonephritis	Proteinuria, hematuria
Tubulointerstitial	ADTKD, drug-induced	Tubular dysfunction, sterile pyuria
Vascular	Hypertensive nephrosclerosis, renal artery stenosis	Hypertension, asymmetric kidney size
Cystic/Congenital	ADPKD, renal dysplasia	Cysts, structural anomalies

Pathophysiology and Mechanism

▸CKD progression converges on a final common pathway of tubulointerstitial fibrosis driven by TGF-β, PFKFB3-mediated glycolysis, and histone lactylation that activates NF-κB signaling [118, 172].
▸Glomerular hyperfiltration, RAAS activation, and lipotoxicity initiate and amplify podocyte loss and tubular injury; all nephroprotective drugs produce an early eGFR dip reflecting reversal of hyperfiltration [162].
▸Necroinflammation, cellular senescence, mitochondrial dysfunction, and the gut-microbial metabolite TMAO form a self-perpetuating loop that is now targetable with novel therapies [142, 195].

The transition from a normal kidney to the permanently scarred organ of chronic kidney disease (CKD) follows a shared final pathway regardless of the initial insult. This pathway unites hemodynamic, metabolic, inflammatory, and cellular injury mechanisms that converge on progressive nephron loss, fibrosis, and eventual loss of glomerular filtration rate (GFR).

Final Common Pathway of Kidney Fibrosis

Kidney fibrosis, the final common histologic endpoint, is driven by transforming growth factor-beta (TGF-β) signaling through Smad2/3, which activates matrix-producing myofibroblasts and suppresses matrix degradation ^[172]^D5. The fibrogenic niche, a spatially confined microenvironment enriched with matricellular proteins, WNTs, and TGF-β, autonomously propagates fibroblast proliferation, tubular injury, and macrophage activation ^[172]^D5.

Metabolic reprogramming amplifies fibrosis. The glycolytic enzyme 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 3 ( ) is markedly induced in proximal tubular cells (PTCs) after injury and correlates with fibrosis severity in human CKD ^[118]^D5. PFKFB3-driven lactate production enhances histone lactylation, particularly , which epigenetically activates NF-κB signaling genes (e.g., Ikbkb, Rela, Relb), creating a feedforward loop of inflammation and fibrosis ^[118]^D5. Targeting this axis reduces fibrosis in murine models ^[118]^D5.

Autophagy, a conserved lysosomal degradation pathway, maintains tubular homeostasis. Dysregulated autophagy contributes to the pathogenesis of both acute kidney injury (AKI) and CKD by impairing cellular quality control and promoting senescence ^[166]^D5.

Hemodynamic and Metabolic Drivers

Single-nephron glomerular hyperfiltration is an early pathophysiologic hallmark. Compensatory hyperfiltration after nephron loss raises intraglomerular capillary pressure, driving podocyte detachment, albuminuria, and proximal tubular overload ^[162]^D5. All nephroprotective drugs in current use, RAAS inhibitors, SGLT2 inhibitors, nonsteroidal mineralocorticoid receptor antagonists, and tolvaptan, induce an early dip in GFR that reflects reversal of hyperfiltration ^[162]^D5.

Activation of the renin-angiotensin-aldosterone system (RAAS) exacerbates hemodynamic stress. Angiotensin II both constricts efferent arterioles (raising intraglomerular pressure) and directly promotes fibrosis and inflammation via AT1 receptor signaling ^[128]^D5^[134]^D5. Lipotoxicity, accumulation of long-chain nonesterified fatty acids, ceramides, and diacylglycerols in tubular and glomerular cells, triggers mitochondrial dysfunction and energetic failure, especially in proteinuric states ^[123]^D5. Obesity and insulin resistance further amplify lipotoxicity and hyperfiltration ^[13]^D5^[152]^D5.

Inflammatory and Cellular Injury Mechanisms

Necroinflammation, an autoamplification loop between tubular cell death and interstitial inflammation, drives progressive injury ^[119]^D5. Injured PTCs release DAMPs that activate innate immune receptors, while the NLRP3 inflammasome links hypoxia and metabolic stress to IL-1β and IL-18 release ^[179]^B2b. Cellular senescence, marked by permanent growth arrest and a senescence-associated secretory phenotype (SASP), accumulates with aging and injury; experimental depletion of senescent cells delays CKD progression ^[142]^D5. Mitochondrial dysfunction, particularly in , impairs ATP generation and increases oxidative stress ^[171]^D5.

Tubular Injury and Cellular Senescence

The proximal tubule is both victim and driver. Filtered proteins (albumin, cytokines) are reabsorbed via megalin and cubilin, but overload triggers lysosomal dysfunction and inflammatory signaling ^[124]^D5. Partial epithelial-mesenchymal transition and cell-cycle arrest at G1/S and G2/M checkpoints convert tubular cells into fibrogenic effector cells ^[119]^D5.

Vascular and Endothelial Dysfunction

Renal endothelial cells are targets and effectors. In glomerular capillaries, glycocalyx loss and complement dysregulation impair the filtration barrier. In peritubular capillaries, endothelial-to-mesenchymal transition contributes to fibrosis ^[175]^D5. Systemic consequences, aortic stiffening, microvascular rarefaction, and elevated pulse pressure, propagate kidney damage and increase cardiovascular risk ^[131]^D5. The gut-microbial metabolite (TMAO) promotes tubulointerstitial fibrosis and functional decline; targeted inhibition of TMAO production can reverse established fibrosis in preclinical models ^[195]^D5.

Controversies and Guideline Disagreement

Question	Position A	Position B	Strength	Implication
Is glomerular hyperfiltration always harmful?	Hyperfiltration is maladaptive and should be reversed ^[162]^D5	Hyperfiltration is a compensatory response that preserves GFR; acute reversal may worsen outcomes ^[162]^D5	Moderate	Drug-induced early eGFR dip (e.g., SGLT2i) is now accepted as hemodynamic, not toxic ^[90]^A1b
Is tubular senescence protective or pathogenic?	Senescence prevents proliferation of damaged cells; elimination may impair repair ^[142]^D5	Senescent cells drive fibrosis via SASP; elimination improves outcomes ^[142]^D5	Moderate	Senolytic therapies are in early-phase trials ^[142]^D5

Pearl: The severity of kidney fibrosis tracks with the magnitude of glycolytic reprogramming and histone lactylation in proximal tubules, targeting PFKFB3 or the NF-κB lactylation axis may offer a novel antifibrotic strategy ^[118]^D5.

Major Pathogenic Mechanisms in CKD Progression

Mechanism	Key Mediators	Consequence
Glomerular hyperfiltration	RAAS, SGLT2 activity	Podocyte detachment, albuminuria ^[162]^D5
Glycolytic reprogramming	PFKFB3, H4K12la	Epigenetic NF-κB activation, fibrosis ^[118]^D5
Necroinflammation	DAMPs, NLRP3	Tubular death → interstitial inflammation ^[119]^D5^[179]^B2b
Cellular senescence	p16, p21, SASP	Fibrogenic microenvironment ^[142]^D5
Lipotoxicity	NEFA, ceramides	Mitochondrial dysfunction, tubular injury ^[123]^D5
Endothelial dysfunction	TMAO, glycocalyx loss	Impaired perfusion, fibrosis ^[175]^D5^[195]^D5

Epidemiology, Etiology and Risk Factors

▸CKD affects approximately 850 million people globally, with rising mortality and projected to become the fifth leading cause of death by 2050.
▸Diabetes and hypertension are the dominant causes; metabolic etiologies are increasing worldwide, including in China where diabetic kidney disease now surpasses glomerulonephritis.
▸AKI, genetic variants (APOL1, monogenic causes), and modifiable lifestyle factors (diet, physical activity, smoking) are key risk determinants that guide prevention and screening.

HY High Yield: AKI is a major modifiable risk factor for CKD, even stage 1 AKI increases risk, with a pooled adjusted HR of 8.8 for subsequent CKD [197].

These pathophysiological processes manifest in a disease that now affects an estimated 850 million people worldwide ^[261]^D5. In 2017, the global prevalence of CKD was 9.1% (697.5 million cases), with 1.2 million deaths directly attributable to CKD ^[158]^B2c. Mortality from CKD increased **** between 1990 and 2017, and by 2050 CKD is projected to become the fifth leading cause of death worldwide ^[158]^B2c^[261]^D5. Prevalence ranges from 8% to 16% across populations, with the highest burden concentrated in low- and middle-income countries ^[263]^D5^[224]^D5.

Demographic Patterns

CKD is more prevalent in older adults, women, and racial minorities ^[224]^D5. However, men experience faster disease progression and higher mortality: in a Swedish nationwide cohort, women had a lower risk of CKD progression (subhazard ratio 0.88) and all-cause mortality (SHR 0.90) compared with men ^[241]^B2b. Black individuals carry a disproportionately high risk of nondiabetic kidney disease due to APOL1 risk variants ^[255]^D5. In China, surpassed glomerulonephritis as the leading cause of CKD in 2011, mirroring the global shift toward metabolic etiologies ^[238]^C4.

Temporal Trends

The all-age prevalence of CKD increased 29.3% from 1990 to 2017, driven by aging populations and rising rates of diabetes, , and obesity ^[158]^B2c^[261]^D5. Age-standardized mortality has remained stable, but absolute deaths continue to rise ^[158]^B2c.

Risk Factors

Diabetes and hypertension account for the majority of CKD in high- and middle-income countries ^[52]^D5^[225]^D5. Obesity independently increases CKD risk through both direct and indirect mechanisms ^[152]^D5. Modifiable lifestyle factors significantly influence incidence: higher dietary potassium (OR 0.78), vegetable intake (OR 0.79), physical activity (OR 0.82), and moderate alcohol consumption (RR 0.86) reduce risk, while high salt intake (OR 1.21) and smoking (OR 1.18) increase it ^[84]^B2a. Acute kidney injury is a potent risk factor, with a pooled adjusted HR of 8.8 for subsequent CKD and 3.1 for ESRD ^[197]^B2a; even stage 1 AKI lasting <3 days carries increased risk ^[208]^B2a. Genetic factors contribute substantially: monogenic causes are identified in 37% of families with CKD, especially when a family history or extrarenal features are present ^[223]^C4. APOL1 high-risk genotypes explain much of the excess CKD burden in individuals of African ancestry ^[255]^D5.

Risk Factor	Odds Ratio / Relative Risk	Evidence Level
Diabetes	OR 2-4 (variable)	Strong
Hypertension	OR ~2	Strong
Obesity	OR 1.5-2	Moderate
Smoking (current vs never)	OR 1.18 ^[84]^B2a	Moderate
High salt intake	OR 1.21 ^[84]^B2a	Low
AKI (any stage)	HR 8.8 for CKD ^[197]^B2a	Strong
APOL1 high-risk genotype	OR 3-7 for FSGS/ESKD	Strong
Family history of CKD	OR 2-3	Moderate

Special Populations and Emerging Risk Factors

Environmental exposures also contribute: chronic high-altitude hypoxia may accelerate CKD progression ^[247]^D5, and extreme heat events are associated with a 4.35-fold increased risk of CKD in survivors ^[242]^B2a. Nephrotoxins such as aristolochic acid in herbal medicines and oxalate from juice cleanses can cause acute and chronic kidney injury ^[254]^D5^[217]^C4. Post-transplant CKD is common after solid organ and hematopoietic cell transplantation, driven by calcineurin inhibitor nephrotoxicity and other factors ^[284]^D5^[109]^B2a.

Pearl: The single most actionable insight from CKD is that AKI, even mild and brief, is a powerful independent risk factor for future CKD, every episode warrants structured follow-up.

Clinical Presentation

▸CKD is asymptomatic until approximately 60% of nephrons are lost; incidental lab findings are the most common presentation.
▸Fatigue (70% prevalence), pruritus (>40% on hemodialysis), and cognitive impairment are under-recognized but treatable symptoms.
▸Volume overload, hypertension, and hyperkalemia are the most clinically urgent features, with thresholds of eGFR <30 mL/min/1.73 m² and serum K >6.0 mmol/L signaling need for intensification.

HY High Yield: Fatigue in CKD is multi-factorial: screen for anemia, acidosis, depression, sleep apnea, and sarcopenia before labeling it 'uremic' [149].

Despite the high global prevalence described above, CKD remains clinically silent until substantial kidney function has been lost, and most patients are diagnosed incidentally through routine laboratory testing ^[52]^D5. Early-stage disease (G1-G3a) typically produces no symptoms; the kidney’s remarkable functional reserve masks injury until roughly 60% of nephrons are lost. When symptoms do emerge, they are often vague, non-specific, and attributable to other comorbid conditions rather than kidney disease itself.

Presenting Symptoms

Fatigue is the most common and debilitating symptom, reported by approximately 70% of patients with CKD, and is severe in up to 25% ^[149]^D5. Its pathogenesis is multi-factorial: anemia of CKD, chronic metabolic acidosis, sarcopenia, sleep fragmentation, and depression all contribute ^[149]^D5. Nocturia, awakening one or more times to void at night, reflects the kidney’s early failure to concentrate urine and may be the first clue. Pruritus (chronic kidney disease-associated pruritus, CKD-aP) affects more than 40% of patients on hemodialysis and is often generalized, scratching leads to excoriations and lichenification ^[302]^D5. Loss of appetite, metallic taste, and early satiety herald uremic toxin accumulation, while nausea and hiccups are late manifestations ^[52]^D5. Peripheral edema, dyspnea on exertion, and orthopnea indicate volume overload that becomes refractory as eGFR declines below 30 mL/min/1.73 m².

Physical Examination Findings

Volume assessment is paramount. JVP may be elevated; dependent edema, pulmonary crackles, and a third heart sound signal hypervolemia. is nearly universal and often difficult to control. Pallor suggests anemia (hemoglobin typically ≤10 g/dL when eGFR <30). Excoriations, xerosis, and sometimes uremic frost (urea crystals on skin, now rare with modern dialysis) are seen. Neurologic examination may reveal (stocking-glove sensory loss) and restless legs syndrome, both linked to uremic toxin accumulation and dopamine dysregulation ^[280]^D5. Cognitive impairment, particularly deficits in executive function, attention, and memory, is increasingly recognized and correlates with both lower eGFR and presence of albuminuria ^[133]^D5. Muscle wasting, especially of the temporalis and thenar eminences, signals protein-energy wasting. A pericardial friction rub, though rare today, is an ominous sign of uremic pericarditis.

Cardiovascular and Pulmonary Findings

Cardiovascular disease is the dominant cause of morbidity and mortality. (LVH) develops early from pressure overload and anemia; it is present in over 70% of patients at dialysis initiation ^[311]^D5. Pulmonary edema may occur with relatively modest volume excess because of coexisting diastolic dysfunction. Pericarditis presents with pleuritic chest pain and a rub; tamponade is a medical emergency.

and Metabolic Findings

Metabolic acidosis (serum bicarbonate <22 mmol/L) accelerates protein catabolism and bone demineralization. As acidosis worsens, Kussmaul respirations may develop. Hyperkalemia becomes a risk, particularly in advanced CKD or with medications such as finerenone; concentrations >6.0 mmol/L prompt urgent intervention ^[201]^B2b. and hyperphosphatemia reflect disturbed mineral metabolism and contribute to pruritus and bone pain.

Red Flags

Uremic encephalopathy (confusion, asterixis, seizures), pericarditis, pulmonary edema, and severe hyperkalemia (K >6.0 mmol/L with ECG changes) require immediate escalation of care, often dialysis. Hyperkalemia-related discontinuation of finerenone occurred in 1.2-2.3% of patients in pivotal trials, but routine monitoring mitigated life-threatening events ^[94]^A1b^[204]^A1b.

Atypical Presentations

CKD may first manifest as an incidentally discovered normocytic anemia, asymptomatic microscopic hematuria, or bilateral small kidneys on imaging. Some patients present with an acute-on-chronic decline after a superimposed insult (e.g., NSAID use, dehydration, contrast exposure) ^[305]^D5. Genetic forms (e.g., HNF1B-related MODY-5) present with young-onset diabetes, renal cysts, and hypomagnesemia, often before CKD is recognized ^[333]^C4.

Phenotypic Variants at Presentation

Clinical Scenario	Typical Features	Likely Underlying Etiology
Heavy proteinuria, edema	Nephrotic-range proteinuria (>3.5 g/day), hypoalbuminemia	Glomerular disease ( , FSGS, membranous)
Asymptomatic hematuria + proteinuria	Low-grade proteinuria, dysmorphic RBCs, casts	IgA nephropathy,
Hypertension + family history	Early-onset hypertension, flank pain, hematuria	Autosomal dominant polycystic kidney disease
Slowly rising creatinine over years	No significant proteinuria, bland sediment	Hypertensive nephrosclerosis, renovascular disease
Young adult with diabetes + CKD	Early microalbuminuria, rapid eGFR decline	(MODY-5 if atypical) ^[333]^C4

Pearl: When a patient with CKD reports fatigue, do not attribute it solely to anemia, evaluate sleep quality, acidosis, depression, and sarcopenia, as each is treatable and contributes independently to symptom burden ^[149]^D5^[280]^D5.

Diagnosis and Workup

▸CKD is diagnosed by sustained eGFR <60 mL/min/1.73 m² or UACR ≥30 mg/g for ≥3 months, using the race‑free CKD‑EPI 2021 equation.
▸Serum cystatin C is the preferred confirmatory test when creatinine‑based eGFR is in the 45-59 range without albuminuria; the combined equation improves accuracy.
▸Renal biopsy is the gold standard for determining the specific cause when non‑invasive evaluation is inconclusive, with a low risk of major bleeding (transfusion 1.6%, death 0.06%).

HY High Yield: The diagnosis of CKD requires two measurements separated by at least 90 days to confirm chronicity. A single low eGFR could reflect acute kidney injury or prerenal states.

Dx Diagnostic Essentials: The combined creatinine-cystatin C equation (eGFRcr‑cys) is the most accurate non‑invasive estimate of GFR and is recommended for confirmation when eGFRcr is 45-59 mL/min/1.73 m² without albuminuria [41,108].

Because most patients with early chronic kidney disease are asymptomatic, the diagnosis is frequently made incidentally when laboratory tests obtained for other reasons reveal reduced eGFR, proteinuria, or abnormal urinary sediment. The clinician's first task is to confirm that the abnormality represents true kidney disease and is chronic, not acute. The second is to identify the underlying cause, since a specific diagnosis guides therapy and prognosis.

History and Physical

History should focus on symptoms of kidney disease (nocturia, foamy urine, haematuria, oedema, fatigue, pruritus) and on conditions that cause CKD: long-standing , , (prior sore throat, rash, arthritis), recurrent urinary tract infections, nephrolithiasis, analgesic use, and family history of kidney disease. Physical examination includes blood pressure (volume-dependent hypertension is common), fundoscopy for hypertensive or , oedema, pallor, and abdominal auscultation for renal artery bruits. The presence of red flags, rapidly rising creatinine, active urinary sediment (dysmorphic red cells, red cell casts), or systemic symptoms (fever, rash, arthralgia), should prompt urgent nephrology referral.

Gold‑Standard Test

The diagnostic gold standard for CKD is persistent reduction in kidney function or evidence of kidney damage for ≥3 months ^[17]^D5^[339]^D5. The essential laboratory measures are:

eGFR <60 mL/min/1.73 m² (using the CKD‑EPI 2021 creatinine equation without race) ^[146]^C4 OR
Markers of kidney damage, primarily urinary albumin-to-creatinine ratio (UACR) ≥30 mg/g (≥3 mg/mmol) ^[10]^B2a^[339]^D5.

These two tests together classify CKD and predict prognosis; the combination of low eGFR and albuminuria carries multiplicative risk for kidney failure and cardiovascular death ^[10]^B2a. If the diagnosis is uncertain (e.g., borderline eGFR in a patient with low muscle mass), confirmatory testing with cystatin C or measured GFR is indicated.

Laboratory Studies

Test	Finding in CKD	Role
Serum creatinine & eGFR (CKD‑EPI 2021)	eGFR <60 mL/min/1.73 m² for >3 months	Initial diagnostic test; staging ^[3]^D5^[146]^C4
Urinary albumin-to-creatinine ratio (UACR)	≥30 mg/g (≥3 mg/mmol)	Detects glomerular damage; grades risk ^[10]^B2a^[339]^D5
Serum cystatin C	eGFRcys <60 mL/min/1.73 m²	Confirmatory test when eGFRcr 45-59 without albuminuria ^[41]^B2c^[108]^C4
Urinalysis with microscopy	Dysmorphic RBCs, RBC casts, pyuria, crystals	Suggests glomerulonephritis or tubulointerstitial disease ^[52]^D5
Serum electrolytes, BUN, bicarbonate	Hyperkalemia, metabolic acidosis	Guides of complications
Serologies: ANCA, anti‑GBM, ANA, complements, hepatitis B/C, HIV	Positive in specific glomerulonephritides	Required if active sediment, rapidly progressive course, or extrarenal symptoms ^[312]^D5
Serum uric acid	Often elevated	Gout common in CKD; treat-to-target may improve flares ^[304]^D5^[336]^B2b

Cystatin C is especially useful when creatinine-based eGFR is unreliable, in patients with extreme muscle mass, amputation, or cirrhosis. The combined creatinine-cystatin C equation (eGFRcr‑cys) improves accuracy, reclassifying approximately 17% of individuals with eGFRcr 45-59 mL/min/1.73 m² to a measured GFR ≥60 mL/min/1.73 m² ^[41]^B2c.

Imaging

Renal is the first-line imaging modality. In CKD, common findings include small kidneys (<9 cm in length) with increased echogenicity, thinned cortex, or cysts. Asymmetric kidneys suggest renovascular disease or congenital abnormality. Ultrasound also excludes obstruction, nephrolithiasis, and polycystic kidney disease. Computed tomography or MRI is reserved for suspected masses, stones, or complex cystic disease. Doppler ultrasound can detect when hypertension is severe or onset is abrupt.

Biopsy / Histology

Native kidney biopsy is the gold standard for diagnosing the specific parenchymal cause of CKD when the etiology remains uncertain after non‑invasive evaluation ^[200]^B2a. Indications include:

Unexplained CKD with active urinary sediment (dysmorphic red cells, red cell casts, cellular casts)
Nephrotic-range proteinuria (UACR >3000 mg/g or spot protein >3.5 g/day)
Rapidly progressive glomerulonephritis (≥50% decline in eGFR over weeks to months)
Suspected systemic disease with kidney involvement (lupus nephritis, ANCA vasculitis, C3 glomerulopathy)

Contraindications include uncontrolled hypertension, bleeding diathesis, solitary kidney, or small echogenic kidneys (in which yield is low). The major complication rate is low: bleeding requiring transfusion in 1.6%, intervention to stop bleeding in 0.3%, and death in 0.06% ^[200]^B2a. Histologic hallmarks include glomerular sclerosis, tubular atrophy, interstitial fibrosis, and specific findings (e.g., mesangial IgA deposits in ). The MEST‑C score (mesangial hypercellularity, endocapillary hypercellularity, segmental sclerosis, tubular atrophy/interstitial fibrosis, crescents) is used for risk stratification in IgA nephropathy ^[15]^D5.

Diagnostic Algorithm

Step 1: Confirm eGFR and albuminuria. Obtain two sets of serum creatinine and UACR separated by ≥3 months. A sustained eGFR <60 mL/min/1.73 m² (CKD‑EPI 2021) or UACR ≥30 mg/g establishes the diagnosis ^[3]^D5^[17]^D5^[79]^D5.

Step 2: Exclude acute kidney injury (AKI). If creatinine has risen over days to weeks, evaluate for AKI (prerenal, intrinsic, postrenal) before labeling as CKD. The Acute Disease Quality Initiative recommends the term acute kidney disease (AKD) for kidney disease persisting 7-90 days ^[296]^D5.

Step 3: Confirm borderline eGFR. If eGFRcr is 45-59 mL/min/1.73 m² without albuminuria, obtain serum cystatin C. An eGFRcys <60 mL/min/1.73 m² confirms CKD; if ≥60, measured GFR (iohexol or inulin clearance) may be needed ^[41]^B2c^[108]^C4.

Step 4: Search for cause. Review urinalysis, sediment, serologies, and imaging. If cause remains unclear and biopsy is indicated (see above), proceed.

Step 5: Stage and risk stratify. Assign GFR category (G1-G5) and albuminuria category (A1-A3) per KDIGO. This is detailed in the next section.

Controversies and Guideline Disagreement

Question	Position A (KDIGO/NKF)	Position B (Alternative)	Strength	Implication
Should race be used in eGFR equations?	No, NKF/ASN Task Force recommends immediate adoption of CKD‑EPI 2021 without race ^[345]^D5	Some European societies use the EKFC equation, which rescales with population median creatinine rather than race ^[65]^D5	Strong consensus to remove race; disagreement on substitute equation	All U.S. labs now report eGFR without race; providers should know the equation used at their institution
Is cystatin C confirmatory or first‑line?	KDIGO suggests confirmatory use when eGFRcr 45-59 ^[108]^C4	Some argue cystatin C adds cost and is not superior in all populations; the EKFC cystatin C equation is proposed as a race‑ and sex‑free alternative ^[65]^D5	Moderate, use is cost‑dependent	In patients with discordant eGFRcr and eGFRcys, a large discrepancy (eGFRdiff) is associated with adverse outcomes; its determinants remain poorly understood ^[348]^B2b
When to biopsy in CKD?	Biopsy is indicated for unexplained active urine sediment or rapidly progressive disease ^[200]^B2a	In advanced CKD (eGFR <30) with atrophic kidneys, biopsy risk outweighs yield	General agreement	Biopsy should be performed at experienced centers with ultrasound guidance and post‑procedure observation

Pearl: When eGFRcr is 45-59 mL/min/1.73 m² in an asymptomatic patient without albuminuria, confirm with cystatin C, up to 23% have measured GFR >60 and do not have CKD ^[108]^C4.

Staging and Risk Stratification (KDIGO)

▸KDIGO staging uses a C-G-A framework (cause, GFR category G1-G5, albuminuria category A1-A3) to produce a prognostic heat-map that guides monitoring and treatment intensity.
▸Confirmatory cystatin C testing is recommended for patients with eGFRcr 45-59 and A1; this reclassifies ~17% of such patients as having normal GFR, avoiding unnecessary CKD labeling.
▸Validated risk equations (e.g., KFRE, CKD-PC) complement the heat-map and identify patients who benefit most from nephrology referral and intensive renoprotective therapy.

HY High Yield: In patients with eGFRcr 45-59 and A1, confirmatory cystatin C testing reclassifies ~17% as having normal GFR, avoiding unnecessary CKD labeling and specialist referral [41].

Dx Diagnostic Essentials: Always classify both GFR category (G1-G5) and albuminuria category (A1-A3); the risk gradient is multiplicative, not additive [10].

Once CKD is diagnosed, the next essential step is to assign its stage and estimate prognosis using the unified KDIGO classification system, which integrates the cause of disease, GFR category, and albuminuria category ^[289]^A1c. This three-axis framework (C-G-A) directly drives monitoring frequency, therapeutic intensity, and referral timing.

The KDIGO Heat-Map: GFR and Albuminuria

GFR is divided into five categories (G1: ≥90, G2: 60-89, G3a: 45-59, G3b: 30-44, G4: 15-29, G5: <15 mL/min/1.73 m²). Albuminuria is classified into three categories (A1: <30, A2: 30-300, A3: >300 mg/g creatinine). When these two axes are crossed, the resulting heat-map assigns a risk stratum (low, moderately increased, high, very high) that predicts all-cause and cardiovascular mortality and kidney failure ^[10]^B2a^[115]^B2a. For instance, a patient with G3a and A2 falls into the high-risk zone, whereas G1A1 is low risk. The association between eGFR and mortality becomes evident below 60 mL/min/1.73 m², with adjusted HRs for all-cause mortality of 1.18 at 60, 1.57 at 45, and 3.14 at 15 mL/min/1.73 m² versus a reference of 95 ^[10]^B2a. Albuminuria (ACR ≥1.1 mg/mmol or 10 mg/g) is an independent, log-linear risk factor with no threshold ^[10]^B2a.

eGFR category	eGFR (mL/min/1.73 m²)	A1 (UACR <30 mg/g)	A2 (UACR 30-300 mg/g)	A3 (UACR >300 mg/g)
G1	≥90	Low	Moderate	High
G2	60-89	Low	Moderate	High
G3a	45-59	Moderate	High	Very high
G3b	30-44	High	Very high	Very high
G4	15-29	Very high	Very high	Very high
G5	<15	Very high	Very high	Very high

The heat-map is derived from the KDIGO 2024 guideline and the underlying Chronic Kidney Disease Prognosis Consortium data ^[289]^A1c^[10]^B2a. Risk increases multiplicatively with lower eGFR and higher albuminuria, without interaction, meaning both measures contribute independently to prognosis ^[10]^B2a^[390]^B2a.

Confirmatory Testing with Cystatin C

When eGFR estimated by creatinine (eGFRcr) falls between 45 and 59 mL/min/1.73 m² (stage 3a) in the absence of albuminuria (A1), KDIGO recommends confirming the GFR with cystatin C (eGFRcys or eGFRcr-cys) ^[289]^A1c^[3]^D5. The CKD-EPI creatinine-cystatin C equation improves classification: among patients with eGFRcr 45-59, 16.9% are correctly reclassified as having GFR ≥60 mL/min/1.73 m² ^[41]^B2c. In a general-population meta-analysis, using cystatin C alone or in combination with creatinine reclassified risk appropriately: reclassification to a higher eGFR was associated with lower mortality risk, and reclassification to a lower eGFR with higher risk (net reclassification improvement 0.23 for death) ^[390]^B2a. This confirmatory step reduces overdiagnosis of CKD in individuals whose low eGFRcr reflects non-GFR determinants of creatinine (e.g., low muscle mass) rather than true kidney disease.

Risk Prediction and Prognostic Tools

Beyond the heat-map, validated equations refine risk stratification for individual patients. The CKD Prognosis Consortium equations incorporate age, sex, race, eGFR, and albuminuria to predict the 5-year risk of kidney failure. The Kidney Failure Risk Equation (KFRE) is endorsed by KDIGO for identifying patients who may benefit from nephrology referral (risk >3-5% over 5 years) ^[289]^A1c^[220]^D5. In the setting of type 2 diabetes, the FIDELITY analysis demonstrated that cardiovascular and kidney benefits of finerenone were consistent across KDIGO risk categories, with combination finerenone- therapy producing additive UACR reductions regardless of baseline risk ^[210]^A1b^[105]^C4.

Genetic risk variants, such as APOL1 in African-ancestry populations, confer a substantially elevated lifetime risk of CKD and can be considered a modifying factor in risk assessment, though they are not yet part of routine KDIGO staging ^[349]^D5.

Acute Kidney Disease (AKD) and the AKI-CKD Continuum

Kidney Injury that does not meet the 90-day duration criterion for CKD but lasts >7 days is classified as acute kidney disease (AKD), a construct harmonized by the 2020 KDIGO Consensus Conference ^[14]^D5. AKD definition: abnormalities of kidney function and/or structure with health implications persisting ≤3 months. Staging of AKD mirrors the AKI severity (stage 1, 2, 3) but also includes subacute GFR decline not meeting AKI thresholds. Recognizing AKD allows earlier intervention and surveillance for progression to CKD.

Controversies and Guideline Disagreement

Question	KDIGO Position	KDOQI Position	Strength	Implication
Use of cystatin C as confirmatory test	Recommended for eGFRcr 45-59 and A1 (Grade 2C)	Largely agrees but notes limited data on outcomes ^[3]^D5^[380]^D5	Conditional recommendation	Implementation varies; cystatin C availability is a barrier
Inclusion of cause in staging	Required; cause assigned as diabetic, glomerular, tubulointerstitial, vascular, cystic/congenital ^[289]^A1c	Concerns about reliability of cause assignment without biopsy ^[3]^D5	Expert opinion	Cause should be recorded but may be imprecise without histology
Age adjustment for GFR thresholds	Not recommended; same GFR thresholds for all adults	Suggests age-modified interpretation in elderly to avoid overdiagnosis ^[33]^D5	Unresolved	Older adults with eGFR 45-59 and no albuminuria may have low risk; clinician judgment needed

Pearl: When a patient's eGFRcr is 45-59 mL/min/1.73 m² with A1, ordering a cystatin C level can confirm or refute the CKD diagnosis, up to one in six such patients will have a true GFR above 60 and should be removed from the CKD register ^[41]^B2c.

Acute Management

▸Life-threatening hyperkalemia (K⁺ > 6.0 with ECG changes) requires immediate calcium gluconate for cardiac protection followed by insulin/glucose and albuterol.
▸Emergent dialysis is indicated by the AEIOU criteria: Acidosis (pH < 7.15), Electrolyte disturbance (refractory hyperkalemia), Intoxication, Overload (refractory pulmonary edema), Uremia (pericarditis/encephalopathy).
▸Sodium zirconium cyclosilicate (SZC 5 g TID × 48h then QD) and patiromer (4.2 g BID) are effective for sustained potassium control and enabling continued RAAS inhibitor use.

HY High Yield: The AEIOU mnemonic for emergent dialysis: Acidosis, Electrolyte disturbance, Intoxication, Overload, Uremia [438].

! Warning: Do NOT rely solely on potassium binders for life-threatening hyperkalemia with ECG changes; always administer calcium gluconate first [246].

With staging and risk stratification complete, the clinician must now recognise and treat the acute, life-threatening complications of advanced CKD. Nephrologic emergencies, severe hyperkalemia, pulmonary edema from volume overload, severe metabolic acidosis, symptomatic uremia, and rapidly progressive glomerulonephritis (RPGN), demand immediate, protocol-driven intervention. The following pathway integrates KDIGO 2024 recommendations ^[289]^A1c with critical care nephrology principles ^[438]^D5.

Step 1: Initial Assessment and Severity Classification

Identify the emergency type and grade its severity. For hyperkalemia, measure serum potassium (K⁺) and obtain a 12-lead ECG. Life-threatening hyperkalemia is defined as K⁺ >6.5 mmol/L or any K⁺ >6.0 mmol/L with ECG changes (peaked T waves, widened QRS, sine wave, or ventricular arrhythmia) ^[246]^D5. Severe metabolic acidosis: arterial pH <7.1 or bicarbonate <10 mmol/L ^[438]^D5. Acute pulmonary edema: oxygen saturation <90% on room air, orthopnea, jugular venous distension, unresponsive to initial diuretics. Symptomatic uremia: altered mental status, pericarditis, asterixis, or seizures ^[437]^D5. RPGN: rapid rise in serum creatinine over days to weeks with active urine sediment (dysmorphic RBCs, RBC casts) and proteinuria; urgent kidney biopsy and immunosuppression are needed, as per KDIGO 2024 framework ^[289]^A1c.

Step 2: First-Line Interventions by Emergency Type

Hyperkalemia, the drug of choice for cardiac protection is calcium gluconate 1 g IV over 2-5 minutes (repeat once if ECG changes persist). Then shift potassium intracellularly: regular insulin 10 units IV followed immediately by 25 g of dextrose 50% (D50) IV to prevent hypoglycemia. Nebulised albuterol (10-20 mg) provides additive effect. For sustained potassium removal, administer a potassium binder: sodium zirconium cyclosilicate (SZC) 5 g PO TID for 48 hours, then 5 g once daily ^[99]^A1b (label), or patiromer 4.2 g PO BID (starting dose, titrated) ^[430]^C4. SZC lowered serum K⁺ by 0.5-0.7 mmol/L at 48 hours (P<0.001) and maintained normokalemia for 12 days ^[99]^A1b. In dialysis-dependent patients, SZC did not reduce arrhythmia-related cardiovascular events (HR 0.98, 95% CI 0.76-1.26) but improved K⁺ control (74% vs. 47% normokalemic at 12 months; OR 3.36, 95%) ^[419]^A1b.

Volume overload / pulmonary edema, administer intravenous loop diuretics: 80-120 mg IV (bolus, or infusion 5-10 mg/hour) after assessing urine output. If no response within 2 hours, proceed to ultrafiltration via dialysis ^[438]^D5.

Severe metabolic acidosis, intravenous sodium bicarbonate (1-2 ampules of 50 mEq in 1 L D5W) is reserved for pH <7.0; evidence does not support routine use for pH ≥7.1 because of risks of hypernatremia, volume overload, and paradoxical intracellular acidosis ^[438]^D5.

Symptomatic uremia or RPGN, the definitive treatment is urgent initiation of renal replacement therapy (RRT). For RPGN, begin high-dose corticosteroids (e.g., 500-1000 mg IV daily × 3 days) while awaiting biopsy; involve the long-term team (Section 8) ^[289]^A1c.

Step 3: Escalation to Renal Replacement Therapy, the AEIOU Criteria

Emergency RRT (hemodialysis, continuous RRT, or peritoneal dialysis) is indicated when any AEIOU criterion is met ^[438]^D5:

Acidosis with pH <7.15 refractory to medical therapy
Electrolyte disturbance: K⁺ >6.5 mmol/L or rapidly rising despite binders
Intoxication: dialyzable toxin (e.g., lithium, salicylate, ethylene glycol) with significant morbidity
Overload: pulmonary edema unresponsive to diuretics
Uremia: pericarditis, encephalopathy, or bleeding diathesis

Step 4: Monitoring and Titration

After initial interventions, monitor serial serum K⁺, arterial blood gases, fluid balance (weights, intake/output), and hourly for the first 4 hours, then every 4-6 hours. Repeat ECG after calcium gluconate and after each insulin/d50 dose. If potassium remains >6.0 mmol/L despite binders and shifting therapies, initiate RRT. For volume overload, track net fluid removal and adjust diuretic dose upward if urine output <50 mL/hour after 2 hours. Titrate bicarbonate infusion to maintain pH ≥7.2, avoiding overcorrection.

Step 5: Resolution and Transition to Definitive Management

Once the acute emergency resolves, K⁺ ≤5.0 mmol/L, pH ≥7.3, resolution of pulmonary edema, and absence of uremic symptoms, transition to chronic therapies. Continue oral potassium binders (SZC or patiromer) as needed to support continued renin-angiotensin-aldosterone system (RAAS) inhibitor use ^[289]^A1c. Reassess volume status and adjust diuretic dose. If RRT was initiated, plan for ongoing dialysis access (KDOQI Life-Plan ^[416]^A1c) and transition to the long-term management strategies covered in Section 8.

What NOT to Do

Do NOT administer sodium bicarbonate for metabolic acidosis with pH ≥7.1 ^[438]^D5.
Do NOT rely solely on potassium binders for life-threatening hyperkalemia with ECG changes; always give calcium gluconate first ^[246]^D5.
Do NOT target hemoglobin >12.0 g/dL with ESAs in non-dialysis CKD; this increases stroke risk without cardiovascular benefit (HR 0.78, 95% CI 0.53-1.14; NNT not calculable) ^[432]^A1b.
Do NOT initiate statin therapy in patients on dialysis (KDIGO 2013 recommends against starting de novo) ^[415]^A1c.

Drug Comparison Table: Potassium Binders

Drug	Starting Dose	Target/Dose Range	Onset of Action	Key Trial	Outcome	Level of Evidence
Sodium zirconium cyclosilicate (SZC)	5 g PO TID × 48 h ^[99]^A1b	5 g once daily maintenance ^[99]^A1b	2-4 hours	ZS-003 ^[99]^A1b	↓ K⁺ 0.5-0.7 mmol/L at 48 h; maintained normokalemia vs. placebo (P<0.001)	1b
Patiromer	4.2 g PO BID ^[430]^C4	Titrate; max 8.4 g BID ^[430]^C4	4-7 hours (delayed onset)	OPAL-HK ^[430]^C4	↓ K⁺ 1.01±0.03 mmol/L at 4 weeks; 76% achieved normokalemia; recurrence of hyperkalemia lower vs. placebo (15% vs. 60%, P<0.001)	4

Dosing Table: Acute Interventions

Drug/Intervention	Dose	Comments
Calcium gluconate 10%	1 g (10 mL) IV over 2-5 min	Repeat ×1 if ECG unchanged; monitor for bradycardia
Regular insulin	10 units IV bolus	Follow with D50W 25 g (50 mL) IV; check blood glucose q30 min × 2 h
Albuterol	10-20 mg nebulised	May cause tachycardia; additive to insulin/glucose
Furosemide	80-120 mg IV bolus	Infusion 5-10 mg/h if oliguric; monitor for ototoxicity
Sodium bicarbonate	50-100 mEq IV over 30-60 min	Only if pH <7.0; risk of volume overload

Treatment Failure Protocol

Hyperkalemia: If K⁺ remains >6.0 mmol/L after 2 hours of insulin/glucose + albuterol + binder, initiate emergent hemodialysis ^[438]^D5.
Volume overload: If no response to furosemide 200 mg IV cumulative, start ultrafiltration.
Acidosis: If pH <7.15 after 1 hour of bicarbonate, begin continuous RRT.

Controversies and Guideline Disagreement

Question	Position A	Position B	Strength	Implication for practice
SZC for cardiovascular prevention in dialysis	DIALIZE-Outcomes found no benefit on arrhythmia-related composite (HR 0.98, 95% CI 0.76-1.26) ^[419]^A1b	Expert opinion supports SZC to maintain K⁺ balance and enable RAAS-i continuation ^[289]^A1c	Moderate (trial stopped early, event rates low)	Use SZC for K⁺ control, not for cardiovascular event reduction; shared decision-making with patient
Target hemoglobin with ESAs	KDIGO 2012 recommends 10-12 g/dL; CREATE trial shows no CV benefit with normalization (HR 0.78, 95% CI 0.53-1.14) ^[432]^A1b	Trials show higher stroke risk with >13 g/dL	Mild (consistent across guidelines)	Maintain Hb 10-12 g/dL; avoid ESA if Hb >12 g/dL

Caption: Figure 1: Acute hyperkalemia management algorithm (adapted from KDIGO 2024 ^[289]^A1c and NEJM trials ^[99]^A1b^[430]^C4).

Pearl: For life-threatening hyperkalemia, calcium gluconate is the first step, do not delay to give potassium binders; then use insulin/glucose and albuterol for shifting, and SZC or patiromer for sustained control; escalate to dialysis if K⁺ remains ≥6.5 mmol/L after medical therapy (AEIOU criteria) ^[99]^A1b^[246]^D5^[289]^A1c^[430]^C4.

Long-term and Definitive Management

▸Long-term nephroprotection follows a sequential evidence ladder: RAS blockade → SGLT2 inhibitor → nonsteroidal MRA → GLP-1 receptor agonist, each supported by landmark trials showing independent kidney and cardiovascular benefits.
▸Do not discontinue RAS inhibitors in advanced CKD (STOP ACEi); continue SGLT2 inhibitors until eGFR <20 mL/min/1.73 m²; finerenone requires potassium monitoring but rarely causes discontinuation.
▸Combination therapy (SGLT2i + finerenone) provides additive albuminuria reduction and is safe with routine monitoring; GLP-1 RAs (semaglutide) reduce kidney failure risk by 24% in diabetic CKD (FLOW).

Rx Drug of Choice: First-line nephroprotective sequence: ACEi/ARB → SGLT2 inhibitor (dapagliflozin 10 mg or empagliflozin 10 mg) → finerenone (10-20 mg) → semaglutide 1.0 mg weekly in diabetic CKD.

! Warning: Do not discontinue RAS inhibitors in advanced CKD without compelling indication (STOP ACEi trial showed no benefit and possible harm). Avoid NSAIDs in all stages of CKD.

Once acute threats are stabilized, the focus shifts to long-term nephroprotection, a sequential, evidence-based deployment of therapies that slow CKD progression and reduce cardiovascular risk. The modern paradigm, supported by landmark trials and the KDIGO 2025 ADPKD guideline ^[1]^A1c, mandates a multi-pillar approach initiated early and continued through advanced stages.

Step 1: Renin-Angiotensin System Blockade

Initiate an ACE inhibitor or ARB at the maximum tolerated dose for all patients with CKD and albuminuria (UACR ≥30 mg/g) or . A Bayesian network meta-analysis of 119 RCTs (n=64,768) demonstrated that ACEi reduced kidney failure by 39% (OR 0.61; 95% CrI 0.47-0.79) and ARB by 30% (OR 0.70; 0.52-0.89) versus placebo ^[83]^A1a. ACEi also reduced all-cause mortality versus active controls (OR 0.72; 0.53-0.92) ^[83]^A1a. Do not discontinue RASi in advanced CKD. The STOP ACEi trial (n=411, eGFR <30) found no benefit to discontinuation: eGFR at 3 years was 12.6 vs 13.3 mL/min/1.73 m² (difference -0.7; 95% CI -2.5 to 1.0; P=0.42), and ESKD occurred in 62% vs 56% (HR 1.28; 0.99-1.65) ^[98]^A1b.

Step 2: SGLT2 Inhibitors

Add an SGLT2 inhibitor ( 10 mg, 10 mg, or 100 mg daily) for CKD with eGFR ≥20-25 mL/min/1.73 m² and UACR ≥200 mg/g, irrespective of diabetes status. In DAPA-CKD (n=4304), dapagliflozin reduced the primary composite (≥50% eGFR decline, ESKD, or renal/CV death) by 39% (HR 0.61; 95% CI 0.51-0.72; NNT 19) ^[93]^A1b. EMPA-KIDNEY (n=6609) showed a 28% reduction (HR 0.72; 0.64-0.82) ^[92]^A1b. A collaborative meta-analysis of 13 trials (n=90,409) confirmed a 37% reduction in kidney disease progression (RR 0.63; 0.58-0.69), with similar effects in patients with and without diabetes ^[8]^A1a. An acute eGFR dip of >10% at 2 weeks occurs in ~49% of patients but is benign and associated with slower long-term decline ^[90]^A1b. Continue SGLT2i until eGFR <20 mL/min/1.73 m² or dialysis initiation.

Step 3: Nonsteroidal Mineralocorticoid Receptor Antagonist

Add finerenone (10 or 20 mg daily based on eGFR) for CKD with type 2 diabetes and albuminuria (UACR ≥30 mg/g, eGFR ≥25 mL/min/1.73 m²). In FIDELIO-DKD (n=5734), finerenone reduced the kidney composite (kidney failure, ≥40% eGFR decline, or renal death) by 18% (HR 0.82; 0.73-0.93) ^[94]^A1b. FIGARO-DKD (n=7437) showed a 13% reduction in the CV composite (HR 0.87; 0.76-0.98) ^[204]^A1b. The INFINITY individual-participant meta-analysis of three trials (n=14,574) demonstrated a 24% reduction in the kidney composite (HR 0.76; 0.68-0.86) and a 20% reduction in CV death/heart failure hospitalization (HR 0.80; 0.70-0.91), with consistent effects across CKD aetiologies and glycaemic status ^[116]^A1a. Hyperkalemia occurs more frequently (21.4% vs 9.2% for K+ >5.5 mmol/L) but rarely leads to discontinuation (2.3% vs 0.9%) ^[201]^B2b; monitor serum K+ and consider concomitant SGLT2i or diuretic to mitigate risk.

Step 4: GLP-1 Receptor Agonists

Consider 1.0 mg subcutaneously weekly for CKD with type 2 diabetes and albuminuria. The FLOW trial (n=3533) demonstrated a 24% reduction in major kidney disease events (HR 0.76; 0.66-0.88; P=0.0003) and a 20% reduction in all-cause mortality (HR 0.80; 0.67-0.95) ^[91]^A1b. A meta-analysis of 12 RCTs in patients with eGFR <60 (n=17,996) found a 15% reduction in composite kidney outcomes (OR 0.85; 0.77-0.94) and a 23% reduction in all-cause mortality (OR 0.77; 0.60-0.98) ^[82]^A1a. Emerging data suggest albuminuria-lowering effects in non-diabetic CKD as well ^[176]^A1a^[365]^A1a, but guideline recommendations remain limited to diabetic populations.

Step 5: Disease-Specific Therapies

For , add SGLT2i, sparsentan (dual endothelin-1/angiotensin II receptor blocker), or nefecon (targeted-release budesonide) as approved ^[488]^D5. For ADPKD, tolvaptan is recommended per KDIGO 2025 ^[1]^A1c. For ANCA-associated vasculitis or lupus nephritis, immunosuppression ( , , ) is indicated ^[312]^D5.

Lifestyle and Blood Pressure Control

Target systolic BP <120 mmHg in patients with CKD and hypertension, based on SPRINT (HR 0.72 for all-cause death; 95% CI 0.53-0.99) ^[87]^A1b. Dietary sodium <2 g/day, a plant-dominant diet ^[135]^D5, and regular exercise (≥150 min/week of moderate activity) improve outcomes ^[84]^B2a^[89]^A1b^[475]^A1b.

Anemia and Metabolic Acidosis

Treat anemia with targeting hemoglobin 10-11.5 g/dL, plus iron repletion. Roxadustat, an oral HIF-PHI, effectively raises hemoglobin and reduces transfusion need (HR 0.37; 0.30-0.44) ^[478]^A1b. For metabolic acidosis (serum bicarbonate <22 mmol/L), sodium bicarbonate 0.5-1.0 mEq/kg/day improves eGFR (SMD 0.33; 0.03-0.63) and reduces hospitalizations (OR 0.37; 0.25-0.55) ^[476]^A1a.

What NOT to Do

Avoid NSAIDs in CKD due to risk of acute kidney injury and accelerated progression ^[305]^D5.
Do not discontinue RASi in advanced CKD without compelling indication ^[98]^A1b.
Do not use >10 mg daily in eGFR <30 mL/min/1.73 m² (increased hematuria, proteinuria, and kidney failure risk) ^[244]^B2b.

Controversies and Guideline Disagreement

Question	Position A	Position B	Strength	Implication
Timing of SGLT2i in CKD stage 4	DAPA-CKD and EMPA-KIDNEY support initiation down to eGFR 20-25 ^[86]^A1b^[92]^A1b	FDA label for some SGLT2i restricts initiation at eGFR <30	Moderate	Off-label use in stage 4 is common; monitor for acute eGFR dip
Finerenone in non-diabetic CKD	INFINITY meta-analysis shows benefit across aetiologies ^[116]^A1a	FIND-CKD (n=1584) is ongoing; no regulatory approval yet	Moderate	Await FIND-CKD results; consider off-label in high-risk non-diabetic patients
Combination SGLT2i + finerenone	CONFIDENCE trial shows additive albuminuria reduction (29% greater vs finerenone alone) ^[95]^A1b	Long-term outcome data pending	Mild	Reasonable to combine; monitor K+ closely

Dosing Table

Drug	Starting dose	Target/max dose	Renal adjustment	Key monitoring
	5-10 mg daily	40 mg daily	eGFR <30: start 2.5 mg	K+, Cr, SBP
	25-50 mg daily	100 mg daily	No adjustment	K+, Cr
Dapagliflozin	10 mg daily	10 mg daily	eGFR <25: avoid initiation	eGFR, volume status
Empagliflozin	10 mg daily	10 mg daily	eGFR <20: avoid initiation	eGFR, volume status
Finerenone	10 mg daily (eGFR ≥60) or 20 mg daily (eGFR <60)	20 mg daily	eGFR <25: not recommended	K+, Cr, SBP
Semaglutide	0.25 mg weekly ×4 wk, then 0.5 mg ×4 wk	1.0 mg weekly	No adjustment	GI tolerability, retinopathy

Pearl: Initiate all four pillars (RASi, SGLT2i, nsMRA, GLP-1 RA) sequentially in patients with diabetic CKD and albuminuria; each adds independent nephroprotection, and combination therapy (e.g., finerenone + empagliflozin) yields additive albuminuria reduction without excess harm ^[95]^A1b^[116]^A1a.

Fluid, Electrolyte & Acid-Base Disorders

▸Hyperkalemia in CKD should be managed by maintaining RAASi therapy with potassium binders (SZC or patiromer) rather than discontinuing nephroprotective medications.
▸Metabolic acidosis (bicarbonate <22 mEq/L) is independently associated with CKD progression; sodium bicarbonate supplementation improves eGFR and reduces hospitalizations, albeit with a risk of systolic BP elevation.
▸Finerenone improves cardiorenal outcomes but requires potassium monitoring; combination with SGLT2 inhibitors is safe and additive for albuminuria reduction.

Long-term renin-angiotensin-aldosterone system (RAAS) inhibitor therapy, while nephroprotective, creates a predictable backdrop for the electrolyte and acid-base disturbances that dominate nephrology consultations. The most consequential is hyperkalemia, defined as serum potassium ≥5.5 mmol/L, which occurs in up to 42% of patients with eGFR <20 mL/min/1.73 m² ^[567]^B2b. Hyperkalemia is not merely a laboratory finding: it is independently associated with all-cause mortality and arrhythmic death, even at modest elevations ^[552]^D5. Critically, RAAS inhibitor discontinuation after an episode of hyperkalemia increases mortality (HR 1.47, 95% CI 1.41-1.52) and dialysis initiation (HR 1.65) compared with continuation ^[528]^B2b. Therefore, the modern approach prioritizes maintaining guideline-directed RAAS inhibitor therapy rather than withdrawing it, using potassium binders as an enabling strategy.

Managing Hyperkalemia to Preserve RAASi

Two oral potassium binders have reshaped chronic hyperkalemia . Sodium zirconium cyclosilicate (SZC) 5 g once daily on non-dialysis days (titratable to 15 g) maintained normokalemia (serum potassium 4.0-5.0 mmol/L) in 74% of hemodialysis patients at 12 months versus 47% with placebo (OR 3.36) ^[419]^A1b. While SZC did not reduce arrhythmia-related cardiovascular events in the DIALIZE-Outcomes trial, hypokalemia was uncommon (3% vs 1.4% placebo) ^[419]^A1b. Patiromer 8.4 g once daily enabled significantly more patients with and stage 4 CKD to remain on at 12 weeks (86% vs 66%, p<0.0001) ^[535]^A1b. In the OPAL-HK trial, patiromer lowered serum potassium by -1.01±0.03 mmol/L over 4 weeks in patients with CKD on RAASi, with recurrence of hyperkalemia (≥5.5 mmol/L) in 60% of placebo-assigned versus 15% of patiromer-assigned patients (p<0.001) ^[430]^C4. Both agents have a role; the choice depends on availability, cost, and patient tolerance. Sodium-glucose cotransporter-2 inhibitors (SGLT2i) also lower the risk of incident hyperkalemia compared with DPP-4 inhibitors (HR 0.74, 95% CI 0.68-0.80) and should be considered as part of a potassium-sparing strategy ^[545]^B2b.

Finerenone and Hyperkalemia

Finerenone, a nonsteroidal mineralocorticoid receptor antagonist, improves cardiorenal outcomes but increases hyperkalemia risk. In FIDELIO-DKD, mild hyperkalemia (>5.5 mmol/L) occurred in 21.4% of finerenone-treated patients versus 9.2% on placebo; hyperkalemia leading to discontinuation was low (2.3% vs 0.9%) ^[94]^A1b. The addition of to finerenone (CONFIDENCE trial) produced a 29% greater albuminuria reduction than finerenone alone (p<0.001), with hyperkalemia-related discontinuation remaining uncommon ^[95]^A1b. Combining finerenone with an SGLT2i appears safe and additive for albuminuria reduction, though potassium monitoring is required.

Metabolic Acidosis

Metabolic acidosis (serum bicarbonate <22 mEq/L) is present in up to 39% of patients with eGFR <20 mL/min/1.73 m² ^[567]^B2b and accelerates CKD progression through endothelin-1 and aldosterone-mediated tubulointerstitial fibrosis ^[563]^D5. Treatment with oral sodium bicarbonate (starting 0.5-1.0 g three times daily, titrated to maintain bicarbonate ≥22 mEq/L) improved eGFR (SMD 0.33, 95% CI 0.03-0.63) and reduced hospitalization (OR 0.37, 95% CI 0.25-0.55) in a meta-analysis of 14 RCTs ^[476]^A1a. However, it is associated with a modest increase in systolic BP (SMD 0.10, 95% CI 0.01-0.20) ^[476]^A1a. Veverimer, a non-absorbed hydrochloric acid binder, also normalized bicarbonate (63% vs 38% at week 52) and improved physical function in CKD patients with metabolic acidosis, but is not yet widely available ^[537]^A1b. Despite guideline recommendations, treatment rates remain low: only 8.7% to 17.6% of eligible patients received sodium bicarbonate in real-world cohorts ^[538]^B2b.

Calcium, Phosphate, and Magnesium

Hyperphosphatemia typically emerges when eGFR falls below 30-40 mL/min/1.73 m² ^[567]^B2b and is managed with dietary phosphate restriction, phosphate binders, and, in advanced CKD, optimization of dialysis. is common but overly aggressive correction may promote vascular calcification ^[548]^D5. Post-transplant hypophosphatemia due to elevated FGF-23 often requires phosphate supplementation in the early post-transplant period ^[547]^D5. Hypomagnesemia is a feature of Gitelman-like syndromes and may be exacerbated by proton pump inhibitors or calcineurin inhibitors.

Controversies and Guideline Disagreement

Question	Position A	Position B	Strength	Implication
Target serum bicarbonate in CKD?	KDIGO suggests maintaining ≥22 mEq/L ^[541]^D5	Some experts propose target 24-26 mEq/L based on acidosis-injury continuum ^[155]^D5^[562]^D5	Low-Consensus	Individualize: lower targets for those with heart failure; higher for those with progressive CKD
Potassium binder use for primary prevention of hyperkalemia?	European guidelines reserve binders for recurrent hyperkalemia despite RAASi optimization ^[533]^D5	In the US, some centers start binders to enable RAASi up-titration ^[546]^D5^[554]^D5	Moderate-Consensus	Use binders as an enabling strategy, not a first-line; monitor for hypokalemia

Pearl: The most common cause of hyperkalemia in CKD is iatrogenic: discontinuing RAASi after an episode of hyperkalemia increases mortality, instead, maintain RAASi and add a potassium binder to preserve the cardiorenal benefit ^[528]^B2b.

The transition to dialysis access and modality (covered next) often occurs against this backdrop of persistent electrolyte and acid-base derangements; timely preparation minimizes peridialytic complications.

Key Therapies for Hyperkalemia and Metabolic Acidosis in CKD

Condition	Intervention	Key Evidence	Safety Considerations
Hyperkalemia (K ≥5.5 mmol/L)	Sodium zirconium cyclosilicate 5-15 g daily	Maintained normokalemia in 74% at 12 months ^[419]^A1b	Hypokalemia 3% vs 1.4% ^[419]^A1b
Hyperkalemia (K ≥5.1 mmol/L)	Patiromer 8.4 g daily	Mean K decrease -1.01±0.03 mmol/L at 4 weeks ^[430]^C4	Constipation 11%, hypokalemia 3% ^[430]^C4
Metabolic acidosis (HCO₃ <22 mEq/L)	Sodium bicarbonate 0.5-1.0 g TID, titrated	Improved eGFR (SMD 0.33) and reduced hospitalizations (OR 0.37) ^[476]^A1a	Increased systolic BP (SMD 0.10) ^[476]^A1a
Metabolic acidosis (HCO₃ 12-20 mEq/L)	Veverimer 6 g daily	Normalized HCO₃ in 63% vs 38% at week 52 ^[537]^A1b	No serious AE excess ^[537]^A1b

Renal Replacement Therapy, Dialysis Access & Transplantation

▸RRT should be initiated based on clinical indications (uremic symptoms, refractory volume overload, hyperkalemia, acidosis) rather than a fixed eGFR threshold; the IDEAL trial showed no benefit to early start.
▸The KDOQI 2019 Life-Plan concept emphasizes individualized vascular access planning, with AVF preferred but not mandated; patient-specific factors determine the optimal access.
▸Kidney transplantation offers the best survival and quality of life; pre-emptive living donor transplantation is the ideal, but access disparities exist by sex, race, and socioeconomic status.

Rx Drug of Choice: For dialysis patients with atrial fibrillation requiring anticoagulation, apixaban 2.5 mg twice daily is an appropriate choice, avoiding vitamin K antagonists due to increased bleeding risk and labile INRs [266].

HY High Yield: The KDOQI 2019 Life-Plan integrates vascular access choice with the patient's overall clinical trajectory, including transplant candidacy; it prioritizes AVF but allows AVG if fistula maturation is unlikely [416].

When progressive CKD reaches stage 5 and the medical of fluid, electrolyte, and acid-base disturbances described in the preceding section is no longer sufficient, renal replacement therapy (RRT) becomes necessary. The KDIGO 2024 guideline recommends initiating RRT when eGFR falls to 15-20 mL/min/1.73 m² together with uremic symptoms, refractory volume overload, hyperkalemia, or acidosis, rather than at a fixed eGFR threshold (practice point) ^[289]^A1c. Earlier initiation based solely on eGFR does not improve outcomes; the IDEAL trial showed no survival benefit with planned early start (eGFR 10-14 vs 5-7 mL/min/1.73 m²) ^[261]^D5.

Modality Selection

Modality choice, hemodialysis (HD), peritoneal dialysis (PD), or kidney transplantation, should be guided by patient preference, medical suitability, and available resources, ideally discussed in a dedicated transition clinic ^[607]^D5. A comparison of key features is provided in Table 1.

Feature	Hemodialysis (HD)	Peritoneal Dialysis (PD)	Kidney Transplantation
Setting	In-center or home (home HD)	Home	Surgical procedure
Vascular/access	AVF, AVG, or CVC	PD catheter	Living or deceased donor
Frequency	3-4 sessions/week, 3-5 hours each	Daily, 4-5 exchanges (CAPD) or overnight cycler (APD)	Once
Survival	Reference	Similar to HD in adjusted analyses (DOPPS) ^[596]^B2b	Best survival; 44 years shorter life expectancy vs general population ^[318]^D5
Quality of life	Variable; intradialytic fatigue common	Greater autonomy, but peritonitis risk	Marked improvement in cognitive function and physical health ^[614]^D5
Key limitation	Vascular access complications; hemodynamic instability	Peritonitis, catheter malfunction, UF failure	Donor organ scarcity; lifelong immunosuppression

Table 1: Comparison of renal replacement therapy modalities.

Dialysis Access

The KDOQI 2019 Clinical Practice Guideline for Vascular Access ^[416]^A1c introduces the concept of an end-stage kidney disease Life-Plan: a personalized, dynamic strategy that considers the patient's expected clinical trajectory, vascular anatomy, and preferences. Arteriovenous fistula (AVF) remains the preferred HD access owing to lower infection and thrombosis rates compared with arteriovenous grafts (AVG) and central venous catheters (CVC) ^[416]^A1c. However, the rigid "Fistula First" approach has been tempered by evidence that AVF has a higher primary failure rate (up to 40%) and a longer maturation time, leading to prolonged catheter dependence ^[603]^D5. The KDOQI 2019 guideline recommends an individualized decision that weighs the likelihood of AVF maturation against the risks of catheter-associated bacteremia and central vein stenosis ^[416]^A1c. For PD, catheter insertion should be performed at least 2 weeks before planned use to allow wound healing and reduce leak risk. The target for CVC use should be <10% of prevalent HD patients ^[416]^A1c.

Kidney Transplantation

Kidney transplantation is the definitive RRT, offering the best survival and quality of life. The KDIGO 2024 guideline emphasizes pre-emptive transplantation (transplant before dialysis initiation) when possible, which avoids the morbidity and mortality associated with dialysis ^[289]^A1c. Living donor kidney transplantation (LDKT) is preferred to deceased donor transplantation; the CONVINCE trial (high-dose hemodiafiltration vs high-flux HD) showed a survival benefit for convective therapy, but transplantation far exceeds any dialysis modality in outcomes ^[592]^A1b. Unfortunately, access to transplantation varies by sex, race, and socioeconomic status. Women are less likely to be referred and placed on the waiting list despite longer survival after transplant ^[363]^D5^[609]^D5. The KDOQI 2019 Life-Plan should include transplantation as the primary goal, with dialysis as a bridge.

Monitoring Dialysis Adequacy

For HD, the KDOQI 2015 guideline recommends a target single-pool Kt/V ≥1.2 per session, with a minimum delivered dose of Kt/V 1.2 (strong recommendation, moderate-quality evidence) ^[417]^A1c. For PD, a total weekly Kt/V ≥1.7 is recommended (practice point) ^[417]^A1c. Regular assessment of volume status, blood pressure, and symptoms is essential.

Controversies

Question	Position A	Position B	Strength	Implication
Timing of dialysis initiation	KDIGO 2024, initiate based on symptoms, not a fixed eGFR threshold ^[289]^A1c	IDEAL trial, no benefit to early start (eGFR 10-14 vs 5-7) ^[261]^D5	Strong (trial vs guideline)	Avoid premature dialysis; monitor closely as eGFR declines below 15
AVF vs AVG as first access	KDOQI 2019, AVF preferred, but individualize based on predicted maturation ^[416]^A1c	Historical "Fistula First", AVF for all unless contraindicated ^[603]^D5	Moderate (guideline update)	Prolonged catheter use with marginal AVF is harmful; AVG may be superior in some patients

Pearl: The RRT Life-Plan should begin early in CKD stage 4, integrating vascular access planning and pre-emptive transplant evaluation; the optimal dialysis dose for HD remains Kt/V ≥1.2 per session, but no fixed eGFR threshold triggers dialysis initiation ^[289]^A1c^[416]^A1c.

History and Evolution of Treatment

▸The therapeutic paradigm for CKD has shifted from delaying progression to achieving remission, driven by SGLT2 inhibitors, GLP-1 receptor agonists, and nonsteroidal MRAs, with additive benefits from combination therapy.
▸Key trials that redefined standard care: CREDENCE (canagliflozin HR 0.70), DAPA-CKD (dapagliflozin HR 0.61; NNT 19), EMPA-KIDNEY (empagliflozin HR 0.72), FLOW (semaglutide HR 0.76), FIDELIO-DKD (finerenone HR 0.82), and CONFIDENCE (additive UACR reduction with finerenone+empagliflozin).
▸Several previously common approaches have been abandoned: routine urate-lowering for CKD progression, high hemoglobin targets, and RAS inhibitor discontinuation in advanced CKD (STOP ACEi showed no benefit).

While renal replacement therapy sustains life after kidney failure, the true breakthrough of the past two decades has been upstream, fundamentally altering the trajectory of earlier chronic kidney disease (CKD) and shifting the goal from delaying inevitable progression to achieving sustained remission ^[120]^D5.

The RAASi Foundation

Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers were the first class to demonstrate renoprotection beyond blood pressure lowering. The SPRINT CKD subgroup ^[87]^A1b showed that targeting a systolic blood pressure <120 mm Hg reduced all-cause death by 28% (HR 0.72; 95% CI 0.53-0.99) without increasing the primary kidney outcome. SHARP ^[386]^A1b demonstrated that plus reduced major atherosclerotic events in CKD (rate ratio 0.83; 95% CI 0.74-0.94;) but did not slow kidney function decline. The STOP ACEi trial ^[98]^A1b answered a longstanding question: among patients with advanced CKD (eGFR <30 mL/min/1.73 m²), discontinuing RAS inhibitors did not improve eGFR at 3 years (difference -0.7 mL/min/1.73 m²; 95% CI -2.5 to 1.0) and trended toward more end-stage kidney disease events (HR 1.28; 95% CI 0.99-1.65). RAASi remains the backbone of therapy but is no longer the sole pillar.

The SGLT2i Revolution

The CREDENCE trial ^[96]^A1b first proved that 100 mg daily reduced the risk of kidney failure and cardiovascular events in type 2 diabetes with albuminuric CKD (primary outcome HR 0.70; 95% CI 0.59-0.82; P=0.00001). DAPA-CKD ^[93]^A1b extended this to non-diabetic CKD, showing 10 mg reduced the primary composite, sustained ≥50% eGFR decline, end-stage kidney disease, or kidney/cardiovascular death, by 39% (HR 0.61; 95% CI 0.51-0.72; P<0.001; NNT 19). EMPA-KIDNEY ^[92]^A1b enrolled the broadest population, including patients with eGFR as low as 20 mL/min/1.73 m², and found 10 mg reduced kidney disease progression or cardiovascular death by 28% (HR 0.72; 95% CI 0.64-0.82; P<0.001). Benefits were consistent across CKD stage 4 ^[86]^A1b, immunoglobulin A nephropathy ^[81]^A1b, and focal segmental glomerulosclerosis ^[629]^B2b. An initial reversible eGFR dip was not associated with worse long-term outcomes ^[90]^A1b, and post-trial follow-up confirmed that the cardiorenal benefits persist for up to 12 months after study drug discontinuation ^[97]^A1b.

GLP-1 Receptor Agonists

The FLOW trial ^[91]^A1b demonstrated that 1.0 mg weekly reduced major kidney disease events, a composite of kidney failure, ≥50% eGFR decline, or kidney/cardiovascular death, by 24% (HR 0.76; 95% CI 0.66-0.88; P=0.0003) and slowed annual eGFR decline by 1.16 mL/min/1.73 m². A meta-analysis of 13 RCTs confirmed that GLP-1 receptor agonists reduced major adverse cardiovascular events by 16% and the composite kidney endpoint by 21%, with benefits additive to SGLT2 inhibitors (interaction P=0.41) ^[409]^A1a.

Nonsteroidal Mineralocorticoid Receptor Antagonists and Combination Therapy

Finerenone reduced CKD progression in type 2 diabetes in FIDELIO-DKD ^[94]^A1b (primary outcome HR 0.82; 95% CI 0.73-0.93; P=0.001) and cardiovascular events in FIGARO-DKD ^[204]^A1b (HR 0.87; 95% CI 0.76-0.98; P=0.03). The CONFIDENCE trial ^[95]^A1b showed that simultaneously initiating finerenone and empagliflozin reduced the urinary albumin-to-creatinine ratio 29% more than finerenone alone (ratio 0.71; 95% CI 0.61-0.82; P<0.001) and 32% more than empagliflozin alone (ratio 0.68; 95% CI 0.59-0.79; P<0.001). Other emerging combinations include the endothelin A receptor antagonist zibotentan plus dapagliflozin, which reduced UACR by **** (P<0.0001) in ZENITH-CKD ^[104]^A1b, and balcinrenone plus dapagliflozin, which showed additive albuminuria reduction in MIRO-CKD ^[387]^A1b.

Anemia: From High Targets to Oral Alternatives

High hemoglobin targets were abandoned after trials demonstrated harm. The 2026 KDIGO guideline ^[378]^A1c recommends a target of 10-12 g/dL. Oral hypoxia-inducible factor prolyl hydroxylase inhibitors provided an alternative to injectable . Roxadustat raised hemoglobin by 1.75 g/dL versus 0.40 g/dL in non-dialysis-dependent CKD and reduced transfusion risk by 63% (HR 0.37; 95% CI 0.30-0.44) ^[478]^A1b, with comparable safety to epoetin alfa in dialysis ^[425]^A1b. Vadadustat ^[423]^A1b and daprodustat ^[297]^A1b were noninferior to standard therapy. Intravenous ferric carboxymaltose targeting a ferritin of 400-600 μg/L delayed the need for other anemia compared with oral iron (HR 0.65; 95% CI 0.44-0.95; P=0.026) ^[434]^A1b.

What Was Abandoned

Routine urate lowering to slow CKD progression has not been supported by trial evidence. Febuxostat did not improve eGFR slope over placebo in stage 3 CKD (difference 0.70 mL/min/1.73 m² per year; 95% CI -0.21 to 1.62; P=0.1) ^[199]^A1b, and the urate transporter‑1 inhibitor verinurad combined with allopurinol did not reduce albuminuria in the SAPPHIRE trial ^[626]^A1b. High-dose erythropoiesis-stimulating agent targets have been replaced by conservative thresholds ^[378]^A1c.

The Remission Paradigm

The cumulative effect of these advances, SGLT2 inhibitors, GLP-1 receptor agonists, nonsteroidal MRAs, and emerging anti-inflammatory therapies such as ziltivekimab, which reduced high-sensitivity C-reactive protein by up to 92% ^[481]^A1b, has changed what is possible. KDIGO 2025 ^[120]^D5 now defines success as remission: an eGFR slope <1 mL/min/1.73 m² per year or normalization of albuminuria with a normal eGFR. The field has moved from managing the inevitable to rewriting the natural history.

Pearl: The transition from RAASi monotherapy to combined SGLT2i, GLP-1 RA, and nonsteroidal MRA produces additive albuminuria reductions of 30-50%, making remission (eGFR slope <1 mL/min/1.73 m² per year) an increasingly attainable standard of care ^[120]^D5.

Complications (Chronic Systemic Sequelae)

▸Anemia management has evolved from ESAs to HIF-PHIs (roxadustat 70 mg thrice weekly), which improve iron homeostasis and reduce transfusion needs.
▸Cardiovascular disease is the leading cause of death; SGLT2 inhibitors (e.g., dapagliflozin 10 mg, empagliflozin 10 mg) reduce CKD progression by 28-39 % and mortality across all stages.
▸Cognitive impairment and frailty affect up to 70 % of patients with advanced CKD yet are underrecognized; kidney transplantation can improve cognitive function.

HY High Yield: Uremic pruritus affects ~40 % of hemodialysis patients; first-line therapy includes emollients and gabapentin, with κ-opioid receptor agonists (nalfurafine) reserved for refractory cases [302].

The therapeutic milestones described above have transformed outcomes, yet CKD continues to exact a heavy toll through a stereotyped cascade of systemic complications that span nearly every organ system. Anemia, mineral bone disease, cardiovascular disease, cognitive decline, uremic pruritus, and coagulation disorders are the dominant sequelae, each requiring specific beyond core nephroprotective therapy ^[52]^D5^[261]^D5.

Anemia

Anemia in CKD results from erythropoietin deficiency, iron dysregulation driven by hepcidin, and chronic inflammation ^[216]^D5^[663]^D5. The KDIGO 2026 guideline recommends treating when hemoglobin falls below 10 g/dL ^[378]^A1c. Traditional therapy combines (ESAs) with intravenous iron; ferric carboxymaltose targeting ferritin 400-600 µg/L delayed the need for ESAs (HR 0.65 vs oral iron) in FIND-CKD ^[434]^A1b. The oral HIF-PHI roxadustat 70 mg thrice weekly raised hemoglobin by 1.75 g/dL over placebo in nondialysis-dependent CKD (weeks 28-52) and reduced transfusion risk by 63 % (HR 0.37) ^[478]^A1b^[332]^B2b. Daprodustat was noninferior to darbepoetin alfa in hemodialysis patients, maintaining hemoglobin at 10.9 g/dL ^[297]^A1b. All agents require monitoring for and thrombotic events ^[664]^A1c.

Cardiovascular Disease

Cardiovascular death is the leading cause of mortality in CKD, driven by shared risk factors, uremic toxins, volume overload, and mineral-metabolic derangements ^[168]^D5. Intensive systolic BP lowering to <120 mm Hg reduced all-cause death (HR 0.72) in SPRINT CKD participants ^[87]^A1b. SGLT2 inhibitors profoundly reduce cardiorenal risk: 10 mg decreased CKD progression or cardiovascular death by 28 % (HR 0.72) in EMPA-KIDNEY ^[92]^A1b; 10 mg cut the primary composite by 39 % (HR 0.61) in DAPA-CKD ^[93]^A1b; and 100 mg reduced end-stage kidney disease by 32 % (HR 0.68) in CREDENCE ^[96]^A1b. GLP-1 receptor agonists provide additional benefit: 1.0 mg weekly lowered major kidney disease events by 24 % (HR 0.76) in FLOW ^[91]^A1b. The nonsteroidal MRA finerenone (10 or 20 mg daily) improved CKD outcomes in FIDELIO-DKD (HR 0.82 for kidney composite) and reduced cardiovascular events in FIGARO-DKD (HR 0.87) ^[94]^A1b^[204]^A1b; combination with empagliflozin produced additive albuminuria reduction ^[95]^A1b.

Cognitive Impairment and Frailty

Cognitive impairment affects 30-70 % of patients with advanced CKD, chiefly manifesting as executive dysfunction and memory deficits driven by cerebrovascular disease and uremic neurotoxin accumulation ^[133]^D5^[170]^D5. Frailty is strongly associated with cognitive decline (OR 3.13 ^[667]^B2a), and both conditions worsen with dialysis initiation but may improve after kidney transplantation ^[133]^D5. Prediction models for cognitive impairment in hemodialysis populations report AUCs of 0.745-0.918, though all have high risk of bias ^[393]^B2a.

Other Systemic Complications

Complication	Frequency in CKD 5/HD	Key Features	Management Summary
Uremic pruritus	~40 % on HD ^[302]^D5	Intense itching, poor QoL	Emollients first line; gabapentin; κ-opioid agonists (nalfurafine) ^[302]^D5
CKD-MBD	>80 % on dialysis	Hyperphosphatemia,	Phosphate binders, active vitamin D, calcimimetics ^[261]^D5
Coagulopathy	Common	Bleeding tendency + paradoxical thrombosis	Correct anemia, cautious anticoagulation ^[665]^D5
Sleep disorders	50-80 %	Restless legs syndrome, OSA, insomnia	Iron replacement, CPAP for OSA, dopamine agonists for RLS ^[280]^D5
Uremic encephalopathy	Advanced CKD	Confusion, asterixis, coma	Trial of dialysis; exclude other causes ^[437]^D5
Gut microbiome alteration	Universal in ESRD ^[661]^B3b	Uremic toxin production	Plant-dominant diet, prebiotics ^[135]^D5^[661]^B3b

Pearl: The transition to dialysis does not abolish systemic complications, pruritus, cognitive decline, and cardiovascular risk often persist; kidney transplantation remains the only intervention that durably reverses most uremic sequelae ^[133]^D5^[302]^D5^[614]^D5.

Systemic Complications of Advanced CKD

Complication	Frequency in CKD 5 or HD	Key Features	Management Summary
Uremic pruritus	~40% on HD ^[302]^D5	Intense itching, poor QoL	Emollients; gabapentin; κ-opioid agonists (nalfurafine) ^[302]^D5
CKD-MBD	>80% on dialysis ^[52]^D5	Hyperphosphatemia, secondary hyperparathyroidism	Phosphate binders; active vitamin D; calcimimetics ^[261]^D5
Coagulopathy	Common ^[665]^D5	Bleeding tendency + paradoxical thrombosis	Correct anemia; cautious anticoagulation ^[665]^D5
Sleep disorders	50-80% ^[280]^D5	Restless legs syndrome, OSA, insomnia	Iron replacement; CPAP for OSA; dopamine agonists for RLS ^[280]^D5
Uremic encephalopathy	Advanced CKD ^[437]^D5	Confusion, asterixis, coma	Trial of dialysis; exclude other causes ^[437]^D5
Gut microbiome alteration	Universal in ESRD ^[661]^B3b	Uremic toxin production	Plant-dominant diet; prebiotics ^[135]^D5^[661]^B3b

Prognosis and Natural History

▸eGFR and albuminuria are multiplicative, independent predictors of mortality and ESKD; no threshold exists for albuminuria risk.
▸AKI confers an 8.8-fold increased hazard for subsequent CKD, with a graded dose-response by AKI severity.
▸SGLT2 inhibitors, GLP-1 receptor agonists, and nonsteroidal mineralocorticoid antagonists can reduce progression risk by 20-40%, and dapagliflozin delays time to kidney failure by ~6.6 years.

HY High Yield: An acute eGFR drop of ≤30% within 2 weeks of starting an SGLT2 inhibitor is a benign hemodynamic effect, not a sign of kidney injury, it is associated with slower long-term eGFR decline (-1.58 vs -2.48 mL/min/1.73 m²/year) and does not require drug discontinuation [90].

! Warning: Discontinuation of renin-angiotensin system inhibitors in advanced CKD (eGFR <30 mL/min/1.73 m²) does not improve eGFR and may increase the risk of ESKD (HR 1.28; 95% CI 0.99-1.65); continuation remains the recommended strategy [98].

The systemic complications described above both reflect and accelerate the underlying disease trajectory; understanding the natural history of CKD, its rate of progression, predictors, and outcomes, is essential for prognostication and treatment planning.

Key Predictors of Progression

The risk of kidney failure and death is driven principally by two measures: estimated glomerular filtration rate (eGFR) and albuminuria. In a landmark meta-analysis of 1,555,332 participants, eGFR <60 mL/min/1.73 m² and a urinary albumin-to-creatinine ratio (UACR) ≥10 mg/g were independent predictors of all-cause and cardiovascular mortality, with no threshold effect for albuminuria ^[10]^B2a^[339]^D5. Compared with an eGFR of 95 mL/min/1.73 m², the adjusted hazard ratio for all-cause mortality at eGFR 45 mL/min/1.73 m² was 1.57, and at eGFR 15 mL/min/1.73 m² it was 3.14 ^[10]^B2a. The relationship between albuminuria and mortality is log-linear: a UACR of 33.9 mg/g confers a mortality hazard of 2.22 compared with 0.6 mg/g ^[10]^B2a. These risks are multiplicative, a patient with both low eGFR and high albuminuria faces dramatically higher adverse event rates ^[115]^B2a.

The rate of eGFR decline (the “slope”) has been validated as a surrogate endpoint for clinical trials. A meta-analysis of 47 randomized trials involving 60,620 participants demonstrated that treatment effects on total eGFR slope over 3 years predict clinical benefit (composite of doubling of creatinine, eGFR <15 mL/min/1.73 m², or ESKD) with a median R² of 0.97 (95% Bayesian credible interval 0.78-1.00) ^[80]^A1a^[101]^D5. A treatment effect of ≥0.75 mL/min/1.73 m²/year on total slope confers at least 96% probability of predicting a clinical benefit ^[80]^A1a.

AKI-to-CKD Transition

Acute kidney injury is not an isolated event, it substantially increases the long-term risk of CKD and ESKD. In a meta-analysis of 13 cohort studies, AKI conferred an adjusted hazard ratio of 8.8 (95% CI 3.1-25.5) for new or progressive CKD, and the risk of ESKD was tripled (adjusted HR 3.1; 95% CI 1.9-5.0) compared with patients without AKI ^[197]^B2a. A broader meta-analysis of 82 studies confirmed a graded risk: increasing severity of AKI corresponded to higher rates of CKD (HR 2.67), ESKD (HR 4.81), and death (HR 1.80; 95% CI 1.61-2.02) ^[418]^B2a. The pooled incidence of CKD after AKI was 17.76 cases per 100 person-years vs 7.59 in controls ^[418]^B2a.

Contemporary Outcomes with Guideline-Directed Therapy

Landmark trials have redefined the prognosis of CKD. In DAPA-CKD, treatment with 10 mg daily reduced the primary composite outcome (≥50% eGFR decline, ESKD, or kidney or cardiovascular death) from 14.5% to 9.2% over a median of 2.4 years (HR 0.61; 95% CI 0.51-0.72; NNT = 19) ^[93]^A1b. The renal-specific composite was reduced even further (HR 0.56; 95% CI 0.45-0.68) ^[93]^A1b. Emulating long-term treatment, a partitioned survival model predicted that dapagliflozin delays mean time to kidney failure by 6.6 years (from 18.5 to 25.2 years) compared with standard therapy ^[106]^A1b. EMPA-KIDNEY demonstrated similar benefits across a broad eGFR range, with a primary outcome event (progression of kidney disease or cardiovascular death) occurring in 13.1% vs 16.9% over 2 years (HR 0.72; 95% CI 0.64-0.82; NNT = 26) ^[92]^A1b. In the FLOW trial, 1.0 mg weekly reduced the risk of major kidney disease events by 24% (HR 0.76; 95% CI 0.66-0.88) in patients with type 2 diabetes and CKD ^[91]^A1b. Finerenone added to maximum renin-angiotensin system blockade reduced progression in FIDELIO-DKD by 18% (HR 0.82; 95% CI 0.73-0.93; NNT = 30) ^[94]^A1b.

The Emerging Goal of Remission

The clinical paradigm is shifting from “slowing progression” to “achieving remission.” Remission can be defined as an eGFR slope <1 mL/min/1.73 m²/year or normalization of albuminuria with preserved eGFR ^[120]^D5. With early detection and combination therapy, such as an SGLT2 inhibitor, GLP-1 receptor agonist, and nonsteroidal mineralocorticoid receptor antagonist, this outcome is increasingly attainable, particularly in glomerular diseases and early ^[120]^D5^[210]^A1b^[509]^B3b.

Sex, Lifestyle, and Modifying Factors

Men with CKD have a higher risk of progression (subhazard ratio 1.14 vs women) and steeper eGFR decline, driven partly by higher baseline albuminuria and primary kidney disease type ^[241]^B2b. Modifiable lifestyle factors, higher vegetable intake (OR 0.79), moderate alcohol (RR 0.86), and higher potassium intake (OR 0.78), each associate with lower odds of incident CKD, while smoking (OR 1.18) and high salt intake (OR 1.21) increase risk ^[84]^B2a. Hyperuricemia (time-averaged SUA ≥360 μmol/L) independently predicts faster renal decline in type 2 diabetes ^[275]^B3b.

Mortality and the Cardiovascular Link

Most patients with CKD die from cardiovascular disease before reaching kidney failure. The 5-year mortality for a 65-year-old with stage 4 CKD approached 45% in registry analyses, versus approximately 10% in age-matched controls ^[52]^D5. The relative risk of death rises exponentially as eGFR falls below 60 mL/min/1.73 m², and albuminuria amplifies that risk at every eGFR level ^[10]^B2a^[115]^B2a.

Pearl: The single most actionable prognostic tool is the combination of eGFR and UACR, a patient with eGFR 45 mL/min/1.73 m² and UACR >300 mg/g carries a mortality risk over 3-fold higher than a patient with eGFR >60 and normal albuminuria, and contemporary therapies can delay kidney failure by >6 years when initiated early ^[10]^B2a^[93]^A1b^[106]^A1b.

Contemporary Trial Effects on CKD Progression

Intervention	Hazard Ratio (95% CI) for Kidney Composite	Absolute Risk Reduction	NNT	Follow-up
Dapagliflozin 10 mg	0.61 (0.51-0.72) ^[93]^A1b	5.3%	19	2.4 years
Empagliflozin 10 mg	0.72 (0.64-0.82) ^[92]^A1b	3.8%	26	2.0 years
Semaglutide 1.0 mg weekly	0.76 (0.66-0.88) ^[91]^A1b	4.5%*	22	3.4 years
Finerenone (FIDELIO-DKD)	0.82 (0.73-0.93) ^[94]^A1b	3.3%	30	2.6 years
Canagliflozin 100 mg	0.70 (0.59-0.82) ^[96]^A1b	1.8 per 100 pt-yr	-	2.6 years

*Estimated from published event rates in FLOW trial (331/1767 vs 410/1766).

Special Populations

▸In children with CKD, use the bedside Schwartz formula (0.413 × height/Scr) for eGFR; GH therapy at 0.045-0.05 mg/kg/day is indicated for persistent growth failure.
▸Pregnancy in CKD increases preeclampsia risk (OR 10.36) but does not accelerate CKD progression; ACEi/ARB are contraindicated.
▸In elderly CKD patients, intensive BP lowering to <120 mm Hg reduces cardiovascular events and mortality, but frailty and comorbidity require individualized targets.

HY High Yield: For children with CKD, use the bedside Schwartz formula: eGFR = 0.413 × (height in cm / serum creatinine in mg/dL). For GH therapy, dose is 0.045-0.05 mg/kg/day subcutaneously [144][422].

Having examined the natural history and prognosis of CKD across its stages, the clinician must now navigate the distinct challenges posed by specific patient populations, pediatrics, pregnancy, the elderly, and the immunocompromised, where renal physiology, drug clearance, and diagnostic targets diverge sharply.

Pediatrics

Children with CKD present unique diagnostic and therapeutic challenges. GFR should be estimated using the bedside Schwartz formula: eGFR (mL/min/1.73 m²) = 0.413 × (height in cm / serum creatinine in mg/dL) ^[144]^C4. The full CKiD equation incorporating cystatin C, BUN, and sex improves accuracy but is not always available ^[144]^C4. Growth failure is common; recombinant human growth hormone (GH) is recommended at 0.045-0.05 mg/kg/day subcutaneously for children with stage 3-5 CKD and persistent height <3rd percentile with height velocity <25th percentile, once other correctable causes are addressed ^[422]^A1c. GH therapy is deferred until 1 year post-transplant in the absence of spontaneous catch-up growth ^[422]^A1c. requires weight-based dosing of IV iron preparations; oral iron may be inadequate in advanced CKD ^[143]^D5.

Pregnancy

Pregnancy in women with CKD carries substantially elevated risks for both mother and fetus. A meta-analysis of 23 studies reported odds ratios for preeclampsia of 10.36 (95% CI 6.28-17.09), premature delivery 5.72 (3.26-10.03), and small-for-gestational-age/low birth weight 4.85 (3.03-7.76) ^[477]^B2a. Importantly, pregnancy itself did not accelerate CKD progression over a median follow-up of 5 years (OR 0.96, 95% CI 0.69-1.35) ^[477]^B2a; however, subgroup analysis showed higher preeclampsia risk with macroproteinuria compared with microproteinuria ^[477]^B2a. Antihypertensive during pregnancy must avoid ACE inhibitors and ARBs due to fetotoxicity; labetalol, nifedipine, and methyldopa are preferred. Low-dose (81-150 mg daily) is recommended from 12 weeks to reduce preeclampsia risk. Delivery planning involves multidisciplinary care with maternal-fetal medicine and nephrology, aiming for term delivery if safely achievable.

Elderly

CKD in octogenarians is highly prevalent, approximately 51% have an eGFR <60 mL/min/1.73 m² by the CKD-EPI creatinine equation ^[351]^C4. The association with cardiovascular disease is strongest when GFR is estimated using cystatin C-based equations, suggesting that creatinine-based estimates may misclassify risk in the very old ^[351]^C4. Intensive BP lowering to a systolic target <120 mm Hg, as tested in SPRINT, reduced major cardiovascular events (HR 0.81, 95% CI 0.63-1.05) and all-cause mortality (HR 0.72, 95% CI 0.53-0.99) in participants with CKD, without excess kidney harm ^[87]^A1b. However, frailty, polypharmacy, and cognitive impairment demand individualized targets; emerging therapies such as SGLT2 inhibitors and GLP-1 receptor agonists appear safe and effective in older populations ^[458]^D5. Nutritional guidance recommends a total calcium intake of 800-1000 mg/day (not exceeding 1500 mg/day) to maintain neutral calcium balance ^[455]^A1c.

Immunocompromised Patients

Immunocompromised populations, including kidney transplant recipients and hematopoietic cell transplant (HCT) survivors, are at high risk for CKD. After HCT, approximately 16.6% of survivors develop CKD, with a mean eGFR decline of 24.5 mL/min/1.73 m² at 24 months; the decline is greater after allogeneic HCT (ΔeGFR -40.0 vs -18.6 for autologous) ^[109]^B2a. Acute renal failure in the first 100 days post-HCT is a strong predictor (adjusted OR 32.8, 95% CI 4.3-250) ^[287]^B2b. In kidney transplant recipients, cystatin C-based equations do not reliably confirm stage 3A CKD and should not replace measured GFR ^[108]^C4. Calcineurin inhibitor nephrotoxicity requires regular monitoring of drug levels and eGFR, with dose reduction or conversion to mTOR inhibitors considered when GFR declines progressively. Prevention of further nephrotoxic insults, avoiding NSAIDs, minimizing contrast exposure, and treating aggressively, is paramount.

Pearl: In pregnant women with CKD, preeclampsia risk is tenfold higher, but pregnancy does not accelerate CKD progression; low-dose aspirin from 12 weeks and avoidance of ACEi/ARB are the cornerstones of management ^[477]^B2a.

Controversies and Guideline Disagreement

Question	Position A	Position B	Strength	Implication
BP target in elderly CKD	SPRINT: SBP <120 mm Hg reduces CV events and death ^[87]^A1b	KDIGO 2024: target <130 mm Hg with individualized approach ^[289]^A1c	Moderate	For fit elderly, intensive target may be beneficial; for frail, higher target is safer.
Growth hormone after transplant	ESPN: start GH 1 year post-transplant if no catch-up growth ^[422]^A1c	Some centers initiate earlier based on growth velocity	Weak	Delay GH to avoid rejection risk; consensus is to wait at least 1 year.

Pregnancy Outcomes in CKD: Meta-Analysis Odds Ratios

Outcome	Odds Ratio (95% CI)
Preeclampsia	10.36 (6.28-17.09)
Premature delivery	5.72 (3.26-10.03)
Small for gestational age / low birth weight	4.85 (3.03-7.76)
Cesarean section	2.67 (2.01-3.54)
Failure of pregnancy	1.80 (1.03-3.13)

*Data from Zhang et al. ^[477]^B2a

Prevention, Screening & Surveillance

▸Case-finding in high-risk populations (diabetes, hypertension, age >60, family history) using eGFR + UACR is cost-effective and endorsed by KDIGO/ISN; universal population screening is not recommended in low-prevalence settings.
▸ELISA-based IGRA is preferred over tuberculin skin testing for latent TB screening in ESKD, as it correlates more strongly with clinical risk factors.
▸Patient education on nephrotoxin avoidance (NSAIDs, Chinese herbal medicines, certain decongestants) and lifestyle modification (diet, exercise, smoking cessation) is a cornerstone of primary prevention.

HY High Yield: IGRA (ELISA-based) is the test of choice for latent TB screening in CKD/ESKD over TST, it is more specific and correlates better with clinical risk factors [684].

Having addressed the unique challenges of CKD in pregnancy, the focus now shifts to the prevention strategies and screening frameworks that can curb the global burden at the population level. The paradigm has shifted from inevitable progression to achievable remission, making early detection and preventive therapy essential ^[120]^D5.

Primary Prevention

Modifiable lifestyle factors consistently predict CKD incidence. In a meta-analysis of 104 studies with 2.7 million participants, higher vegetable intake (OR 0.79, 95% CI 0.70-0.90) and moderate alcohol consumption (RR 0.86, 95% CI 0.79-0.93) reduced risk, while current smoking (OR 1.18, 95% CI 1.10-1.27) and high salt intake (OR 1.21, 95% CI 1.06-1.38) increased it ^[84]^B2a. Physical activity lowered odds by 18% (OR 0.82, 95% CI 0.69-0.98) ^[84]^B2a. Regular users of Chinese herbal medicines had a 20% higher risk of developing CKD (OR 1.20) ^[11]^B2b. Nephrotoxin avoidance, NSAIDs, herbal nephrotoxins, and careful periprocedural hydration reduce contrast-associated AKI; infusion of 1000 mL IV fluids starting ≥1 hour before contrast is adequate (lower volumes <964 mL were associated with higher risk) ^[688]^B2b. In patients with eGFR <30 mL/min/1.73 m², the risk of contrast-induced nephropathy is high and requires proactive measures ^[704]^D5. Magnesium oxide slowed coronary artery calcification progression in stage 3-4 CKD (median change 11.3% vs 39.5%), though larger trials are needed ^[686]^A1b. SGLT2 inhibitors may reduce AKI risk ^[505]^D5.

Screening: Who, When, and How

Kidney disease remains asymptomatic until late stages, yet awareness in affected populations is <4% ^[11]^B2b. The 2025 World Kidney Day statement calls for case-finding in high-risk populations: individuals with diabetes, , cardiovascular disease, obesity, family history of kidney disease, age >60 years, or belonging to high-risk ethnic groups ^[693]^D5. Screening combines serum creatinine (eGFR) and urine albumin-to-creatinine ratio (UACR); both are required because eGFR alone misses early CKD (stages 1-2) where albuminuria signals risk ^[718]^D5. Cost-effectiveness is favorable in diabetic and hypertensive populations (ICER $5,298-$73,939/QALY for proteinuria screening) ^[683]^B2a. Population-based screening in the general public may be cost-effective only in regions with higher CKD incidence and more effective drug therapy ^[683]^B2a. Machine learning models such as MERWACS, using non-invasive parameters, can prioritize individuals for definitive testing (AUROC 0.68-0.73) ^[734]^B2b. Pharmacy-based point-of-care screening (HbA1c, lipids, UACR) is feasible and addresses underdetection ^[730]^C4.

Table 1: Screening Recommendations for CKD

Population	Test	Interval	Source
Diabetes (type 1/2)	eGFR + UACR	Annually	KDIGO 2024
Hypertension	eGFR + UACR	Annually	KDIGO 2024
Family history of kidney disease	eGFR + UACR	Every 1-3 years	Expert consensus
Age >60 years	eGFR + UACR	Every 1-2 years	USPSTF (individualize)
Established CVD	eGFR + UACR	Annually	ACC/AHA
High-risk ethnic groups	eGFR + UACR	Every 1-3 years	ISN

Genetic Screening and Hereditary Disease

The KDIGO 2021 Controversies Conference urged clinicians to "think genetic", obtain a three-generation family history, note age of onset, look for extrarenal features, and consider genetic testing ^[196]^A1c. For monogenic causes (e.g., , , ), cascade testing of at-risk relatives is recommended ^[196]^A1c. Genetic findings inform surveillance, therapy choice, and family planning.

Structured Surveillance

Once CKD is diagnosed, surveillance of eGFR and UACR at intervals determined by stage and progression risk is standard (see Section 6, Staging). The 2017 ISN action plan advocates for integrating CKD surveillance into national NCD monitoring systems, including routine albuminuria and creatinine measurement in all large health surveys ^[228]^D5. Registries for dialysis and transplantation are common in high-income countries but scarce for non-dialysis CKD ^[230]^B2c; global efforts are underway to close this gap ^[605]^D5.

Vaccination in CKD

Patients with CKD are at increased risk for infections and vaccine hyporesponsiveness. For latent tuberculosis screening, ELISA-based interferon-gamma release assays (IGRA) are preferred over tuberculin skin testing (TST) in ESKD because they are more strongly associated with clinical risk factors (ROR 4.29 for radiologic TB evidence; ROR 3.36 for TB contact) ^[684]^B2a. Patients with CKD stage 5 have a 3.7-fold higher risk of severe despite booster vaccination ^[721]^B2b. A single dose of RSV prefusion F vaccine induced strong antibody and CD4 T-cell responses in kidney transplant recipients and patients with CKD, though responses were blunted in lung transplant recipients and early post-transplant ^[729]^B2b. Influenza, pneumococcal (PCV20), and hepatitis B vaccines should be administered; doses may need adjustment (e.g., high-dose influenza, double-dose hepatitis B) ^[716]^D5. Vaccination remains underused in this population and should be actively promoted.

Patient Education

Empowering patients, including knowledge of nephrotoxin avoidance (NSAIDs, , decongestants such as pseudoephedrine ^[193]^C4), medication adherence, blood pressure and glucose self-monitoring, and lifestyle modification, is central to living well with kidney disease ^[692]^D5. Public awareness campaigns should communicate that early-stage CKD is asymptomatic and that simple tests (eGFR, UACR) can detect it, enabling timely intervention.

Controversies and Guideline Disagreement

Question	Position A	Position B	Strength	Implication
Population screening vs case-finding	General population screening is not cost-effective in high-income countries (USPSTF 2019) ^[707]^D5	Screening in high-prevalence regions (Southeast Asia, Aboriginal communities) may be justified ^[702]^D5	Moderate	Policy should be context-dependent; low-resource settings should target high-risk groups with opportunistic testing
eGFR vs UACR alone for screening	UACR is essential for detecting early CKD (stages 1-2) ^[714]^D5	eGFR alone is adequate for identifying stage 3+ CKD ^[683]^B2a	Strong	Both tests should be used in combination; UACR adds prognostic value for cardiovascular risk

Pearl: Patient education on nephrotoxin avoidance (NSAIDs, Chinese herbal medicines, certain decongestants) and lifestyle modification (diet, exercise, smoking cessation) is a cornerstone of primary prevention.

References

[1]
Torres VE, Ahn C, Barten TRM et al.. “KDIGO 2025 clinical practice guideline for the evaluation, management, and treatment of autosomal dominant polycystic kidney disease (ADPKD): executive summary.” Kidney international (2025). PMID: 39848746 ↗
L1GUIDELINECited in: Definition, Classification and Nomenclature, Epidemiology, Etiology and Risk Factors, Staging and Risk Stratification (KDIGO), Long-term and Definitive Management, History and Evolution of Treatment, Complications (Chronic Systemic Sequelae), Special Populations & Pregnancy
[2]
Eckardt KU, Alper SL, Antignac C et al.. “Autosomal dominant tubulointerstitial kidney disease: diagnosis, classification, and management--A KDIGO consensus report.” Kidney international (2015). PMID: 25738250 ↗
L5GUIDELINECited in: Definition, Classification and Nomenclature, Staging and Risk Stratification (KDIGO), History and Evolution of Treatment
[3]
Inker LA, Astor BC, Fox CH et al.. “KDOQI US commentary on the 2012 KDIGO clinical practice guideline for the evaluation and management of CKD.” American journal of kidney diseases : the official journal of the National Kidney Foundation (2014). PMID: 24647050 ↗
L5GUIDELINECited in: Definition, Classification and Nomenclature, Diagnosis and Workup, Staging and Risk Stratification (KDIGO), Prognosis and Natural History
[4]
Yang C, Tonelli M, James MT et al.. “Incidence and Adverse Outcomes of Acute Kidney Disease: A Systematic Review and Meta-Analysis.” American journal of kidney diseases : the official journal of the National Kidney Foundation (2025). PMID: 40609854 ↗
L2SR_OBSCited in: Definition, Classification and Nomenclature
[5]
Pickering JW, James MT, Palmer SC. “Acute kidney injury and prognosis after cardiopulmonary bypass: a meta-analysis of cohort studies.” American journal of kidney diseases : the official journal of the National Kidney Foundation (2014). PMID: 25445101 ↗
L2SR_OBSCited in: Definition, Classification and Nomenclature
[6]
Vlasschaert ME, Bejaimal SA, Hackam DG et al.. “Validity of administrative database coding for kidney disease: a systematic review.” American journal of kidney diseases : the official journal of the National Kidney Foundation (2011). PMID: 21184918 ↗
L2SR_OBSCited in: Definition, Classification and Nomenclature
[7]
Grams ME, Plantinga LC, Hedgeman E et al.. “Validation of CKD and related conditions in existing data sets: A systematic review.” American journal of kidney diseases : the official journal of the National Kidney Foundation (2010). PMID: 20692079 ↗
L2SR_OBSCited in: Definition, Classification and Nomenclature
[8]
. “Impact of diabetes on the effects of sodium glucose co-transporter-2 inhibitors on kidney outcomes: collaborative meta-analysis of large placebo-controlled trials.” Lancet (London, England) (2022). PMID: 36351458 ↗
L1SR_OBSCited in: Definition, Classification and Nomenclature, Long-term and Definitive Management, Fluid, Electrolyte & Acid-Base Disorders, Complications (Chronic Systemic Sequelae), Prognosis and Natural History
[9]
Nagler EV, Webster AC, Vanholder R et al.. “Antidepressants for depression in stage 3-5 chronic kidney disease: a systematic review of pharmacokinetics, efficacy and safety with recommendations by European Renal Best Practice (ERBP).” Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association (2012). PMID: 22859791 ↗
L2SR_OBSCited in: Definition, Classification and Nomenclature, Staging and Risk Stratification (KDIGO)
[10]
Matsushita K, van der Velde M, Astor BC et al.. “Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: a collaborative meta-analysis.” Lancet (London, England) (2010). PMID: 20483451 ↗
L2SR_OBSCited in: Definition, Classification and Nomenclature, Pathophysiology and Mechanism, Epidemiology, Etiology and Risk Factors, Clinical Presentation, Diagnosis and Workup, Staging and Risk Stratification (KDIGO), Prognosis and Natural History, Special Populations & Pregnancy
[11]
Wen CP, Cheng TY, Tsai MK et al.. “All-cause mortality attributable to chronic kidney disease: a prospective cohort study based on 462 293 adults in Taiwan.” Lancet (London, England) (2008). PMID: 18586172 ↗
L2COHORTCited in: Definition, Classification and Nomenclature, Prevention, Screening & Surveillance
[12]
Dahl NK, August P, Besse W et al.. “KDOQI US Commentary on the KDIGO 2025 Clinical Practice Guideline for the Evaluation, Management, and Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD).” American journal of kidney diseases : the official journal of the National Kidney Foundation (2026). PMID: 41864657 ↗
L5GUIDELINECited in: Definition, Classification and Nomenclature
[13]
Bansal A, Chonchol M. “Metabolic dysfunction-associated kidney disease: pathogenesis and clinical manifestations.” Kidney international (2025). PMID: 40379048 ↗
L5REVIEW_NARRATIVECited in: Definition, Classification and Nomenclature, Pathophysiology and Mechanism, Epidemiology, Etiology and Risk Factors, Clinical Presentation, Long-term and Definitive Management, Complications (Chronic Systemic Sequelae), Prognosis and Natural History
[14]
Lameire NH, Levin A, Kellum JA et al.. “Harmonizing acute and chronic kidney disease definition and classification: report of a Kidney Disease: Improving Global Outcomes (KDIGO) Consensus Conference.” Kidney international (2021). PMID: 34252450 ↗
L5OTHERCited in: Definition, Classification and Nomenclature, Epidemiology, Etiology and Risk Factors, Clinical Presentation, Staging and Risk Stratification (KDIGO), Acute Management
[15]
Trimarchi H, Barratt J, Cattran DC et al.. “Oxford Classification of IgA nephropathy 2016: an update from the IgA Nephropathy Classification Working Group.” Kidney international (2017). PMID: 28341274 ↗
L5REVIEW_NARRATIVECited in: Definition, Classification and Nomenclature, Pathophysiology and Mechanism, Clinical Presentation, Diagnosis and Workup, Staging and Risk Stratification (KDIGO), Long-term and Definitive Management, Prognosis and Natural History
[16]
Fouque D, Kalantar-Zadeh K, Kopple J et al.. “A proposed nomenclature and diagnostic criteria for protein-energy wasting in acute and chronic kidney disease.” Kidney international (2007). PMID: 18094682 ↗
L5OTHERCited in: Definition, Classification and Nomenclature, Staging and Risk Stratification (KDIGO)
[17]
Levey AS, Eckardt KU, Dorman NM et al.. “Nomenclature for kidney function and disease: report of a Kidney Disease: Improving Global Outcomes (KDIGO) Consensus Conference.” Kidney international (2020). PMID: 32409237 ↗
L5OTHERCited in: Definition, Classification and Nomenclature, Pathophysiology and Mechanism, Diagnosis and Workup, Prognosis and Natural History
[18]
Moe S, Drüeke T, Cunningham J et al.. “Definition, evaluation, and classification of renal osteodystrophy: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO).” Kidney international (2006). PMID: 16641930 ↗
L5OTHERCited in: Definition, Classification and Nomenclature
[19]
Chan EY, Marks SD. “Childhood-onset lupus nephritis: unique aspects and challenges in management.” Kidney international (2025). PMID: 40846176 ↗
L5REVIEW_NARRATIVECited in: Definition, Classification and Nomenclature
[20]
Sourij H, Aberer F, Antlanger M et al.. “[Diabetic kidney disease (Update 2026) : Guidelines in a collaboration of the Austrian Diabetes Association and the Austrian Society of Nephrology].” Wiener klinische Wochenschrift (2026). PMID: 42162473 ↗
L1GUIDELINECited in: Definition, Classification and Nomenclature
[21]
Farris AB, Alpers CE. “What is the best way to measure renal fibrosis?: A pathologist's perspective.” Kidney international supplements (2014). PMID: 26312144 ↗
L5REVIEW_NARRATIVECited in: Definition, Classification and Nomenclature
[22]
Agarwal R, Martinez-Castelao A, Wiecek A et al.. “The lingering dilemma of arterial pressure in CKD: what do we know, where do we go?” Kidney international supplements (2011). PMID: 25018898 ↗
L5REVIEW_NARRATIVECited in: Definition, Classification and Nomenclature
[23]
Bazeley JW, Wish JB. “Recent and Emerging Therapies for Iron Deficiency in Anemia of CKD: A Review.” American journal of kidney diseases : the official journal of the National Kidney Foundation (2021). PMID: 34758368 ↗
L5REVIEW_NARRATIVECited in: Definition, Classification and Nomenclature, Staging and Risk Stratification (KDIGO), Long-term and Definitive Management, Fluid, Electrolyte & Acid-Base Disorders
[24]
Vellanki K, Hou S. “Menopause in CKD.” American journal of kidney diseases : the official journal of the National Kidney Foundation (2018). PMID: 29530509 ↗
L5REVIEW_NARRATIVECited in: Definition, Classification and Nomenclature, Epidemiology, Etiology and Risk Factors, Acute Management, Renal Replacement Therapy, Dialysis Access & Transplantation
[25]
Walther CP, Nambi V, Hanania NA et al.. “Diagnosis and Management of Pulmonary Hypertension in Patients With CKD.” American journal of kidney diseases : the official journal of the National Kidney Foundation (2020). PMID: 32199709 ↗
L5REVIEW_NARRATIVECited in: Definition, Classification and Nomenclature
[26]
Fay KS, Cohen DL. “Resistant Hypertension in People With CKD: A Review.” American journal of kidney diseases : the official journal of the National Kidney Foundation (2020). PMID: 32712185 ↗
L5REVIEW_NARRATIVECited in: Definition, Classification and Nomenclature
[27]
Chung J, Yu A, Robinson C et al.. “Ambulatory hypertension and left ventricular hypertrophy in pediatric chronic kidney disease: a systematic review and meta-analysis.” European journal of pediatrics (2026). PMID: 42283864 ↗
L1SR_OBSCited in: Definition, Classification and Nomenclature
[28]
Cianciolo G, Vetrano D, Tomassetti A et al.. “Efficacy of ARNIs on hard renal outcomes in heart failure with and without chronic kidney disease: when endpoint definition matters-an updated meta-analysis.” ESC heart failure (2026). PMID: 42247581 ↗
L1SR_OBSCited in: Definition, Classification and Nomenclature
[29]
Bedram LG, Canziani MEF, Bittencourt ALML et al.. “Renal osteodystrophy in pediatric patients. A systematic review and meta-analysis.” Bone (2026). PMID: 42081926 ↗
L1SR_OBSCited in: Definition, Classification and Nomenclature
[30]
George C, Okpechi IG, Motshwari DD et al.. “Prevalence of CKD Among Adults in Africa: A Systematic Review and Meta-Analysis.” American journal of kidney diseases : the official journal of the National Kidney Foundation (2026). PMID: 42061737 ↗
L1SR_OBSCited in: Definition, Classification and Nomenclature
[31]
Fu H, Liu H, Han Y et al.. “Risk association and diagnostic value of body roundness index for cardiovascular-kidney-metabolic-related outcomes: a systematic review and meta-analysis.” Frontiers in endocrinology (2026). PMID: 42058788 ↗
L2SR_OBSCited in: Definition, Classification and Nomenclature
[32]
Delanaye P, Jager KJ, Bökenkamp A et al.. “CKD: A Call for an Age-Adapted Definition.” Journal of the American Society of Nephrology : JASN (2019). PMID: 31506289 ↗
L5REVIEW_NARRATIVECited in: Definition, Classification and Nomenclature
[33]
Bauer C, Melamed ML, Hostetter TH. “Staging of chronic kidney disease: time for a course correction.” Journal of the American Society of Nephrology : JASN (2008). PMID: 18385419 ↗
L5REVIEW_NARRATIVECited in: Definition, Classification and Nomenclature, Staging and Risk Stratification (KDIGO)
[34]
Kiberd B. “The chronic kidney disease epidemic: stepping back and looking forward.” Journal of the American Society of Nephrology : JASN (2006). PMID: 17035615 ↗
L5REVIEW_NARRATIVECited in: Definition, Classification and Nomenclature
[35]
Agarwal R, Pappas MK, Sinha AD. “Masked Uncontrolled Hypertension in CKD.” Journal of the American Society of Nephrology : JASN (2015). PMID: 26163421 ↗
L2OTHERCited in: Definition, Classification and Nomenclature
[36]
Waikar SS, Bonventre JV. “Creatinine kinetics and the definition of acute kidney injury.” Journal of the American Society of Nephrology : JASN (2009). PMID: 19244578 ↗
L5OTHERCited in: Definition, Classification and Nomenclature
[37]
Anderson S, Eldadah B, Halter JB et al.. “Acute kidney injury in older adults.” Journal of the American Society of Nephrology : JASN (2011). PMID: 21209252 ↗
L5OTHERCited in: Definition, Classification and Nomenclature
[38]
Chailimpamontree W, Dmitrienko S, Li G et al.. “Probability, predictors, and prognosis of posttransplantation glomerulonephritis.” Journal of the American Society of Nephrology : JASN (2009). PMID: 19193778 ↗
L2OTHERCited in: Definition, Classification and Nomenclature
[39]
Limdi NA, Beasley TM, Baird MF et al.. “Kidney function influences warfarin responsiveness and hemorrhagic complications.” Journal of the American Society of Nephrology : JASN (2009). PMID: 19225037 ↗
L2OTHERCited in: Definition, Classification and Nomenclature
[40]
Gurgel do Amaral MS, Reijneveld SA, Geboers B et al.. “Low Health Literacy is Associated with the Onset of CKD during the Life Course.” Journal of the American Society of Nephrology : JASN (2021). PMID: 33766810 ↗
L2OTHERCited in: Definition, Classification and Nomenclature
[41]
Inker LA, Schmid CH, Tighiouart H et al.. “Estimating glomerular filtration rate from serum creatinine and cystatin C.” The New England journal of medicine (2012). PMID: 22762315 ↗
L2OTHERCited in: Definition, Classification and Nomenclature, Pathophysiology and Mechanism, Clinical Presentation, Diagnosis and Workup, Staging and Risk Stratification (KDIGO)
[42]
Braam B, Taler SJ, Rahman M et al.. “Recognition and Management of Resistant Hypertension.” Clinical journal of the American Society of Nephrology : CJASN (2016). PMID: 27895136 ↗
L5REVIEW_NARRATIVECited in: Definition, Classification and Nomenclature
[43]
Cerdá J, Lameire N, Eggers P et al.. “Epidemiology of acute kidney injury.” Clinical journal of the American Society of Nephrology : CJASN (2008). PMID: 18216347 ↗
L5OTHERCited in: Definition, Classification and Nomenclature, Prevention, Screening & Surveillance
[44]
Hernandez JD, Wesseling K, Pereira R et al.. “Technical approach to iliac crest biopsy.” Clinical journal of the American Society of Nephrology : CJASN (2008). PMID: 18988702 ↗
L5REVIEW_NARRATIVECited in: Definition, Classification and Nomenclature
[45]
Parfrey PS, Block GA, Correa-Rotter R et al.. “Lessons Learned from EVOLVE for Planning of Future Randomized Trials in Patients on Dialysis.” Clinical journal of the American Society of Nephrology : CJASN (2015). PMID: 26614406 ↗
L5REVIEW_NARRATIVECited in: Definition, Classification and Nomenclature
[46]
Zappitelli M, Parikh CR, Kaufman JS et al.. “Acute Kidney Injury and Risk of CKD and Hypertension after Pediatric Cardiac Surgery.” Clinical journal of the American Society of Nephrology : CJASN (2020). PMID: 32948644 ↗
L2OTHERCited in: Definition, Classification and Nomenclature
[47]
Johal M, Levin A. “Vitamin D and parathyroid hormone in general populations: understandings in 2009 and applications to chronic kidney disease.” Clinical journal of the American Society of Nephrology : CJASN (2009). PMID: 19556377 ↗
L5REVIEW_NARRATIVECited in: Definition, Classification and Nomenclature
[48]
Tong A, Levey AS, Eckardt KU et al.. “Patient and Caregiver Perspectives on Terms Used to Describe Kidney Health.” Clinical journal of the American Society of Nephrology : CJASN (2020). PMID: 32586923 ↗
L4OTHERCited in: Definition, Classification and Nomenclature
[49]
Piccoli GB, Conijn A, Consiglio V et al.. “Pregnancy in dialysis patients: is the evidence strong enough to lead us to change our counseling policy?” Clinical journal of the American Society of Nephrology : CJASN (2009). PMID: 19965547 ↗
L2REVIEW_NARRATIVECited in: Definition, Classification and Nomenclature
[50]
Lefebvre CE, Filion KB, Reynier P et al.. “Primary Care Prescriptions of Potentially Nephrotoxic Medications in Children with CKD.” Clinical journal of the American Society of Nephrology : CJASN (2019). PMID: 31831578 ↗
L2OTHERCited in: Definition, Classification and Nomenclature
[51]
Afrifa J, Asum K, Fosu SAB et al.. “Prevalence and Causes of Acute Kidney Injury and Chronic Kidney Disease in Ghana: A Systematic Review and Meta-Analysis.” Journal of epidemiology and global health (2026). PMID: 41793628 ↗
L2SR_OBSCited in: Definition, Classification and Nomenclature
[52]
Webster AC, Nagler EV, Morton RL et al.. “Chronic Kidney Disease.” Lancet (London, England) (2016). PMID: 27887750 ↗
L5REVIEW_NARRATIVECited in: Definition, Classification and Nomenclature, Pathophysiology and Mechanism, Epidemiology, Etiology and Risk Factors, Clinical Presentation, Diagnosis and Workup, Long-term and Definitive Management, Complications (Chronic Systemic Sequelae), Prognosis and Natural History
[53]
Levey AS, Coresh J. “Chronic kidney disease.” Lancet (London, England) (2011). PMID: 21840587 ↗
L5REVIEW_NARRATIVECited in: Definition, Classification and Nomenclature, Pathophysiology and Mechanism, Epidemiology, Etiology and Risk Factors, Clinical Presentation, Diagnosis and Workup, Complications (Chronic Systemic Sequelae), Prognosis and Natural History
[54]
Eckardt KU, Coresh J, Devuyst O et al.. “Evolving importance of kidney disease: from subspecialty to global health burden.” Lancet (London, England) (2013). PMID: 23727165 ↗
L5REVIEW_NARRATIVECited in: Definition, Classification and Nomenclature, Acute Management
[55]
Fraser WD. “Hyperparathyroidism.” Lancet (London, England) (2009). PMID: 19595349 ↗
L5REVIEW_NARRATIVECited in: Definition, Classification and Nomenclature, Diagnosis and Workup, Prevention, Screening & Surveillance
[56]
Lameire NH, Bagga A, Cruz D et al.. “Acute kidney injury: an increasing global concern.” Lancet (London, England) (2013). PMID: 23727171 ↗
L5REVIEW_NARRATIVECited in: Definition, Classification and Nomenclature, Acute Management, Renal Replacement Therapy, Dialysis Access & Transplantation
[57]
Khunti K, Zaccardi F, Mehta R et al.. “Epidemiology of cardiometabolic multiple long-term conditions.” Lancet (London, England) (2026). PMID: 42259340 ↗
L5REVIEW_NARRATIVECited in: Definition, Classification and Nomenclature
[58]
Banerjee D, Ali MA, Wang AY et al.. “Acute kidney injury in acute heart failure-when to worry and when not to worry?” Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association (2024). PMID: 38944413 ↗
L5REVIEW_NARRATIVECited in: Definition, Classification and Nomenclature, Acute Management
[59]
Ortiz A, Mattace-Raso F, Soler MJ et al.. “Ageing meets kidney disease.” Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association (2023). PMID: 35768068 ↗
L5OTHERCited in: Definition, Classification and Nomenclature, Pathophysiology and Mechanism, Long-term and Definitive Management, Complications (Chronic Systemic Sequelae), Prognosis and Natural History
[60]
Halbritter J, Figueres L, Van Eerde AM et al.. “Chronic Kidney Disease of unexplained cause (CKDx): a consensus statement by the Genes & Kidney Working Group of the ERA.” Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association (2025). PMID: 40459916 ↗
L1OTHERCited in: Definition, Classification and Nomenclature, Clinical Presentation
[61]
Symonides B, Lewandowski J, Małyszko J. “Resistant hypertension in dialysis.” Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association (2023). PMID: 36898677 ↗
L5REVIEW_NARRATIVECited in: Definition, Classification and Nomenclature, Acute Management, Renal Replacement Therapy, Dialysis Access & Transplantation, Special Populations & Pregnancy
[62]
Kanbay M, Basile C, Battaglia Y et al.. “Shared decision making in elderly patients with kidney failure.” Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association (2024). PMID: 37742209 ↗
L5REVIEW_NARRATIVECited in: Definition, Classification and Nomenclature
[63]
Simms RJ, Ong AC. “How simple are 'simple renal cysts'?” Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association (2014). PMID: 25165175 ↗
L5REVIEW_NARRATIVECited in: Definition, Classification and Nomenclature
[64]
Ruggiero B, Vivarelli M, Gianviti A et al.. “Outcome of childhood-onset full-house nephropathy.” Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association (2017). PMID: 27270291 ↗
L2OTHERCited in: Definition, Classification and Nomenclature
[65]
Delanaye P, Pottel H, Cavalier E et al.. “Diagnostic standard: assessing glomerular filtration rate.” Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association (2024). PMID: 37950562 ↗
L5REVIEW_NARRATIVECited in: Definition, Classification and Nomenclature, Pathophysiology and Mechanism, Diagnosis and Workup
[66]
Schefold JC, Filippatos G, Hasenfuss G et al.. “Heart failure and kidney dysfunction: epidemiology, mechanisms and management.” Nature reviews. Nephrology (2016). PMID: 27573728 ↗
L5REVIEW_NARRATIVECited in: Definition, Classification and Nomenclature, Acute Management
[67]
Prowle JR, Forni LG, Bell M et al.. “Postoperative acute kidney injury in adult non-cardiac surgery: joint consensus report of the Acute Disease Quality Initiative and PeriOperative Quality Initiative.” Nature reviews. Nephrology (2021). PMID: 33976395 ↗
L1REVIEW_NARRATIVECited in: Definition, Classification and Nomenclature, Staging and Risk Stratification (KDIGO), Prevention, Screening & Surveillance
[68]
Wang TY, Wang RF, Bu ZY et al.. “Association of metabolic dysfunction-associated fatty liver disease with kidney disease.” Nature reviews. Nephrology (2022). PMID: 35013596 ↗
L5REVIEW_NARRATIVECited in: Definition, Classification and Nomenclature
[69]
Zoccali C, Vanholder R, Massy ZA et al.. “The systemic nature of CKD.” Nature reviews. Nephrology (2017). PMID: 28435157 ↗
L5REVIEW_NARRATIVECited in: Definition, Classification and Nomenclature, Staging and Risk Stratification (KDIGO)
[70]
Kellum JA, Ronco C, Bellomo R. “Conceptual advances and evolving terminology in acute kidney disease.” Nature reviews. Nephrology (2021). PMID: 33712812 ↗
L5REVIEW_NARRATIVECited in: Definition, Classification and Nomenclature
[71]
Romagnani P, Chan JCN, Anders HJ. “Multifactorial chronic kidney disease and the kidney capacity-workload balance.” Nature reviews. Nephrology (2026). PMID: 41491877 ↗
L5REVIEW_NARRATIVECited in: Definition, Classification and Nomenclature
[72]
Freedman BI, Cohen AH. “Hypertension-attributed nephropathy: what's in a name?” Nature reviews. Nephrology (2015). PMID: 26553514 ↗
L5REVIEW_NARRATIVECited in: Definition, Classification and Nomenclature, History and Evolution of Treatment
[73]
Eddy S, Mariani LH, Kretzler M. “Integrated multi-omics approaches to improve classification of chronic kidney disease.” Nature reviews. Nephrology (2020). PMID: 32424281 ↗
L5REVIEW_NARRATIVECited in: Definition, Classification and Nomenclature
[74]
Perazella MA, Coca SG. “Three feasible strategies to minimize kidney injury in 'incipient AKI'.” Nature reviews. Nephrology (2013). PMID: 23649020 ↗
L5REVIEW_NARRATIVECited in: Definition, Classification and Nomenclature
[75]
Cohen RA, Oraichi D, Mwakingwe-Omari A et al.. “Age-specific Risk of Herpes Zoster in Immunocompetent Adults ≥18 Years-of-age-A Retrospective Cohort Study in the United States.” Open forum infectious diseases (2026). PMID: 41959657 ↗
L2COHORTCited in: Definition, Classification and Nomenclature
[76]
Gill JS. “Potential advantages and limitations of applying the chronic kidney disease classification to kidney transplant recipients.” American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons (2006). PMID: 17061995 ↗
L5REVIEW_NARRATIVECited in: Definition, Classification and Nomenclature, Epidemiology, Etiology and Risk Factors, Clinical Presentation, Staging and Risk Stratification (KDIGO), Renal Replacement Therapy, Dialysis Access & Transplantation, Complications (Chronic Systemic Sequelae)
[77]
Barri Y, Parker T, Kaplan B et al.. “Primum non Nocere: is chronic kidney disease staging appropriate in living kidney transplant donors?” American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons (2009). PMID: 19344458 ↗
L5OTHERCited in: Definition, Classification and Nomenclature, Staging and Risk Stratification (KDIGO)
[78]
Ladin K, Rodrigue JR, Hanto DW. “Framing disparities along the continuum of care from chronic kidney disease to transplantation: barriers and interventions.” American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons (2009). PMID: 19344460 ↗
L5OTHERCited in: Definition, Classification and Nomenclature
[79]
Shlipak MG, Tummalapalli SL, Boulware LE et al.. “The case for early identification and intervention of chronic kidney disease: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference.” Kidney international (2020). PMID: 33127436 ↗
L5GUIDELINECited in: Pathophysiology and Mechanism, Diagnosis and Workup, Prognosis and Natural History
[80]
Inker LA, Heerspink HJL, Tighiouart H et al.. “GFR Slope as a Surrogate End Point for Kidney Disease Progression in Clinical Trials: A Meta-Analysis of Treatment Effects of Randomized Controlled Trials.” Journal of the American Society of Nephrology : JASN (2019). PMID: 31292197 ↗
L1SR_MA_RCTCited in: Pathophysiology and Mechanism, Diagnosis and Workup, Long-term and Definitive Management, Complications (Chronic Systemic Sequelae), Prognosis and Natural History
[81]
Wheeler DC, Toto RD, Stefánsson BV et al.. “A pre-specified analysis of the DAPA-CKD trial demonstrates the effects of dapagliflozin on major adverse kidney events in patients with IgA nephropathy.” Kidney international (2021). PMID: 33878338 ↗
L1RCTCited in: Pathophysiology and Mechanism, Diagnosis and Workup, Long-term and Definitive Management, History and Evolution of Treatment, Prognosis and Natural History
[82]
Chen JY, Hsu TW, Liu JH et al.. “Kidney and Cardiovascular Outcomes Among Patients With CKD Receiving GLP-1 Receptor Agonists: A Systematic Review and Meta-Analysis of Randomized Trials.” American journal of kidney diseases : the official journal of the National Kidney Foundation (2025). PMID: 39863261 ↗
L1SR_OBSCited in: Pathophysiology and Mechanism, Diagnosis and Workup, Long-term and Definitive Management, Complications (Chronic Systemic Sequelae), Prognosis and Natural History
[83]
Xie X, Liu Y, Perkovic V et al.. “Renin-Angiotensin System Inhibitors and Kidney and Cardiovascular Outcomes in Patients With CKD: A Bayesian Network Meta-analysis of Randomized Clinical Trials.” American journal of kidney diseases : the official journal of the National Kidney Foundation (2015). PMID: 26597926 ↗
L1SR_OBSCited in: Pathophysiology and Mechanism, Long-term and Definitive Management, Complications (Chronic Systemic Sequelae)
[84]
Kelly JT, Su G, Zhang L et al.. “Modifiable Lifestyle Factors for Primary Prevention of CKD: A Systematic Review and Meta-Analysis.” Journal of the American Society of Nephrology : JASN (2020). PMID: 32868398 ↗
L2SR_OBSCited in: Pathophysiology and Mechanism, Epidemiology, Etiology and Risk Factors, Diagnosis and Workup, Long-term and Definitive Management, Complications (Chronic Systemic Sequelae), Prognosis and Natural History, Prevention, Screening & Surveillance
[85]
Wilkinson TJ, Tarca B, Lightfoot CJ et al.. “Prescribing Physical Activity and Exercise for People with CKD: A Practical Guide by the Global Renal Exercise Network.” Clinical journal of the American Society of Nephrology : CJASN (2025). PMID: 40085159 ↗
L1GUIDELINECited in: Pathophysiology and Mechanism, Clinical Presentation, Diagnosis and Workup, History and Evolution of Treatment
[86]
Chertow GM, Vart P, Jongs N et al.. “Effects of Dapagliflozin in Stage 4 Chronic Kidney Disease.” Journal of the American Society of Nephrology : JASN (2021). PMID: 34272327 ↗
L1RCTCited in: Pathophysiology and Mechanism, Epidemiology, Etiology and Risk Factors, Clinical Presentation, Diagnosis and Workup, Long-term and Definitive Management, History and Evolution of Treatment, Complications (Chronic Systemic Sequelae), Prognosis and Natural History, Special Populations & Pregnancy
[87]
Cheung AK, Rahman M, Reboussin DM et al.. “Effects of Intensive BP Control in CKD.” Journal of the American Society of Nephrology : JASN (2017). PMID: 28642330 ↗
L1RCTCited in: Pathophysiology and Mechanism, Epidemiology, Etiology and Risk Factors, Diagnosis and Workup, Long-term and Definitive Management, History and Evolution of Treatment, Complications (Chronic Systemic Sequelae), Prognosis and Natural History, Special Populations & Pregnancy
[88]
Provenzano M, Puchades MJ, Garofalo C et al.. “Albuminuria-Lowering Effect of Dapagliflozin, Eplerenone, and Their Combination in Patients with Chronic Kidney Disease: A Randomized Crossover Clinical Trial.” Journal of the American Society of Nephrology : JASN (2022). PMID: 35440501 ↗
L1RCTCited in: Pathophysiology and Mechanism, Clinical Presentation, Diagnosis and Workup, Staging and Risk Stratification (KDIGO), Long-term and Definitive Management, Fluid, Electrolyte & Acid-Base Disorders, History and Evolution of Treatment, Complications (Chronic Systemic Sequelae), Prognosis and Natural History
[89]
Beetham KS, Krishnasamy R, Stanton T et al.. “Effect of a 3-Year Lifestyle Intervention in Patients with Chronic Kidney Disease: A Randomized Clinical Trial.” Journal of the American Society of Nephrology : JASN (2021). PMID: 34893535 ↗
L1RCTCited in: Pathophysiology and Mechanism, Epidemiology, Etiology and Risk Factors, Long-term and Definitive Management, History and Evolution of Treatment, Special Populations & Pregnancy
[90]
Jongs N, Chertow GM, Greene T et al.. “Correlates and Consequences of an Acute Change in eGFR in Response to the SGLT2 Inhibitor Dapagliflozin in Patients with CKD.” Journal of the American Society of Nephrology : JASN (2022). PMID: 35977807 ↗
L1RCTCited in: Pathophysiology and Mechanism, Clinical Presentation, Diagnosis and Workup, Staging and Risk Stratification (KDIGO), Long-term and Definitive Management, History and Evolution of Treatment, Complications (Chronic Systemic Sequelae), Prognosis and Natural History
[91]
Perkovic V, Tuttle KR, Rossing P et al.. “Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes.” The New England journal of medicine (2024). PMID: 38785209 ↗
L1RCTCited in: Pathophysiology and Mechanism, Epidemiology, Etiology and Risk Factors, Diagnosis and Workup, Long-term and Definitive Management, History and Evolution of Treatment, Complications (Chronic Systemic Sequelae), Prognosis and Natural History, Special Populations & Pregnancy
[92]
Herrington WG, Staplin N, Wanner C et al.. “Empagliflozin in Patients with Chronic Kidney Disease.” The New England journal of medicine (2022). PMID: 36331190 ↗
L1RCTCited in: Pathophysiology and Mechanism, Diagnosis and Workup, Long-term and Definitive Management, History and Evolution of Treatment, Complications (Chronic Systemic Sequelae), Prognosis and Natural History
[93]
Heerspink HJL, Stefánsson BV, Correa-Rotter R et al.. “Dapagliflozin in Patients with Chronic Kidney Disease.” The New England journal of medicine (2020). PMID: 32970396 ↗
L1RCTCited in: Pathophysiology and Mechanism, Epidemiology, Etiology and Risk Factors, Diagnosis and Workup, Long-term and Definitive Management, History and Evolution of Treatment, Complications (Chronic Systemic Sequelae), Prognosis and Natural History, Special Populations & Pregnancy
[94]
Bakris GL, Agarwal R, Anker SD et al.. “Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes.” The New England journal of medicine (2020). PMID: 33264825 ↗
L1RCTCited in: Pathophysiology and Mechanism, Epidemiology, Etiology and Risk Factors, Clinical Presentation, Diagnosis and Workup, Staging and Risk Stratification (KDIGO), Long-term and Definitive Management, Fluid, Electrolyte & Acid-Base Disorders, History and Evolution of Treatment, Complications (Chronic Systemic Sequelae), Prognosis and Natural History, Special Populations & Pregnancy
[95]
Agarwal R, Green JB, Heerspink HJL et al.. “Finerenone with Empagliflozin in Chronic Kidney Disease and Type 2 Diabetes.” The New England journal of medicine (2025). PMID: 40470996 ↗
L1RCTCited in: Pathophysiology and Mechanism, Clinical Presentation, Diagnosis and Workup, Staging and Risk Stratification (KDIGO), Long-term and Definitive Management, Fluid, Electrolyte & Acid-Base Disorders, History and Evolution of Treatment, Complications (Chronic Systemic Sequelae), Prognosis and Natural History, Special Populations & Pregnancy
[96]
Perkovic V, Jardine MJ, Neal B et al.. “Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy.” The New England journal of medicine (2019). PMID: 30990260 ↗
L1RCTCited in: Pathophysiology and Mechanism, Epidemiology, Etiology and Risk Factors, Diagnosis and Workup, Long-term and Definitive Management, History and Evolution of Treatment, Complications (Chronic Systemic Sequelae), Prognosis and Natural History, Special Populations & Pregnancy
[97]
Herrington WG, Staplin N, Agrawal N et al.. “Long-Term Effects of Empagliflozin in Patients with Chronic Kidney Disease.” The New England journal of medicine (2024). PMID: 39453837 ↗
L1RCTCited in: Pathophysiology and Mechanism, Epidemiology, Etiology and Risk Factors, Clinical Presentation, Diagnosis and Workup, Long-term and Definitive Management, History and Evolution of Treatment, Complications (Chronic Systemic Sequelae), Prognosis and Natural History
[98]
Bhandari S, Mehta S, Khwaja A et al.. “Renin-Angiotensin System Inhibition in Advanced Chronic Kidney Disease.” The New England journal of medicine (2022). PMID: 36326117 ↗
L1RCTCited in: Pathophysiology and Mechanism, Diagnosis and Workup, Long-term and Definitive Management, History and Evolution of Treatment, Complications (Chronic Systemic Sequelae), Prognosis and Natural History
[99]
Packham DK, Rasmussen HS, Lavin PT et al.. “Sodium zirconium cyclosilicate in hyperkalemia.” The New England journal of medicine (2014). PMID: 25415807 ↗
L1RCTCited in: Pathophysiology and Mechanism, Acute Management, Long-term and Definitive Management, Fluid, Electrolyte & Acid-Base Disorders
[100]
Heerspink HJL, Birkenfeld AL, Cherney DZI et al.. “Finerenone in Type 1 Diabetes and Chronic Kidney Disease.” The New England journal of medicine (2026). PMID: 41780000 ↗
L1RCTCited in: Pathophysiology and Mechanism, Epidemiology, Etiology and Risk Factors, Clinical Presentation, Diagnosis and Workup, Staging and Risk Stratification (KDIGO), Fluid, Electrolyte & Acid-Base Disorders, Prognosis and Natural History
[101]
Levey AS, Gansevoort RT, Coresh J et al.. “Change in Albuminuria and GFR as End Points for Clinical Trials in Early Stages of CKD: A Scientific Workshop Sponsored by the National Kidney Foundation in Collaboration With the US Food and Drug Administration and European Medicines Agency.” American journal of kidney diseases : the official journal of the National Kidney Foundation (2019). PMID: 31473020 ↗
L5TRIAL_NONRANDOMCited in: Pathophysiology and Mechanism, Diagnosis and Workup, Staging and Risk Stratification (KDIGO), Long-term and Definitive Management, Complications (Chronic Systemic Sequelae), Prognosis and Natural History
[102]
Sarafidis P, Agarwal R, Pitt B et al.. “Outcomes with Finerenone in Participants with Stage 4 CKD and Type 2 Diabetes: A FIDELITY Subgroup Analysis.” Clinical journal of the American Society of Nephrology : CJASN (2023). PMID: 36927680 ↗
L1RCTCited in: Pathophysiology and Mechanism, Epidemiology, Etiology and Risk Factors, Diagnosis and Workup, Staging and Risk Stratification (KDIGO), Long-term and Definitive Management, Fluid, Electrolyte & Acid-Base Disorders, History and Evolution of Treatment, Complications (Chronic Systemic Sequelae), Prognosis and Natural History, Special Populations & Pregnancy
[103]
Heerspink HJL, Parving HH, Andress DL et al.. “Atrasentan and renal events in patients with type 2 diabetes and chronic kidney disease (SONAR): a double-blind, randomised, placebo-controlled trial.” Lancet (London, England) (2019). PMID: 30995972 ↗
L1RCTCited in: Pathophysiology and Mechanism, Long-term and Definitive Management, History and Evolution of Treatment, Prognosis and Natural History, Special Populations & Pregnancy
[104]
Heerspink HJL, Kiyosue A, Wheeler DC et al.. “Zibotentan in combination with dapagliflozin compared with dapagliflozin in patients with chronic kidney disease (ZENITH-CKD): a multicentre, randomised, active-controlled, phase 2b, clinical trial.” Lancet (London, England) (2023). PMID: 37931629 ↗
L1RCTCited in: Pathophysiology and Mechanism, Staging and Risk Stratification (KDIGO), History and Evolution of Treatment, Prognosis and Natural History, Special Populations & Pregnancy
[105]
Agarwal R, Green JB, Heerspink HJL et al.. “COmbinatioN effect of FInerenone anD EmpaglifloziN in participants with chronic kidney disease and type 2 diabetes using a UACR Endpoint (CONFIDENCE) trial: baseline clinical characteristics.” Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association (2025). PMID: 39916475 ↗
L4RCTCited in: Pathophysiology and Mechanism, Clinical Presentation, Diagnosis and Workup, Staging and Risk Stratification (KDIGO), Long-term and Definitive Management, History and Evolution of Treatment
[106]
McEwan P, Gabb PD, Davis JA et al.. “The long-term effects of dapagliflozin in chronic kidney disease: a time-to-event analysis.” Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association (2024). PMID: 38730538 ↗
L1RCTCited in: Pathophysiology and Mechanism, Diagnosis and Workup, Long-term and Definitive Management, History and Evolution of Treatment, Complications (Chronic Systemic Sequelae), Prognosis and Natural History
[107]
Wheeler DC, Stefansson BV, Batiushin M et al.. “The dapagliflozin and prevention of adverse outcomes in chronic kidney disease (DAPA-CKD) trial: baseline characteristics.” Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association (2020). PMID: 32862232 ↗
L4RCTCited in: Pathophysiology and Mechanism, Diagnosis and Workup, Long-term and Definitive Management, History and Evolution of Treatment, Prognosis and Natural History
[108]
Masson I, Maillard N, Cavalier E et al.. “KDIGO Guidelines and Kidney Transplantation: Is the Cystatin-C Based Recommendation Relevant?” American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons (2015). PMID: 25808194 ↗
L4GUIDELINECited in: Pathophysiology and Mechanism, Diagnosis and Workup, Staging and Risk Stratification (KDIGO), Renal Replacement Therapy, Dialysis Access & Transplantation, History and Evolution of Treatment, Prognosis and Natural History, Special Populations & Pregnancy
[109]
Ellis MJ, Parikh CR, Inrig JK et al.. “Chronic kidney disease after hematopoietic cell transplantation: a systematic review.” American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons (2008). PMID: 18925905 ↗
L2SR_OBSCited in: Pathophysiology and Mechanism, Epidemiology, Etiology and Risk Factors, Diagnosis and Workup, Renal Replacement Therapy, Dialysis Access & Transplantation, Prognosis and Natural History, Special Populations & Pregnancy
[110]
Heerspink HJL, Agarwal R, Bakris GL et al.. “Design and baseline characteristics of the Finerenone, in addition to standard of care, on the progression of kidney disease in patients with Non-Diabetic Chronic Kidney Disease (FIND-CKD) randomized trial.” Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association (2025). PMID: 38858818 ↗
L4TRIAL_NONRANDOMCited in: Pathophysiology and Mechanism, Long-term and Definitive Management, Complications (Chronic Systemic Sequelae), Prognosis and Natural History
[111]
Judge PK, Tuttle KR, Staplin N et al.. “The potential for improving cardio-renal outcomes in chronic kidney disease with the aldosterone synthase inhibitor vicadrostat (BI 690517): a rationale for the EASi-KIDNEY trial.” Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association (2025). PMID: 39533115 ↗
L5TRIAL_NONRANDOMCited in: Pathophysiology and Mechanism
[112]
Heerspink HJL, Stefansson BV, Chertow GM et al.. “Rationale and protocol of the Dapagliflozin And Prevention of Adverse outcomes in Chronic Kidney Disease (DAPA-CKD) randomized controlled trial.” Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association (2020). PMID: 32030417 ↗
L5TRIAL_NONRANDOMCited in: Pathophysiology and Mechanism, Diagnosis and Workup, Long-term and Definitive Management, Prognosis and Natural History
[113]
Cherney DZI, Belmar N, Bjornstad P et al.. “Rationale, design and baseline characteristics of REMODEL, a mechanism-of-action trial with semaglutide in people with type 2 diabetes and chronic kidney disease.” Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association (2025). PMID: 40608494 ↗
L4TRIAL_NONRANDOMCited in: Pathophysiology and Mechanism
[114]
Bakker WM, Heerspink HJL, Berger SP et al.. “Rationale and design of the Renal Lifecycle trial assessing the effect of dapagliflozin on cardiorenal outcomes in severe chronic kidney disease.” Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association (2025). PMID: 40053493 ↗
L5TRIAL_NONRANDOMCited in: Pathophysiology and Mechanism, Diagnosis and Workup, Prognosis and Natural History
[115]
Fox CS, Matsushita K, Woodward M et al.. “Associations of kidney disease measures with mortality and end-stage renal disease in individuals with and without diabetes: a meta-analysis.” Lancet (London, England) (2012). PMID: 23013602 ↗
L2SR_OBSCited in: Pathophysiology and Mechanism, Staging and Risk Stratification (KDIGO), Prognosis and Natural History, Special Populations & Pregnancy
[116]
Neuen BL, Heerspink HJL, Perkovic V et al.. “Efficacy and safety of finerenone in patients with chronic kidney disease: an individual participant data pooled analysis (INFINITY).” Lancet (London, England) (2026). PMID: 42248158 ↗
L1SR_OBSCited in: Pathophysiology and Mechanism, Long-term and Definitive Management
[117]
Gane EJ, Dagooc R, Ray-Chaudhuri D et al.. “Safety and efficacy of tenofovir alafenamide in preventing hepatitis B virus recurrence after liver transplantation in patients with chronic kidney disease maintained on tenofovir disoproxil fumarate: Results from a phase 2 randomized trial.” American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons (2025). PMID: 40972902 ↗
L1RCTCited in: Pathophysiology and Mechanism, Epidemiology, Etiology and Risk Factors, Diagnosis and Workup, Long-term and Definitive Management, History and Evolution of Treatment, Complications (Chronic Systemic Sequelae)
[118]
Wang Y, Li H, Jiang S et al.. “The glycolytic enzyme PFKFB3 drives kidney fibrosis through promoting histone lactylation-mediated NF-κB family activation.” Kidney international (2024). PMID: 38789037 ↗
L5OTHERCited in: Pathophysiology and Mechanism
[119]
Liu BC, Tang TT, Lv LL et al.. “Renal tubule injury: a driving force toward chronic kidney disease.” Kidney international (2018). PMID: 29361307 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology and Mechanism, Long-term and Definitive Management, Complications (Chronic Systemic Sequelae)
[120]
Tangri N, Neuen BL, Cherney DZ et al.. “From progression to remission: a new paradigm for success in chronic kidney disease.” Kidney international (2025). PMID: 41205673 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology and Mechanism, Diagnosis and Workup, Long-term and Definitive Management, History and Evolution of Treatment, Complications (Chronic Systemic Sequelae), Prognosis and Natural History, Prevention, Screening & Surveillance
[121]
Li X, Bhattacharya D, Yuan Y et al.. “Chronic kidney disease in a murine model of non-alcoholic steatohepatitis (NASH).” Kidney international (2023). PMID: 38159678 ↗
L5OTHERCited in: Pathophysiology and Mechanism, Diagnosis and Workup
[122]
Pierce CB, Muñoz A, Ng DK et al.. “Age- and sex-dependent clinical equations to estimate glomerular filtration rates in children and young adults with chronic kidney disease.” Kidney international (2020). PMID: 33301749 ↗
L4OTHERCited in: Pathophysiology and Mechanism, Diagnosis and Workup, Prognosis and Natural History
[123]
Weinberg JM. “Lipotoxicity.” Kidney international (2006). PMID: 16955100 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology and Mechanism
[124]
Nielsen R, Christensen EI, Birn H. “Megalin and cubilin in proximal tubule protein reabsorption: from experimental models to human disease.” Kidney international (2016). PMID: 26759048 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology and Mechanism
[125]
Kazama JJ, Iwasaki Y, Fukagawa M. “Uremic osteoporosis.” Kidney international supplements (2013). PMID: 25019028 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology and Mechanism
[126]
Wong MG, Pollock CA. “Biomarkers in kidney fibrosis: are they useful?” Kidney international supplements (2014). PMID: 26312155 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology and Mechanism
[127]
Dusso AS. “Kidney disease and vitamin D levels: 25-hydroxyvitamin D, 1,25-dihydroxyvitamin D, and VDR activation.” Kidney international supplements (2011). PMID: 25018912 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology and Mechanism
[128]
Ferrario CM, Groban L, Wang H et al.. “The renin-angiotensin system biomolecular cascade: a 2022 update of newer insights and concepts.” Kidney international supplements (2022). PMID: 35529089 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology and Mechanism
[129]
Obrador GT, Schultheiss UT, Kretzler M et al.. “Genetic and environmental risk factors for chronic kidney disease.” Kidney international supplements (2017). PMID: 30675423 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology and Mechanism
[130]
Kuro-O M. “A phosphate-centric paradigm for pathophysiology and therapy of chronic kidney disease.” Kidney international supplements (2013). PMID: 25019024 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology and Mechanism
[131]
London G, Covic A, Goldsmith D et al.. “Arterial aging and arterial disease: interplay between central hemodynamics, cardiac work, and organ flow-implications for CKD and cardiovascular disease.” Kidney international supplements (2011). PMID: 25018896 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology and Mechanism
[132]
Gallo Marin B, Aghagoli G, Hu SL et al.. “Calciphylaxis and Kidney Disease: A Review.” American journal of kidney diseases : the official journal of the National Kidney Foundation (2022). PMID: 35970430 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology and Mechanism, Clinical Presentation
[133]
Drew DA, Weiner DE, Sarnak MJ. “Cognitive Impairment in CKD: Pathophysiology, Management, and Prevention.” American journal of kidney diseases : the official journal of the National Kidney Foundation (2019). PMID: 31378643 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology and Mechanism, Clinical Presentation, Staging and Risk Stratification (KDIGO), Acute Management, Long-term and Definitive Management, Renal Replacement Therapy, Dialysis Access & Transplantation, Complications (Chronic Systemic Sequelae), Special Populations & Pregnancy
[134]
Ku E, Lee BJ, Wei J et al.. “Hypertension in CKD: Core Curriculum 2019.” American journal of kidney diseases : the official journal of the National Kidney Foundation (2019). PMID: 30898362 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology and Mechanism, Complications (Chronic Systemic Sequelae)
[135]
Joshi S, McMacken M, Kalantar-Zadeh K. “Plant-Based Diets for Kidney Disease: A Guide for Clinicians.” American journal of kidney diseases : the official journal of the National Kidney Foundation (2020). PMID: 33075387 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology and Mechanism, Epidemiology, Etiology and Risk Factors, Clinical Presentation, Long-term and Definitive Management, Fluid, Electrolyte & Acid-Base Disorders, Complications (Chronic Systemic Sequelae)
[136]
Lo KB, Janakiraman A, Rangaswami J. “Kidney Dysfunction in Heart Failure: Core Curriculum 2025.” American journal of kidney diseases : the official journal of the National Kidney Foundation (2025). PMID: 40380970 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology and Mechanism, Complications (Chronic Systemic Sequelae)
[137]
Inker LA, Titan S. “Measurement and Estimation of GFR for Use in Clinical Practice: Core Curriculum 2021.” American journal of kidney diseases : the official journal of the National Kidney Foundation (2021). PMID: 34518032 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology and Mechanism, Clinical Presentation, Diagnosis and Workup, Staging and Risk Stratification (KDIGO), Prognosis and Natural History
[138]
Murray SL, Wolf M. “Calcium and Phosphate Disorders: Core Curriculum 2024.” American journal of kidney diseases : the official journal of the National Kidney Foundation (2023). PMID: 38099870 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology and Mechanism
[139]
Demoulin N, Aydin S, Gillion V et al.. “Pathophysiology and Management of Hyperoxaluria and Oxalate Nephropathy: A Review.” American journal of kidney diseases : the official journal of the National Kidney Foundation (2021). PMID: 34508834 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology and Mechanism
[140]
Ix JH, Shlipak MG. “The Promise of Tubule Biomarkers in Kidney Disease: A Review.” American journal of kidney diseases : the official journal of the National Kidney Foundation (2021). PMID: 34051308 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology and Mechanism, Diagnosis and Workup, Staging and Risk Stratification (KDIGO), Prognosis and Natural History
[141]
Ko GJ, Rhee CM, Kalantar-Zadeh K et al.. “The Effects of High-Protein Diets on Kidney Health and Longevity.” Journal of the American Society of Nephrology : JASN (2020). PMID: 32669325 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology and Mechanism, Diagnosis and Workup, Prognosis and Natural History
[142]
Docherty MH, O'Sullivan ED, Bonventre JV et al.. “Cellular Senescence in the Kidney.” Journal of the American Society of Nephrology : JASN (2019). PMID: 31000567 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology and Mechanism, Epidemiology, Etiology and Risk Factors
[143]
Batchelor EK, Kapitsinou P, Pergola PE et al.. “Iron Deficiency in Chronic Kidney Disease: Updates on Pathophysiology, Diagnosis, and Treatment.” Journal of the American Society of Nephrology : JASN (2020). PMID: 32041774 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology and Mechanism, Epidemiology, Etiology and Risk Factors, Clinical Presentation, Diagnosis and Workup, Staging and Risk Stratification (KDIGO), Acute Management, Long-term and Definitive Management, Renal Replacement Therapy, Dialysis Access & Transplantation, Complications (Chronic Systemic Sequelae), Special Populations & Pregnancy
[144]
Schwartz GJ, Muñoz A, Schneider MF et al.. “New equations to estimate GFR in children with CKD.” Journal of the American Society of Nephrology : JASN (2009). PMID: 19158356 ↗
L4OTHERCited in: Pathophysiology and Mechanism, Diagnosis and Workup, Prognosis and Natural History, Special Populations & Pregnancy
[145]
Guo X, Xu L, Velazquez H et al.. “Kidney-Targeted Renalase Agonist Prevents Cisplatin-Induced Chronic Kidney Disease by Inhibiting Regulated Necrosis and Inflammation.” Journal of the American Society of Nephrology : JASN (2021). PMID: 34921111 ↗
L5OTHERCited in: Pathophysiology and Mechanism, Diagnosis and Workup, Prognosis and Natural History
[146]
Inker LA, Eneanya ND, Coresh J et al.. “New Creatinine- and Cystatin C-Based Equations to Estimate GFR without Race.” The New England journal of medicine (2021). PMID: 34554658 ↗
L4OTHERCited in: Pathophysiology and Mechanism, Diagnosis and Workup
[147]
Boussina A, Allison C, Quintero K et al.. “Medical Record Abstraction for Quality Improvement in Sepsis Care Using Artificial Intelligence: A Cluster Randomized Trial.” JAMA network open (2026). PMID: 42348212 ↗
L1RCTCited in: Pathophysiology and Mechanism, Long-term and Definitive Management, History and Evolution of Treatment, Special Populations & Pregnancy
[148]
Perazella MA, Rosner MH. “Drug-Induced Acute Kidney Injury.” Clinical journal of the American Society of Nephrology : CJASN (2022). PMID: 35273009 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology and Mechanism, Acute Management
[149]
Gregg LP, Bossola M, Ostrosky-Frid M et al.. “Fatigue in CKD: Epidemiology, Pathophysiology, and Treatment.” Clinical journal of the American Society of Nephrology : CJASN (2021). PMID: 33858827 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology and Mechanism, Clinical Presentation, Fluid, Electrolyte & Acid-Base Disorders
[150]
Levey AS, Titan SM, Powe NR et al.. “Kidney Disease, Race, and GFR Estimation.” Clinical journal of the American Society of Nephrology : CJASN (2020). PMID: 32393465 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology and Mechanism, Epidemiology, Etiology and Risk Factors, Clinical Presentation, Diagnosis and Workup, Prognosis and Natural History
[151]
Banerjee D, Rosano G, Herzog CA. “Management of Heart Failure Patient with CKD.” Clinical journal of the American Society of Nephrology : CJASN (2021). PMID: 33495289 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology and Mechanism, Epidemiology, Etiology and Risk Factors, Long-term and Definitive Management, Fluid, Electrolyte & Acid-Base Disorders, Renal Replacement Therapy, Dialysis Access & Transplantation, Complications (Chronic Systemic Sequelae)
[152]
Kovesdy CP. “Obesity and Metabolic Health in CKD.” Clinical journal of the American Society of Nephrology : CJASN (2025). PMID: 40085173 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology and Mechanism, Epidemiology, Etiology and Risk Factors, Clinical Presentation, Prognosis and Natural History
[153]
Davison SN. “Clinical Pharmacology Considerations in Pain Management in Patients with Advanced Kidney Failure.” Clinical journal of the American Society of Nephrology : CJASN (2019). PMID: 30833302 ↗
L5OTHERCited in: Pathophysiology and Mechanism, Clinical Presentation, Acute Management, Long-term and Definitive Management, Renal Replacement Therapy, Dialysis Access & Transplantation, Prognosis and Natural History, Special Populations & Pregnancy
[154]
Spinowitz BS, Fishbane S, Pergola PE et al.. “Sodium Zirconium Cyclosilicate among Individuals with Hyperkalemia: A 12-Month Phase 3 Study.” Clinical journal of the American Society of Nephrology : CJASN (2019). PMID: 31110051 ↗
L4OTHERCited in: Pathophysiology and Mechanism, Fluid, Electrolyte & Acid-Base Disorders, History and Evolution of Treatment
[155]
Wesson DE. “The Continuum of Acid Stress.” Clinical journal of the American Society of Nephrology : CJASN (2021). PMID: 33741720 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology and Mechanism, Diagnosis and Workup, Fluid, Electrolyte & Acid-Base Disorders, Prognosis and Natural History
[156]
Zachariah T, Radhakrishnan J. “Potential Role of Mineralocorticoid Receptor Antagonists in Nondiabetic Chronic Kidney Disease and Glomerular Disease.” Clinical journal of the American Society of Nephrology : CJASN (2024). PMID: 39037799 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology and Mechanism, Clinical Presentation, Long-term and Definitive Management
[157]
Ronco C, Bellomo R, Kellum JA. “Acute kidney injury.” Lancet (London, England) (2019). PMID: 31777389 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology and Mechanism, Epidemiology, Etiology and Risk Factors, Clinical Presentation, Diagnosis and Workup, Staging and Risk Stratification (KDIGO), Acute Management, Complications (Chronic Systemic Sequelae)
[158]
. “Global, regional, and national burden of chronic kidney disease, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017.” Lancet (London, England) (2020). PMID: 32061315 ↗
L2OTHERCited in: Pathophysiology and Mechanism, Epidemiology, Etiology and Risk Factors, Staging and Risk Stratification (KDIGO), Complications (Chronic Systemic Sequelae)
[159]
Lopez A, Cacoub P, Macdougall IC et al.. “Iron deficiency anaemia.” Lancet (London, England) (2015). PMID: 26314490 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology and Mechanism, Clinical Presentation, Diagnosis and Workup, Long-term and Definitive Management, Complications (Chronic Systemic Sequelae)
[160]
Gansevoort RT, Correa-Rotter R, Hemmelgarn BR et al.. “Chronic kidney disease and cardiovascular risk: epidemiology, mechanisms, and prevention.” Lancet (London, England) (2013). PMID: 23727170 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology and Mechanism, Diagnosis and Workup, Prognosis and Natural History
[161]
Zhang L, Wang F, Wang L et al.. “Prevalence of chronic kidney disease in China: a cross-sectional survey.” Lancet (London, England) (2012). PMID: 22386035 ↗
L2OTHERCited in: Pathophysiology and Mechanism, Diagnosis and Workup
[162]
Kanbay M, Copur S, Bakir CN et al.. “Glomerular hyperfiltration as a therapeutic target for CKD.” Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association (2024). PMID: 38308513 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology and Mechanism, Diagnosis and Workup, Prognosis and Natural History
[163]
Herzog CA. “Kidney disease in cardiology.” Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association (2010). PMID: 21135041 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology and Mechanism, Diagnosis and Workup, Staging and Risk Stratification (KDIGO), Prognosis and Natural History
[164]
Phipps EA, Thadhani R, Benzing T et al.. “Pre-eclampsia: pathogenesis, novel diagnostics and therapies.” Nature reviews. Nephrology (2019). PMID: 30792480 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology and Mechanism, Epidemiology, Etiology and Risk Factors, Clinical Presentation, Diagnosis and Workup, History and Evolution of Treatment, Special Populations & Pregnancy
[165]
Bargagli M, Scoglio M, Howles SA et al.. “Kidney stone disease: risk factors, pathophysiology and management.” Nature reviews. Nephrology (2025). PMID: 40790363 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology and Mechanism, Epidemiology, Etiology and Risk Factors
[166]
Tang C, Livingston MJ, Liu Z et al.. “Autophagy in kidney homeostasis and disease.” Nature reviews. Nephrology (2020). PMID: 32704047 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology and Mechanism
[167]
Anders HJ, Huber TB, Isermann B et al.. “CKD in diabetes: diabetic kidney disease versus nondiabetic kidney disease.” Nature reviews. Nephrology (2018). PMID: 29654297 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology and Mechanism, Epidemiology, Etiology and Risk Factors, Clinical Presentation, Diagnosis and Workup, Long-term and Definitive Management, Complications (Chronic Systemic Sequelae), Prognosis and Natural History, Prevention, Screening & Surveillance
[168]
Matsushita K, Ballew SH, Wang AY et al.. “Epidemiology and risk of cardiovascular disease in populations with chronic kidney disease.” Nature reviews. Nephrology (2022). PMID: 36104509 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology and Mechanism, Epidemiology, Etiology and Risk Factors, Diagnosis and Workup, Complications (Chronic Systemic Sequelae), Prognosis and Natural History
[169]
Zarbock A, Nadim MK, Pickkers P et al.. “Sepsis-associated acute kidney injury: consensus report of the 28th Acute Disease Quality Initiative workgroup.” Nature reviews. Nephrology (2023). PMID: 36823168 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology and Mechanism, Epidemiology, Etiology and Risk Factors, Clinical Presentation, Diagnosis and Workup, Acute Management, Complications (Chronic Systemic Sequelae)
[170]
Viggiano D, Wagner CA, Martino G et al.. “Mechanisms of cognitive dysfunction in CKD.” Nature reviews. Nephrology (2020). PMID: 32235904 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology and Mechanism, Epidemiology, Etiology and Risk Factors, Clinical Presentation, Diagnosis and Workup, Renal Replacement Therapy, Dialysis Access & Transplantation, Complications (Chronic Systemic Sequelae)
[171]
Forbes JM, Thorburn DR. “Mitochondrial dysfunction in diabetic kidney disease.” Nature reviews. Nephrology (2018). PMID: 29456246 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology and Mechanism, Long-term and Definitive Management, Complications (Chronic Systemic Sequelae), Prognosis and Natural History
[172]
Li L, Fu H, Liu Y. “The fibrogenic niche in kidney fibrosis: components and mechanisms.” Nature reviews. Nephrology (2022). PMID: 35788561 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology and Mechanism
[173]
François H, Mariette X. “Renal involvement in primary Sjögren syndrome.” Nature reviews. Nephrology (2015). PMID: 26568188 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology and Mechanism, Clinical Presentation, Diagnosis and Workup, Complications (Chronic Systemic Sequelae), Prevention, Screening & Surveillance
[174]
Ferro CJ, Mark PB, Kanbay M et al.. “Lipid management in patients with chronic kidney disease.” Nature reviews. Nephrology (2018). PMID: 30361677 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology and Mechanism, Epidemiology, Etiology and Risk Factors, Diagnosis and Workup, Staging and Risk Stratification (KDIGO), Long-term and Definitive Management, Complications (Chronic Systemic Sequelae), Prognosis and Natural History
[175]
Jourde-Chiche N, Fakhouri F, Dou L et al.. “Endothelium structure and function in kidney health and disease.” Nature reviews. Nephrology (2019). PMID: 30607032 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology and Mechanism
[176]
Huang R, Wang B. “Effect of glucagon-like peptide-1 receptor agonists on body weight and urinary albumin-to-creatinine ratio in patients with and without type 2 diabetes: A systematic review and meta-analysis.” The Journal of international medical research (2026). PMID: 42424036 ↗
L1SR_OBSCited in: Pathophysiology and Mechanism, Clinical Presentation, Diagnosis and Workup, Staging and Risk Stratification (KDIGO), Long-term and Definitive Management, Complications (Chronic Systemic Sequelae), Prognosis and Natural History
[177]
Lin YC, Lai TS, Chou YH et al.. “Pentoxifylline and cardiorenal outcomes in advanced CKD with untreated dyslipidemia: a longitudinal cohort study.” Renal failure (2026). PMID: 42393494 ↗
L2COHORTCited in: Pathophysiology and Mechanism, Epidemiology, Etiology and Risk Factors, Diagnosis and Workup, Long-term and Definitive Management, History and Evolution of Treatment, Complications (Chronic Systemic Sequelae), Prognosis and Natural History, Special Populations & Pregnancy
[178]
Xue N, Ma L, Zhou Z et al.. “Insulin resistance surrogate indices and incident cardiovascular disease across cardiovascular-kidney-metabolic stages 0-3: a prospective cohort study.” Cardiovascular diabetology (2026). PMID: 42380905 ↗
L2COHORTCited in: Pathophysiology and Mechanism
[179]
Cai P, Li B, Li Y et al.. “Association of peripheral NLRP3 inflammasome activation with prevalent and incident chronic kidney disease in patients with obstructive sleep apnea: a prospective study.” Sleep & breathing = Schlaf & Atmung (2026). PMID: 42377775 ↗
L2COHORTCited in: Pathophysiology and Mechanism, Clinical Presentation, Diagnosis and Workup, Prognosis and Natural History
[180]
Mu X, Li H, Huang T et al.. “Non-insulin-dependent insulin resistance surrogate indexes for predicting chronic kidney disease in diabetic individuals: a prospective cohort study.” BMC endocrine disorders (2026). PMID: 42351084 ↗
L2COHORTCited in: Pathophysiology and Mechanism, Prognosis and Natural History
[181]
Holle J, Reitmeir R, Behrens F et al.. “Gut microbiome alterations precede graft rejection in kidney transplantation patients.” American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons (2025). PMID: 39978595 ↗
L2OTHERCited in: Pathophysiology and Mechanism, Epidemiology, Etiology and Risk Factors, Clinical Presentation, Diagnosis and Workup, Renal Replacement Therapy, Dialysis Access & Transplantation, Prognosis and Natural History, Special Populations & Pregnancy
[182]
Evans MD, Helgeson ES, Rule AD et al.. “Consequences of low estimated glomerular filtration rate either before or early after kidney donation.” American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons (2024). PMID: 38878866 ↗
L2OTHERCited in: Pathophysiology and Mechanism, Diagnosis and Workup, Prognosis and Natural History
[183]
Wang C, Garg AX, Luo B et al.. “Defining pre-emptive living kidney donor transplantation as a quality indicator.” American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons (2024). PMID: 38395149 ↗
L2OTHERCited in: Pathophysiology and Mechanism, Epidemiology, Etiology and Risk Factors, Diagnosis and Workup, Renal Replacement Therapy, Dialysis Access & Transplantation, Prognosis and Natural History
[184]
Huang N, Foster MC, Lentine KL et al.. “Estimated GFR for Living Kidney Donor Evaluation.” American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons (2015). PMID: 26594819 ↗
L2OTHERCited in: Pathophysiology and Mechanism, Diagnosis and Workup
[185]
Kim HJ, Hong N, Kim HW et al.. “Low skeletal muscle mass is associated with mortality in kidney transplant recipients.” American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons (2023). PMID: 36695681 ↗
L2OTHERCited in: Pathophysiology and Mechanism, Diagnosis and Workup
[186]
Levitsky J, Salomon DR, Abecassis M et al.. “Clinical and plasma proteomic markers correlating with chronic kidney disease after liver transplantation.” American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons (2011). PMID: 21794091 ↗
L2OTHERCited in: Pathophysiology and Mechanism, Diagnosis and Workup, Complications (Chronic Systemic Sequelae)
[187]
Williams C, Borges K, Banh T et al.. “Patterns of kidney injury in pediatric nonkidney solid organ transplant recipients.” American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons (2018). PMID: 29286569 ↗
L2OTHERCited in: Pathophysiology and Mechanism, Diagnosis and Workup
[188]
Canales M, Youssef P, Spong R et al.. “Predictors of chronic kidney disease in long-term survivors of lung and heart-lung transplantation.” American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons (2006). PMID: 16827787 ↗
L2OTHERCited in: Pathophysiology and Mechanism, Clinical Presentation, Diagnosis and Workup, Long-term and Definitive Management
[189]
Stephany BR, Alao B, Budev M et al.. “Hyperlipidemia is associated with accelerated chronic kidney disease progression after lung transplantation.” American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons (2007). PMID: 17868063 ↗
L2OTHERCited in: Pathophysiology and Mechanism, Long-term and Definitive Management
[190]
Priyadharshini J, Padma J, Jayanivash J et al.. “Impact of Blood Flow Rate and Duration of Dialysis Session on Nutritional Status in Hemodialysis Patients.” Giornale italiano di nefrologia : organo ufficiale della Societa italiana di nefrologia (2026). PMID: 42423056 ↗
L1RCTCited in: Pathophysiology and Mechanism, Acute Management, Long-term and Definitive Management, Renal Replacement Therapy, Dialysis Access & Transplantation, History and Evolution of Treatment, Complications (Chronic Systemic Sequelae), Prognosis and Natural History, Special Populations & Pregnancy
[191]
El Samaloty NM, Senousy MA, Sabry S et al.. “Integrative analysis of circ_DLGAP4, lncRNA KCNQ1OT1, and the miR-9/SOX7 interaction network in chronic kidney disease progression: a case-control study.” Functional & integrative genomics (2026). PMID: 42400831 ↗
L3CASE_CONTROLCited in: Pathophysiology and Mechanism
[192]
Normand MH, Gougeon F, Bhojani N et al.. “Chronic kidney disease and reduced renal COX2 expression in xanthinuria: a case-control study.” BMC nephrology (2026). PMID: 42380780 ↗
L4CASE_CONTROLCited in: Pathophysiology and Mechanism
[193]
Anatriello A, Cantone A, Pentella C et al.. “The onset of posterior reversible encephalopathy syndrome (PRES) and reversible cerebral vasoconstriction syndrome (RCVS) with the use of decongestant agents: a European pharmacovigilance analysis.” Pharmacological reports : PR (2026). PMID: 42432411 ↗
L4OTHERCited in: Pathophysiology and Mechanism, Prevention, Screening & Surveillance
[194]
Morgan A, Hasberg C, Winkler C et al.. “Cell-based calcification assays - magnesium overrules calcium phosphate saturation in overall outcome1.” Bone (2026). PMID: 42431289 ↗
L5OTHERCited in: Pathophysiology and Mechanism
[195]
DiDonato JA, Weeks TL, Gupta N et al.. “Targeted Inhibition of Gut-Microbial Trimethylamine N -Oxide Production Fosters Regression of CKD Phenotypes.” Journal of the American Society of Nephrology : JASN (2026). PMID: 42430743 ↗
L5OTHERCited in: Pathophysiology and Mechanism
[196]
. “Genetics in chronic kidney disease: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference.” Kidney international (2022). PMID: 35460632 ↗
L1GUIDELINECited in: Epidemiology, Etiology and Risk Factors, Prevention, Screening & Surveillance
[197]
Coca SG, Singanamala S, Parikh CR. “Chronic kidney disease after acute kidney injury: a systematic review and meta-analysis.” Kidney international (2011). PMID: 22113526 ↗
L2SR_OBSCited in: Epidemiology, Etiology and Risk Factors, Prognosis and Natural History
[198]
Palmer S, Vecchio M, Craig JC et al.. “Prevalence of depression in chronic kidney disease: systematic review and meta-analysis of observational studies.” Kidney international (2013). PMID: 23486521 ↗
L2SR_OBSCited in: Epidemiology, Etiology and Risk Factors, Special Populations & Pregnancy
[199]
Kimura K, Hosoya T, Uchida S et al.. “Febuxostat Therapy for Patients With Stage 3 CKD and Asymptomatic Hyperuricemia: A Randomized Trial.” American journal of kidney diseases : the official journal of the National Kidney Foundation (2018). PMID: 30177485 ↗
L1RCTCited in: Epidemiology, Etiology and Risk Factors, Diagnosis and Workup, Staging and Risk Stratification (KDIGO), History and Evolution of Treatment, Prognosis and Natural History, Special Populations & Pregnancy
[200]
Poggio ED, McClelland RL, Blank KN et al.. “Systematic Review and Meta-Analysis of Native Kidney Biopsy Complications.” Clinical journal of the American Society of Nephrology : CJASN (2020). PMID: 33060160 ↗
L2SR_OBSCited in: Epidemiology, Etiology and Risk Factors, Clinical Presentation, Diagnosis and Workup
[201]
Agarwal R, Joseph A, Anker SD et al.. “Hyperkalemia Risk with Finerenone: Results from the FIDELIO-DKD Trial.” Journal of the American Society of Nephrology : JASN (2021). PMID: 34732509 ↗
L2RCTCited in: Epidemiology, Etiology and Risk Factors, Clinical Presentation, Diagnosis and Workup, Long-term and Definitive Management, Fluid, Electrolyte & Acid-Base Disorders, History and Evolution of Treatment, Complications (Chronic Systemic Sequelae), Special Populations & Pregnancy
[202]
Marso SP, Bain SC, Consoli A et al.. “Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes.” The New England journal of medicine (2016). PMID: 27633186 ↗
L1RCTCited in: Epidemiology, Etiology and Risk Factors, Long-term and Definitive Management, History and Evolution of Treatment, Complications (Chronic Systemic Sequelae), Special Populations & Pregnancy
[203]
McGuire DK, Marx N, Mulvagh SL et al.. “Oral Semaglutide and Cardiovascular Outcomes in High-Risk Type 2 Diabetes.” The New England journal of medicine (2025). PMID: 40162642 ↗
L1RCTCited in: Epidemiology, Etiology and Risk Factors, Long-term and Definitive Management, History and Evolution of Treatment, Complications (Chronic Systemic Sequelae), Special Populations & Pregnancy
[204]
Pitt B, Filippatos G, Agarwal R et al.. “Cardiovascular Events with Finerenone in Kidney Disease and Type 2 Diabetes.” The New England journal of medicine (2021). PMID: 34449181 ↗
L1RCTCited in: Epidemiology, Etiology and Risk Factors, Clinical Presentation, Diagnosis and Workup, Staging and Risk Stratification (KDIGO), Long-term and Definitive Management, Fluid, Electrolyte & Acid-Base Disorders, History and Evolution of Treatment, Complications (Chronic Systemic Sequelae), Special Populations & Pregnancy
[205]
Butler J, Jones WS, Udell JA et al.. “Empagliflozin after Acute Myocardial Infarction.” The New England journal of medicine (2024). PMID: 38587237 ↗
L1RCTCited in: Epidemiology, Etiology and Risk Factors, Long-term and Definitive Management
[206]
Chertow GM, Pergola PE, Farag YMK et al.. “Vadadustat in Patients with Anemia and Non-Dialysis-Dependent CKD.” The New England journal of medicine (2021). PMID: 33913637 ↗
L1RCTCited in: Epidemiology, Etiology and Risk Factors
[207]
Ettehad D, Emdin CA, Kiran A et al.. “Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and meta-analysis.” Lancet (London, England) (2015). PMID: 26724178 ↗
L1SR_OBSCited in: Epidemiology, Etiology and Risk Factors, Long-term and Definitive Management, History and Evolution of Treatment, Complications (Chronic Systemic Sequelae)
[208]
Veltkamp DMJ, Porras CP, Gant CM et al.. “Long-term risks of adverse kidney outcomes after acute kidney injury: a systematic review and meta-analysis.” Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association (2025). PMID: 40424522 ↗
L2SR_OBSCited in: Epidemiology, Etiology and Risk Factors, Long-term and Definitive Management, Complications (Chronic Systemic Sequelae)
[209]
Kosiborod MN, Deanfield J, Pratley R et al.. “Semaglutide versus placebo in patients with heart failure and mildly reduced or preserved ejection fraction: a pooled analysis of the SELECT, FLOW, STEP-HFpEF, and STEP-HFpEF DM randomised trials.” Lancet (London, England) (2024). PMID: 39222642 ↗
L2RCTCited in: Epidemiology, Etiology and Risk Factors, Clinical Presentation, Long-term and Definitive Management, History and Evolution of Treatment, Special Populations & Pregnancy
[210]
Vaduganathan M, Green JB, Heerspink HJL et al.. “Simultaneous initiation of finerenone and empagliflozin across the spectrum of kidney risk in the CONFIDENCE trial.” Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association (2025). PMID: 40886054 ↗
L1RCTCited in: Epidemiology, Etiology and Risk Factors, Diagnosis and Workup, Staging and Risk Stratification (KDIGO), Fluid, Electrolyte & Acid-Base Disorders, History and Evolution of Treatment, Prognosis and Natural History
[211]
Piccini JP, Patel MR, Steffel J et al.. “Asundexian versus Apixaban in Patients with Atrial Fibrillation.” The New England journal of medicine (2024). PMID: 39225267 ↗
L1TRIAL_NONRANDOMCited in: Epidemiology, Etiology and Risk Factors
[212]
Alvarado F, Cervantes CE, Crews DC et al.. “Examining post-donation outcomes in Hispanic/Latinx living kidney donors in the United States: A systematic review.” American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons (2022). PMID: 35258164 ↗
L2SR_OBSCited in: Epidemiology, Etiology and Risk Factors, Renal Replacement Therapy, Dialysis Access & Transplantation, Prognosis and Natural History, Special Populations & Pregnancy
[213]
Elenjickal EJ, Travlos CK, Luu J et al.. “Efficacy and Safety of Sodium-Glucose Cotransporter-2 Inhibitors in Patients with and without Advanced CKD: Systematic Review and Meta-Analysis.” Clinical journal of the American Society of Nephrology : CJASN (2025). PMID: 40137838 ↗
L1SR_OBSCited in: Epidemiology, Etiology and Risk Factors
[214]
Chaudhry ZS, Williams JD, Vahia A et al.. “Clinical characteristics and outcomes of COVID-19 in solid organ transplant recipients: A cohort study.” American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons (2020). PMID: 32654332 ↗
L2COHORTCited in: Epidemiology, Etiology and Risk Factors
[215]
Nigwekar SU, Kroshinsky D, Nazarian RM et al.. “Calciphylaxis: risk factors, diagnosis, and treatment.” American journal of kidney diseases : the official journal of the National Kidney Foundation (2015). PMID: 25960299 ↗
L5CASE_REPORTCited in: Epidemiology, Etiology and Risk Factors, Clinical Presentation, Complications (Chronic Systemic Sequelae)
[216]
Fishbane S, Spinowitz B. “Update on Anemia in ESRD and Earlier Stages of CKD: Core Curriculum 2018.” American journal of kidney diseases : the official journal of the National Kidney Foundation (2018). PMID: 29336855 ↗
L5CASE_REPORTCited in: Epidemiology, Etiology and Risk Factors, Clinical Presentation, Staging and Risk Stratification (KDIGO), Long-term and Definitive Management, Complications (Chronic Systemic Sequelae)
[217]
Makkapati S, D'Agati VD, Balsam L. “"Green Smoothie Cleanse" Causing Acute Oxalate Nephropathy.” American journal of kidney diseases : the official journal of the National Kidney Foundation (2017). PMID: 29203127 ↗
L4CASE_REPORTCited in: Epidemiology, Etiology and Risk Factors, Clinical Presentation, Acute Management, Long-term and Definitive Management, Renal Replacement Therapy, Dialysis Access & Transplantation, History and Evolution of Treatment, Complications (Chronic Systemic Sequelae), Prognosis and Natural History, Special Populations & Pregnancy
[218]
Chan GC, Kalantar-Zadeh K, Ng JK et al.. “Frailty in patients on dialysis.” Kidney international (2024). PMID: 38705274 ↗
L5REVIEW_NARRATIVECited in: Epidemiology, Etiology and Risk Factors, Acute Management, Renal Replacement Therapy, Dialysis Access & Transplantation, Special Populations & Pregnancy
[219]
Barrera-Chimal J, Girerd S, Jaisser F. “Mineralocorticoid receptor antagonists and kidney diseases: pathophysiological basis.” Kidney international (2019). PMID: 31133455 ↗
L5REVIEW_NARRATIVECited in: Epidemiology, Etiology and Risk Factors, Acute Management, Long-term and Definitive Management, Fluid, Electrolyte & Acid-Base Disorders, Complications (Chronic Systemic Sequelae)
[220]
Xu X, Shao X, Hou FF. “Risk stratification of metabolic disorder-associated kidney disease.” Kidney international (2025). PMID: 40157500 ↗
L5REVIEW_NARRATIVECited in: Epidemiology, Etiology and Risk Factors, Staging and Risk Stratification (KDIGO), Long-term and Definitive Management
[221]
Matsuura R, Doi K, Rabb H. “Acute kidney injury and distant organ dysfunction-network system analysis.” Kidney international (2023). PMID: 37030663 ↗
L5REVIEW_NARRATIVECited in: Epidemiology, Etiology and Risk Factors, Acute Management
[222]
Ott C, Schmieder RE. “Diagnosis and treatment of arterial hypertension 2021.” Kidney international (2021). PMID: 34757122 ↗
L5REVIEW_NARRATIVECited in: Epidemiology, Etiology and Risk Factors, Special Populations & Pregnancy
[223]
Connaughton DM, Kennedy C, Shril S et al.. “Monogenic causes of chronic kidney disease in adults.” Kidney international (2019). PMID: 30773290 ↗
L4OTHERCited in: Epidemiology, Etiology and Risk Factors, Clinical Presentation, History and Evolution of Treatment, Special Populations & Pregnancy
[224]
Kovesdy CP. “Epidemiology of chronic kidney disease: an update 2022.” Kidney international supplements (2022). PMID: 35529086 ↗
L5REVIEW_NARRATIVECited in: Epidemiology, Etiology and Risk Factors
[225]
Luyckx VA, Tuttle KR, Garcia-Garcia G et al.. “Reducing major risk factors for chronic kidney disease.” Kidney international supplements (2017). PMID: 30675422 ↗
L5REVIEW_NARRATIVECited in: Epidemiology, Etiology and Risk Factors
[226]
Yang CW, Harris DCH, Luyckx VA et al.. “Global case studies for chronic kidney disease/end-stage kidney disease care.” Kidney international supplements (2020). PMID: 32149007 ↗
L5REVIEW_NARRATIVECited in: Epidemiology, Etiology and Risk Factors
[227]
Sharma K. “Obesity, oxidative stress, and fibrosis in chronic kidney disease.” Kidney international supplements (2014). PMID: 25401040 ↗
L5REVIEW_NARRATIVECited in: Epidemiology, Etiology and Risk Factors
[228]
Coresh J, Hu JR, Bello AK et al.. “Action plan for determining and monitoring the prevalence of chronic kidney disease.” Kidney international supplements (2017). PMID: 30675421 ↗
L5REVIEW_NARRATIVECited in: Epidemiology, Etiology and Risk Factors, Prevention, Screening & Surveillance
[229]
Fried L, Kovesdy CP, Palmer BF. “New options for the management of chronic hyperkalemia.” Kidney international supplements (2017). PMID: 30675431 ↗
L5REVIEW_NARRATIVECited in: Epidemiology, Etiology and Risk Factors, Fluid, Electrolyte & Acid-Base Disorders
[230]
See EJ, Alrukhaimi M, Ashuntantang GE et al.. “Global coverage of health information systems for kidney disease: availability, challenges, and opportunities for development.” Kidney international supplements (2018). PMID: 30675441 ↗
L2REVIEW_NARRATIVECited in: Epidemiology, Etiology and Risk Factors, Prevention, Screening & Surveillance
[231]
Okpechi IG, Alrukhaimi M, Ashuntantang GE et al.. “Global capacity for clinical research in nephrology: a survey by the International Society of Nephrology.” Kidney international supplements (2018). PMID: 30675442 ↗
L2REVIEW_NARRATIVECited in: Epidemiology, Etiology and Risk Factors
[232]
Prikhodina L, Komissarov K, Bulanov N et al.. “Capacity for the management of kidney failure in the International Society of Nephrology Newly Independent States and Russia region: report from the 2023 ISN Global Kidney Health Atlas (ISN-GKHA).” Kidney international supplements (2024). PMID: 38618496 ↗
L2REVIEW_NARRATIVECited in: Epidemiology, Etiology and Risk Factors
[233]
Sengul S, Erdem Y, Batuman V et al.. “Hypertension and chronic kidney disease in Turkey.” Kidney international supplements (2013). PMID: 25019009 ↗
L4OTHERCited in: Epidemiology, Etiology and Risk Factors
[234]
Lowe-Jones R, Ethier I, Fisher LA et al.. “Capacity for the management of kidney failure in the International Society of Nephrology North America and the Caribbean region: report from the 2023 ISN Global Kidney Health Atlas (ISN-GKHA).” Kidney international supplements (2024). PMID: 38618503 ↗
L2REVIEW_NARRATIVECited in: Epidemiology, Etiology and Risk Factors
[235]
Wing-Shing Fung W, Park HC, Hirakawa Y et al.. “Capacity for the management of kidney failure in the International Society of Nephrology North and East Asia region: report from the 2023 ISN Global Kidney Health Atlas (ISN-GKHA).” Kidney international supplements (2024). PMID: 38618501 ↗
L2REVIEW_NARRATIVECited in: Epidemiology, Etiology and Risk Factors
[236]
MacLaughlin HL, Friedman AN, Ikizler TA. “Nutrition in Kidney Disease: Core Curriculum 2022.” American journal of kidney diseases : the official journal of the National Kidney Foundation (2021). PMID: 34862042 ↗
L5REVIEW_NARRATIVECited in: Epidemiology, Etiology and Risk Factors, Acute Management, Renal Replacement Therapy, Dialysis Access & Transplantation, Special Populations & Pregnancy
[237]
Pazianas M, Miller PD. “Osteoporosis and Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD): Back to Basics.” American journal of kidney diseases : the official journal of the National Kidney Foundation (2021). PMID: 33774081 ↗
L5REVIEW_NARRATIVECited in: Epidemiology, Etiology and Risk Factors
[238]
Yang C, Wang H, Zhao X et al.. “CKD in China: Evolving Spectrum and Public Health Implications.” American journal of kidney diseases : the official journal of the National Kidney Foundation (2019). PMID: 31492486 ↗
L4REVIEW_NARRATIVECited in: Epidemiology, Etiology and Risk Factors, Renal Replacement Therapy, Dialysis Access & Transplantation, Complications (Chronic Systemic Sequelae), Prevention, Screening & Surveillance
[239]
Johnson RJ, Bakris GL, Borghi C et al.. “Hyperuricemia, Acute and Chronic Kidney Disease, Hypertension, and Cardiovascular Disease: Report of a Scientific Workshop Organized by the National Kidney Foundation.” American journal of kidney diseases : the official journal of the National Kidney Foundation (2018). PMID: 29496260 ↗
L5REVIEW_NARRATIVECited in: Epidemiology, Etiology and Risk Factors
[240]
Lambourg EJ, Fu EL, McGurnaghan S et al.. “Stopping Versus Continuing Metformin in Patients With Advanced CKD: A Nationwide Scottish Target Trial Emulation Study.” American journal of kidney diseases : the official journal of the National Kidney Foundation (2024). PMID: 39521399 ↗
L2OTHERCited in: Epidemiology, Etiology and Risk Factors, Diagnosis and Workup, History and Evolution of Treatment, Prognosis and Natural History
[241]
Swartling O, Rydell H, Stendahl M et al.. “CKD Progression and Mortality Among Men and Women: A Nationwide Study in Sweden.” American journal of kidney diseases : the official journal of the National Kidney Foundation (2021). PMID: 33434591 ↗
L2OTHERCited in: Epidemiology, Etiology and Risk Factors, Diagnosis and Workup, Renal Replacement Therapy, Dialysis Access & Transplantation, Prognosis and Natural History
[242]
Wahid F, Ahmed S, Islam MT et al.. “Heatstroke Over the Past Decade: Risk Factors, Long-Term Health Consequences, and Preventive Measures.” Journal of general internal medicine (2026). PMID: 42414802 ↗
L2SR_OBSCited in: Epidemiology, Etiology and Risk Factors
[243]
Brodsky S, Eikelboom J, Hebert LA. “Anticoagulant-Related Nephropathy.” Journal of the American Society of Nephrology : JASN (2018). PMID: 30420420 ↗
L5REVIEW_NARRATIVECited in: Epidemiology, Etiology and Risk Factors, Diagnosis and Workup, History and Evolution of Treatment
[244]
Shin JI, Fine DM, Sang Y et al.. “Association of Rosuvastatin Use with Risk of Hematuria and Proteinuria.” Journal of the American Society of Nephrology : JASN (2022). PMID: 35853713 ↗
L2OTHERCited in: Epidemiology, Etiology and Risk Factors, Clinical Presentation, Diagnosis and Workup, Long-term and Definitive Management, Prevention, Screening & Surveillance
[245]
Lee AM, Hu J, Xu Y et al.. “Using Machine Learning to Identify Metabolomic Signatures of Pediatric Chronic Kidney Disease Etiology.” Journal of the American Society of Nephrology : JASN (2022). PMID: 35017168 ↗
L2OTHERCited in: Epidemiology, Etiology and Risk Factors
[246]
Montford JR, Linas S. “How Dangerous Is Hyperkalemia?” Journal of the American Society of Nephrology : JASN (2017). PMID: 28778861 ↗
L5REVIEW_NARRATIVECited in: Epidemiology, Etiology and Risk Factors, Clinical Presentation, Acute Management, Fluid, Electrolyte & Acid-Base Disorders, Complications (Chronic Systemic Sequelae)
[247]
Luks AM, Johnson RJ, Swenson ER. “Chronic kidney disease at high altitude.” Journal of the American Society of Nephrology : JASN (2008). PMID: 18842990 ↗
L5REVIEW_NARRATIVECited in: Epidemiology, Etiology and Risk Factors, Clinical Presentation, Prognosis and Natural History
[248]
Tsunoda R, Ohigashi T, Hoshino J et al.. “Kidney and Cardiovascular Outcomes by CKD stage and etiology of CKD: A Randomly Selected Nationwide Prospective Multicenter Cohort Study in Japan (Reach-J Study).” American journal of nephrology (2026). PMID: 42430293 ↗
L2COHORTCited in: Epidemiology, Etiology and Risk Factors, History and Evolution of Treatment
[249]
Huang J, Ge C, He X et al.. “Temperature-related indicators and risk of incident cardiovascular-kidney-metabolic multimorbidity in middle-aged and older adults: a longitudinal cohort study from CHARLS.” Frontiers in public health (2026). PMID: 42428937 ↗
L2COHORTCited in: Epidemiology, Etiology and Risk Factors, Complications (Chronic Systemic Sequelae), Special Populations & Pregnancy
[250]
Teles RM, Menezes RC, Ferreira IBB et al.. “ICU-acquired acute kidney injury in critically ill adults: a retrospective cohort study of risk factors and KDIGO stage dynamics in a Brazilian ICU.” Renal failure (2026). PMID: 42410341 ↗
L2COHORTCited in: Epidemiology, Etiology and Risk Factors, Clinical Presentation, Diagnosis and Workup, Staging and Risk Stratification (KDIGO), Special Populations & Pregnancy
[251]
Youmbi CT, Santos A, Bridger A et al.. “Acute Kidney Injury Following Antibiotic-Loaded Spacer Insertion in Two-Stage Knee Arthroplasty Revision for Periprosthetic Joint Infection: A Retrospective Cohort Study.” The Journal of arthroplasty (2026). PMID: 42409293 ↗
L3COHORTCited in: Epidemiology, Etiology and Risk Factors, Staging and Risk Stratification (KDIGO)
[252]
Zhang D, Li G, Xu G et al.. “Association of the serum uric acid to high-density lipoprotein cholesterol ratio with in-hospital mortality in patients with acute kidney injury: a retrospective cohort study.” Frontiers in endocrinology (2026). PMID: 42404348 ↗
L3COHORTCited in: Epidemiology, Etiology and Risk Factors, Staging and Risk Stratification (KDIGO), Special Populations & Pregnancy
[253]
Li J, Zhao F, Lu R et al.. “Effect of Vitamin C on bleeding and pain after kidney biopsy: a randomized controlled trial.” BMC medicine (2026). PMID: 42399956 ↗
L1RCTCited in: Epidemiology, Etiology and Risk Factors
[254]
Yang B, Xie Y, Guo M et al.. “Nephrotoxicity and Chinese Herbal Medicine.” Clinical journal of the American Society of Nephrology : CJASN (2018). PMID: 29615394 ↗
L5REVIEW_NARRATIVECited in: Epidemiology, Etiology and Risk Factors
[255]
Friedman DJ, Pollak MR. “APOL1 Nephropathy: From Genetics to Clinical Applications.” Clinical journal of the American Society of Nephrology : CJASN (2020). PMID: 32616495 ↗
L5REVIEW_NARRATIVECited in: Epidemiology, Etiology and Risk Factors, Renal Replacement Therapy, Dialysis Access & Transplantation, Complications (Chronic Systemic Sequelae), Prognosis and Natural History, Special Populations & Pregnancy
[256]
Lea-Henry TN, Carland JE, Stocker SL et al.. “Clinical Pharmacokinetics in Kidney Disease: Fundamental Principles.” Clinical journal of the American Society of Nephrology : CJASN (2018). PMID: 29934432 ↗
L5REVIEW_NARRATIVECited in: Epidemiology, Etiology and Risk Factors
[257]
McEwan P, Darlington O, Miller R et al.. “Cost-Effectiveness of Dapagliflozin as a Treatment for Chronic Kidney Disease: A Health-Economic Analysis of DAPA-CKD.” Clinical journal of the American Society of Nephrology : CJASN (2022). PMID: 36323444 ↗
L2OTHERCited in: Epidemiology, Etiology and Risk Factors, Long-term and Definitive Management, Complications (Chronic Systemic Sequelae)
[258]
Vlasschaert C, Moran SM, Rauh MJ. “The Myeloid-Kidney Interface in Health and Disease.” Clinical journal of the American Society of Nephrology : CJASN (2021). PMID: 34507968 ↗
L5REVIEW_NARRATIVECited in: Epidemiology, Etiology and Risk Factors, Prevention, Screening & Surveillance
[259]
Arzhan S, Roumelioti ME, Litvinovich I et al.. “Outcomes of Hospital-Acquired Hypernatremia.” Clinical journal of the American Society of Nephrology : CJASN (2023). PMID: 37722368 ↗
L3OTHERCited in: Epidemiology, Etiology and Risk Factors, Fluid, Electrolyte & Acid-Base Disorders
[260]
Ostermann M, Lumlertgul N, Jeong R et al.. “Acute kidney injury.” Lancet (London, England) (2025). PMID: 39826969 ↗
L5REVIEW_NARRATIVECited in: Epidemiology, Etiology and Risk Factors, Clinical Presentation, Diagnosis and Workup, Acute Management, Renal Replacement Therapy, Dialysis Access & Transplantation, Complications (Chronic Systemic Sequelae), Prevention, Screening & Surveillance
[261]
Herrington WG, Judge PK, Grams ME et al.. “Chronic kidney disease.” Lancet (London, England) (2025). PMID: 41314225 ↗
L5REVIEW_NARRATIVECited in: Epidemiology, Etiology and Risk Factors, Clinical Presentation, Diagnosis and Workup, Renal Replacement Therapy, Dialysis Access & Transplantation, Complications (Chronic Systemic Sequelae), Prognosis and Natural History
[262]
Tabák AG, Herder C, Rathmann W et al.. “Prediabetes: a high-risk state for diabetes development.” Lancet (London, England) (2012). PMID: 22683128 ↗
L5REVIEW_NARRATIVECited in: Epidemiology, Etiology and Risk Factors, Long-term and Definitive Management, Complications (Chronic Systemic Sequelae), Prognosis and Natural History
[263]
Jha V, Garcia-Garcia G, Iseki K et al.. “Chronic kidney disease: global dimension and perspectives.” Lancet (London, England) (2013). PMID: 23727169 ↗
L5REVIEW_NARRATIVECited in: Epidemiology, Etiology and Risk Factors
[264]
Floege J, Amann K. “Primary glomerulonephritides.” Lancet (London, England) (2016). PMID: 26921911 ↗
L5REVIEW_NARRATIVECited in: Epidemiology, Etiology and Risk Factors, Diagnosis and Workup, Long-term and Definitive Management, Prognosis and Natural History
[265]
Zoccali C, Lameire N, Ronco C et al.. “Acute kidney injury, acute kidney disease and chronic kidney disease: challenges and research perspectives.” Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association (2025). PMID: 40353771 ↗
L5REVIEW_NARRATIVECited in: Epidemiology, Etiology and Risk Factors, Long-term and Definitive Management, Complications (Chronic Systemic Sequelae)
[266]
De Vriese AS, Heine G. “Anticoagulation management in haemodialysis patients with atrial fibrillation: evidence and opinion.” Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association (2022). PMID: 33647941 ↗
L5OTHERCited in: Epidemiology, Etiology and Risk Factors, Acute Management, Renal Replacement Therapy, Dialysis Access & Transplantation, Special Populations & Pregnancy
[267]
Cozzolino M, Mangano M, Stucchi A et al.. “Cardiovascular disease in dialysis patients.” Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association (2018). PMID: 30281132 ↗
L5REVIEW_NARRATIVECited in: Epidemiology, Etiology and Risk Factors, Acute Management, Renal Replacement Therapy, Dialysis Access & Transplantation, Special Populations & Pregnancy
[268]
Podestà MA, Cucchiari D, Ciceri P et al.. “Cardiovascular calcifications in kidney transplant recipients.” Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association (2022). PMID: 33620476 ↗
L5REVIEW_NARRATIVECited in: Epidemiology, Etiology and Risk Factors, Acute Management, Renal Replacement Therapy, Dialysis Access & Transplantation, Special Populations & Pregnancy
[269]
Goto H, Iseri K, Hida N. “Fibrates and the risk of cardiovascular outcomes in chronic kidney disease patients.” Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association (2024). PMID: 38012115 ↗
L3OTHERCited in: Epidemiology, Etiology and Risk Factors
[270]
Chillon JM, Massy ZA, Stengel B. “Neurological complications in chronic kidney disease patients.” Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association (2015). PMID: 26359201 ↗
L5REVIEW_NARRATIVECited in: Epidemiology, Etiology and Risk Factors
[271]
Cheung CY, Tang SCW. “An update on cancer after kidney transplantation.” Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association (2019). PMID: 30260424 ↗
L5REVIEW_NARRATIVECited in: Epidemiology, Etiology and Risk Factors, Renal Replacement Therapy, Dialysis Access & Transplantation, Prevention, Screening & Surveillance
[272]
Kelly DM, Pinheiro AA, Koini M et al.. “Impaired kidney function, cerebral small vessel disease and cognitive disorders: the Framingham Heart Study.” Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association (2024). PMID: 38565317 ↗
L2OTHERCited in: Epidemiology, Etiology and Risk Factors, Diagnosis and Workup
[273]
Malyszko J, Golenia A, Farisco M et al.. “Cognitive impairment in kidney transplanted patients.” Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association (2025). PMID: 40080090 ↗
L5REVIEW_NARRATIVECited in: Epidemiology, Etiology and Risk Factors
[274]
Mafra D, Guebre-Egziabher F, Fouque D. “Body mass index, muscle and fat in chronic kidney disease: questions about survival.” Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association (2008). PMID: 18390566 ↗
L5REVIEW_NARRATIVECited in: Epidemiology, Etiology and Risk Factors
[275]
Zhang S, Zhao X, Xie J et al.. “Association Between Time-Averaged Serum Uric Acid and Renal Outcomes in Patients with Type 2 Diabetes Mellitus with Chronic Kidney Disease: A Multicenter Retrospective Cohort Study.” Diabetes therapy : research, treatment and education of diabetes and related disorders (2026). PMID: 42424028 ↗
L3COHORTCited in: Epidemiology, Etiology and Risk Factors, Prognosis and Natural History
[276]
Hashi Mohamed A, Mire Waberi M, Aksu F et al.. “Intradialytic blood pressure instability and associated factors among hemodialysis patients in Somalia: a retrospective study.” Frontiers in nephrology (2026). PMID: 42416209 ↗
L4COHORTCited in: Epidemiology, Etiology and Risk Factors, Renal Replacement Therapy, Dialysis Access & Transplantation
[277]
Martins CA, de Paiva Souza Klippel L, Dos Santos Barbosa K et al.. “Association between abdominal obesity indicators and survival among individuals undergoing hemodialysis: Retrospective observational cohort study.” Nutrition in clinical practice : official publication of the American Society for Parenteral and Enteral Nutrition (2026). PMID: 42414815 ↗
L2COHORTCited in: Epidemiology, Etiology and Risk Factors, Prognosis and Natural History
[278]
Lee Y, Seong JE, Lee JA et al.. “Ceftazidime-Avibactam Effectiveness in Carbapenem-Resistant Enterobacterales Bacteremia: A Retrospective Cohort Study in Korea.” Journal of Korean medical science (2026). PMID: 42411238 ↗
L2COHORTCited in: Epidemiology, Etiology and Risk Factors, Long-term and Definitive Management, Prognosis and Natural History, Special Populations & Pregnancy
[279]
Francis A, Harhay MN, Ong ACM et al.. “Chronic kidney disease and the global public health agenda: an international consensus.” Nature reviews. Nephrology (2024). PMID: 38570631 ↗
L5REVIEW_NARRATIVECited in: Epidemiology, Etiology and Risk Factors, Prognosis and Natural History, Prevention, Screening & Surveillance
[280]
Lyons OD. “Sleep disorders in chronic kidney disease.” Nature reviews. Nephrology (2024). PMID: 38789686 ↗
L5REVIEW_NARRATIVECited in: Epidemiology, Etiology and Risk Factors, Clinical Presentation, Acute Management, Renal Replacement Therapy, Dialysis Access & Transplantation, Complications (Chronic Systemic Sequelae), Special Populations & Pregnancy
[281]
Mitrofanova A, Merscher S, Fornoni A. “Kidney lipid dysmetabolism and lipid droplet accumulation in chronic kidney disease.” Nature reviews. Nephrology (2023). PMID: 37500941 ↗
L5REVIEW_NARRATIVECited in: Epidemiology, Etiology and Risk Factors
[282]
Ruiz-Ortega M, Rayego-Mateos S, Lamas S et al.. “Targeting the progression of chronic kidney disease.” Nature reviews. Nephrology (2020). PMID: 32060481 ↗
L5REVIEW_NARRATIVECited in: Epidemiology, Etiology and Risk Factors, Long-term and Definitive Management, Complications (Chronic Systemic Sequelae), Prognosis and Natural History
[283]
Miguel V, Shaw IW, Kramann R. “Metabolism at the crossroads of inflammation and fibrosis in chronic kidney disease.” Nature reviews. Nephrology (2024). PMID: 39289568 ↗
L5REVIEW_NARRATIVECited in: Epidemiology, Etiology and Risk Factors
[284]
Clajus C, Hanke N, Gottlieb J et al.. “Renal comorbidity after solid organ and stem cell transplantation.” American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons (2012). PMID: 22676355 ↗
L5REVIEW_NARRATIVECited in: Epidemiology, Etiology and Risk Factors
[285]
Engels EA, Fraser GE, Kasiske BL et al.. “Cancer risk in living kidney donors.” American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons (2022). PMID: 35510728 ↗
L2OTHERCited in: Epidemiology, Etiology and Risk Factors, Renal Replacement Therapy, Dialysis Access & Transplantation, Special Populations & Pregnancy
[286]
Bloom RD, Doyle AM. “Kidney disease after heart and lung transplantation.” American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons (2006). PMID: 16539623 ↗
L5REVIEW_NARRATIVECited in: Epidemiology, Etiology and Risk Factors
[287]
Weiss AS, Sandmaier BM, Storer B et al.. “Chronic kidney disease following non-myeloablative hematopoietic cell transplantation.” American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons (2006). PMID: 16433761 ↗
L2OTHERCited in: Epidemiology, Etiology and Risk Factors, Complications (Chronic Systemic Sequelae), Prognosis and Natural History, Special Populations & Pregnancy
[288]
Levitsky J, O'Leary JG, Asrani S et al.. “Protecting the Kidney in Liver Transplant Recipients: Practice-Based Recommendations From the American Society of Transplantation Liver and Intestine Community of Practice.” American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons (2016). PMID: 26932352 ↗
L5REVIEW_NARRATIVECited in: Epidemiology, Etiology and Risk Factors, Prognosis and Natural History
[289]
Levin A, Ahmed SB, Carrero JJ et al.. “Executive summary of the KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease: known knowns and known unknowns.” Kidney international (2024). PMID: 38519239 ↗
L1GUIDELINECited in: Clinical Presentation, Staging and Risk Stratification (KDIGO), Acute Management, Renal Replacement Therapy, Dialysis Access & Transplantation, History and Evolution of Treatment, Special Populations & Pregnancy
[290]
Ketteler M, Evenepoel P, Holden RM et al.. “Chronic kidney disease-mineral and bone disorder: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference.” Kidney international (2025). PMID: 39864017 ↗
L5GUIDELINECited in: Clinical Presentation, Staging and Risk Stratification (KDIGO), History and Evolution of Treatment
[291]
Ku E, Del Vecchio L, Eckardt KU et al.. “Novel anemia therapies in chronic kidney disease: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference.” Kidney international (2023). PMID: 37236424 ↗
L5GUIDELINECited in: Clinical Presentation, Staging and Risk Stratification (KDIGO), Long-term and Definitive Management, History and Evolution of Treatment, Complications (Chronic Systemic Sequelae)
[292]
Iatridi F, Carrero JJ, Cornec-Le Gall E et al.. “KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease in Children and Adults: a commentary from the European Renal Best Practice (ERBP).” Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association (2025). PMID: 39299913 ↗
L5GUIDELINECited in: Clinical Presentation, Staging and Risk Stratification (KDIGO)
[293]
Agarwal R, Sinha AD, Cramer AE et al.. “Chlorthalidone for Hypertension in Advanced Chronic Kidney Disease.” The New England journal of medicine (2021). PMID: 34739197 ↗
L1RCTCited in: Clinical Presentation, Diagnosis and Workup, Staging and Risk Stratification (KDIGO), Prognosis and Natural History
[294]
Bhatt DL, Szarek M, Pitt B et al.. “Sotagliflozin in Patients with Diabetes and Chronic Kidney Disease.” The New England journal of medicine (2020). PMID: 33200891 ↗
L1RCTCited in: Clinical Presentation, Fluid, Electrolyte & Acid-Base Disorders
[295]
Fishbane S, Jamal A, Munera C et al.. “A Phase 3 Trial of Difelikefalin in Hemodialysis Patients with Pruritus.” The New England journal of medicine (2019). PMID: 31702883 ↗
L1RCTCited in: Clinical Presentation, Acute Management, Renal Replacement Therapy, Dialysis Access & Transplantation, Prognosis and Natural History
[296]
Chawla LS, Bellomo R, Bihorac A et al.. “Acute kidney disease and renal recovery: consensus report of the Acute Disease Quality Initiative (ADQI) 16 Workgroup.” Nature reviews. Nephrology (2017). PMID: 28239173 ↗
L5GUIDELINECited in: Clinical Presentation, Diagnosis and Workup, Staging and Risk Stratification (KDIGO), Acute Management, History and Evolution of Treatment
[297]
Akizawa T, Nangaku M, Yonekawa T et al.. “Efficacy and Safety of Daprodustat Compared with Darbepoetin Alfa in Japanese Hemodialysis Patients with Anemia: A Randomized, Double-Blind, Phase 3 Trial.” Clinical journal of the American Society of Nephrology : CJASN (2020). PMID: 32723804 ↗
L1TRIAL_NONRANDOMCited in: Clinical Presentation, Acute Management, Long-term and Definitive Management, Renal Replacement Therapy, Dialysis Access & Transplantation, History and Evolution of Treatment, Complications (Chronic Systemic Sequelae), Special Populations & Pregnancy
[298]
Samstein B, Smith AR, Freise CE et al.. “Complications and Their Resolution in Recipients of Deceased and Living Donor Liver Transplants: Findings From the A2ALL Cohort Study.” American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons (2015). PMID: 26461803 ↗
L2COHORTCited in: Clinical Presentation
[299]
Kassam AF, Mirza A, Kim Y et al.. “Long-term outcomes in patients with obesity and renal disease after sleeve gastrectomy.” American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons (2019). PMID: 31605562 ↗
L2TRIAL_NONRANDOMCited in: Clinical Presentation, Renal Replacement Therapy, Dialysis Access & Transplantation, Complications (Chronic Systemic Sequelae), Special Populations & Pregnancy
[300]
Moore PK, Hsu RK, Liu KD. “Management of Acute Kidney Injury: Core Curriculum 2018.” American journal of kidney diseases : the official journal of the National Kidney Foundation (2018). PMID: 29478864 ↗
L5CASE_REPORTCited in: Clinical Presentation, Staging and Risk Stratification (KDIGO), Acute Management, Renal Replacement Therapy, Dialysis Access & Transplantation
[301]
Vargas-Santos AB, Neogi T. “Management of Gout and Hyperuricemia in CKD.” American journal of kidney diseases : the official journal of the National Kidney Foundation (2017). PMID: 28456346 ↗
L5CASE_REPORTCited in: Clinical Presentation, Acute Management, Long-term and Definitive Management, Renal Replacement Therapy, Dialysis Access & Transplantation, Special Populations & Pregnancy
[302]
Mettang T, Kremer AE. “Uremic pruritus.” Kidney international (2014). PMID: 24402092 ↗
L5REVIEW_NARRATIVECited in: Clinical Presentation, Complications (Chronic Systemic Sequelae)
[303]
Fakhouri F, Schwotzer N, Cabiddu G et al.. “Glomerular diseases in pregnancy: pragmatic recommendations for clinical management.” Kidney international (2022). PMID: 36481180 ↗
L5REVIEW_NARRATIVECited in: Clinical Presentation
[304]
Johnson RJ, Mandell BF, Schlesinger N et al.. “Controversies and practical management of patients with gout and chronic kidney disease.” Kidney international (2024). PMID: 39033815 ↗
L5REVIEW_NARRATIVECited in: Clinical Presentation, Diagnosis and Workup, Acute Management, Long-term and Definitive Management, Renal Replacement Therapy, Dialysis Access & Transplantation, History and Evolution of Treatment, Special Populations & Pregnancy
[305]
Baker M, Perazella MA. “NSAIDs in CKD: Are They Safe?” American journal of kidney diseases : the official journal of the National Kidney Foundation (2020). PMID: 32479922 ↗
L5REVIEW_NARRATIVECited in: Clinical Presentation, Long-term and Definitive Management, Fluid, Electrolyte & Acid-Base Disorders
[306]
Hansen D, Jørgensen HS, Andersen TL et al.. “Multidisciplinary team approach for CKD-associated osteoporosis.” Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association (2024). PMID: 39315700 ↗
L5CASE_REPORTCited in: Clinical Presentation
[307]
Dahl NK, Bloom MS, Chebib FT et al.. “The Clinical Utility of Genetic Testing in the Diagnosis and Management of Adults with Chronic Kidney Disease.” Journal of the American Society of Nephrology : JASN (2023). PMID: 37794564 ↗
L4OTHERCited in: Clinical Presentation, Diagnosis and Workup
[308]
Maynard SE, Thadhani R. “Pregnancy and the kidney.” Journal of the American Society of Nephrology : JASN (2008). PMID: 19118150 ↗
L5REVIEW_NARRATIVECited in: Clinical Presentation, Renal Replacement Therapy, Dialysis Access & Transplantation, Prognosis and Natural History
[309]
Hayek SS, Sever S, Ko YA et al.. “Soluble Urokinase Receptor and Chronic Kidney Disease.” The New England journal of medicine (2015). PMID: 26539835 ↗
L2OTHERCited in: Clinical Presentation
[310]
Murphy M, Ding A, Berk J et al.. “Kidney Disease among People Who Are Incarcerated.” Clinical journal of the American Society of Nephrology : CJASN (2021). PMID: 34135025 ↗
L5REVIEW_NARRATIVECited in: Clinical Presentation
[311]
de Wolski K, Bansal N. “Cardiac Biomarkers in Chronic Kidney Disease: Signal or Noise?” Clinical journal of the American Society of Nephrology : CJASN (2025). PMID: 41171316 ↗
L5REVIEW_NARRATIVECited in: Clinical Presentation
[312]
Kronbichler A, Bajema IM, Bruchfeld A et al.. “Diagnosis and management of ANCA-associated vasculitis.” Lancet (London, England) (2024). PMID: 38368016 ↗
L5REVIEW_NARRATIVECited in: Clinical Presentation, Diagnosis and Workup, Long-term and Definitive Management, Complications (Chronic Systemic Sequelae), Prognosis and Natural History
[313]
Ye C, Ebeling P, Kline G. “Osteoporosis.” Lancet (London, England) (2025). PMID: 40946719 ↗
L5REVIEW_NARRATIVECited in: Clinical Presentation, Diagnosis and Workup, Long-term and Definitive Management, Complications (Chronic Systemic Sequelae)
[314]
Georgianos PI, Agarwal R. “Hypertension in chronic kidney disease-treatment standard 2023.” Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association (2023). PMID: 37355779 ↗
L5REVIEW_NARRATIVECited in: Clinical Presentation, Fluid, Electrolyte & Acid-Base Disorders
[315]
Mehta S, Lightle A, Judson MA. “Renal sarcoidosis.” Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association (2023). PMID: 35867874 ↗
L5OTHERCited in: Clinical Presentation
[316]
Ruilope LM, Pitt B, Anker SD et al.. “Kidney outcomes with finerenone: an analysis from the FIGARO-DKD study.” Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association (2023). PMID: 35451488 ↗
L1OTHERCited in: Clinical Presentation, Diagnosis and Workup, Staging and Risk Stratification (KDIGO)
[317]
Evenepoel P, Cunningham J, Ferrari S et al.. “European Consensus Statement on the diagnosis and management of osteoporosis in chronic kidney disease stages G4-G5D.” Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association (2021). PMID: 33098421 ↗
L5REVIEW_NARRATIVECited in: Clinical Presentation
[318]
Ortiz A, Yanagita M, Yokoi H et al.. “Evolving strategies for early diagnosis, proactive prevention and treatment of CKD.” Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association (2026). PMID: 40795360 ↗
L5REVIEW_NARRATIVECited in: Clinical Presentation, Renal Replacement Therapy, Dialysis Access & Transplantation, Prevention, Screening & Surveillance
[319]
Malyszko J, Basak G, Batko K et al.. “Haematological disorders following kidney transplantation.” Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association (2022). PMID: 33150431 ↗
L5REVIEW_NARRATIVECited in: Clinical Presentation, Renal Replacement Therapy, Dialysis Access & Transplantation, Special Populations & Pregnancy
[320]
Shimoyama Y, Kadono N, Umegaki O. “The Toxic Filter: Chronic Kidney Disease Drives Neuro-Psychiatric Toxicity and Agitation in Sepsis Survivors Aged ≥ 90 Years: A Retrospective Cohort Study Using the National Database of Japan.” Psychogeriatrics : the official journal of the Japanese Psychogeriatric Society (2026). PMID: 42411180 ↗
L2COHORTCited in: Clinical Presentation, Long-term and Definitive Management, Complications (Chronic Systemic Sequelae), Special Populations & Pregnancy
[321]
Arık H, Tınazlı M, Süer K. “Vitamin D Levels and Uropathogen Distribution in Urinary Tract Infections: A Six-Year Retrospective Study from Cyprus.” Medicina (Kaunas, Lithuania) (2026). PMID: 42356125 ↗
L4COHORTCited in: Clinical Presentation, Special Populations & Pregnancy
[322]
Kolvenbach CM, Shril S, Hildebrandt F. “The genetics and pathogenesis of CAKUT.” Nature reviews. Nephrology (2023). PMID: 37524861 ↗
L5REVIEW_NARRATIVECited in: Clinical Presentation, Diagnosis and Workup
[323]
Kalantar-Zadeh K, Lockwood MB, Rhee CM et al.. “Patient-centred approaches for the management of unpleasant symptoms in kidney disease.” Nature reviews. Nephrology (2022). PMID: 34980890 ↗
L5REVIEW_NARRATIVECited in: Clinical Presentation, Acute Management, Renal Replacement Therapy, Dialysis Access & Transplantation, Special Populations & Pregnancy
[324]
Taylor CT, Scholz CC. “The effect of HIF on metabolism and immunity.” Nature reviews. Nephrology (2022). PMID: 35726016 ↗
L5REVIEW_NARRATIVECited in: Clinical Presentation
[325]
Ku E, McCulloch CE, Roll GR et al.. “Association between bariatric surgery after kidney transplantation and graft and survival outcomes.” American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons (2025). PMID: 39848339 ↗
L2OTHERCited in: Clinical Presentation, Renal Replacement Therapy, Dialysis Access & Transplantation, Complications (Chronic Systemic Sequelae)
[326]
Kovesdy CP, Czira ME, Rudas A et al.. “Body mass index, waist circumference and mortality in kidney transplant recipients.” American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons (2010). PMID: 21087417 ↗
L2OTHERCited in: Clinical Presentation
[327]
Nadim MK, Davis CL, Sung R et al.. “Simultaneous liver-kidney transplantation: a survey of US transplant centers.” American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons (2012). PMID: 22759208 ↗
L5OTHERCited in: Clinical Presentation, Staging and Risk Stratification (KDIGO)
[328]
Kido R, Shibagaki Y, Iwadoh K et al.. “How do living kidney donors develop end-stage renal disease?” American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons (2009). PMID: 19681812 ↗
L3OTHERCited in: Clinical Presentation, Long-term and Definitive Management, Complications (Chronic Systemic Sequelae)
[329]
Winther S, Svensson M, Jørgensen HS et al.. “Repeated Contrast Administration Is Associated With Low Risk of Postcontrast Acute Kidney Injury and Long-Term Complications in Patients With Severe Chronic Kidney Disease.” American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons (2015). PMID: 26663699 ↗
L2OTHERCited in: Clinical Presentation, Staging and Risk Stratification (KDIGO), Prevention, Screening & Surveillance
[330]
Paz-Pacheco E, Oliva RV, Acuin CS et al.. “Philippine Clinical Practice Guidelines for Periodic Health Examination: Screening for Renal, Metabolic, Nutritional, and Endocrine Disorders.” Acta medica Philippina (2026). PMID: 42382928 ↗
L5GUIDELINECited in: Clinical Presentation
[331]
Mohsen M, Jaber E, Naserallah Q et al.. “Acquired reactive perforating collagenosis in a patient with multiple comorbidities: a case report from Palestine.” Frontiers in medicine (2026). PMID: 42433980 ↗
L4CASE_REPORTCited in: Clinical Presentation
[332]
Khan SR, Gupta RD, Asadujjaman M et al.. “Comparative Effectiveness of Roxadustat versus Erythropoietin in the Management of Anemia among the Patients of Non Dialytic Chronic Kidney Disease Stage 5: A Retrospective Cohort Study.” Mymensingh medical journal : MMJ (2026). PMID: 42375043 ↗
L2COHORTCited in: Clinical Presentation, Complications (Chronic Systemic Sequelae)
[333]
Carvalho T, Lavrador M, Saraiva J et al.. “HNF1B-MODY (MODY-5): a rare form of diabetes with multisystemic features-two case reports.” Frontiers in endocrinology (2026). PMID: 42369057 ↗
L4CASE_REPORTCited in: Clinical Presentation, Fluid, Electrolyte & Acid-Base Disorders, Prevention, Screening & Surveillance
[334]
Aziz A, Wajid A. “Clinicopathological profile, risk factors and outcome of adult biopsy-proven infection-related glomerulonephritis: A single centre prospective study.” JPMA. The Journal of the Pakistan Medical Association (2026). PMID: 42363333 ↗
L2COHORTCited in: Clinical Presentation, Diagnosis and Workup, Complications (Chronic Systemic Sequelae)
[335]
Selvarajah V, Robertson D, Hansen L et al.. “A randomized phase 2b trial examined the effects of the glucagon-like peptide-1 and glucagon receptor agonist cotadutide on kidney outcomes in patients with diabetic kidney disease.” Kidney international (2024). PMID: 39218393 ↗
L1RCTCited in: Diagnosis and Workup
[336]
Helget LN, Davis-Karim A, O'Dell JR et al.. “Efficacy and Safety of Allopurinol and Febuxostat in Patients With Gout and CKD: Subgroup Analysis of the STOP Gout Trial.” American journal of kidney diseases : the official journal of the National Kidney Foundation (2024). PMID: 38906504 ↗
L2RCTCited in: Diagnosis and Workup, History and Evolution of Treatment, Prognosis and Natural History, Special Populations & Pregnancy
[337]
Badve SV, Pascoe EM, Tiku A et al.. “Effects of Allopurinol on the Progression of Chronic Kidney Disease.” The New England journal of medicine (2020). PMID: 32579811 ↗
L1RCTCited in: Diagnosis and Workup, Prognosis and Natural History
[338]
Inker LA, Heerspink HJL, Tighiouart H et al.. “Association of Treatment Effects on Early Change in Urine Protein and Treatment Effects on GFR Slope in IgA Nephropathy: An Individual Participant Meta-analysis.” American journal of kidney diseases : the official journal of the National Kidney Foundation (2021). PMID: 33775708 ↗
L1SR_OBSCited in: Diagnosis and Workup, Prognosis and Natural History
[339]
Levey AS, de Jong PE, Coresh J et al.. “The definition, classification, and prognosis of chronic kidney disease: a KDIGO Controversies Conference report.” Kidney international (2010). PMID: 21150873 ↗
L5OTHERCited in: Diagnosis and Workup, Prognosis and Natural History
[340]
House AA, Wanner C, Sarnak MJ et al.. “Heart failure in chronic kidney disease: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference.” Kidney international (2019). PMID: 31053387 ↗
L5OTHERCited in: Diagnosis and Workup, Renal Replacement Therapy, Dialysis Access & Transplantation, Prognosis and Natural History
[341]
Bomback AS, Santoriello D, Avasare RS et al.. “C3 glomerulonephritis and dense deposit disease share a similar disease course in a large United States cohort of patients with C3 glomerulopathy.” Kidney international (2018). PMID: 29310824 ↗
L2OTHERCited in: Diagnosis and Workup, Prognosis and Natural History
[342]
Astley ME, Chesnaye NC, Hallan S et al.. “Age- and sex-specific reference values of estimated glomerular filtration rate for European adults.” Kidney international (2025). PMID: 40122341 ↗
L2OTHERCited in: Diagnosis and Workup
[343]
Markowitz GS, Perazella MA. “Acute phosphate nephropathy.” Kidney international (2009). PMID: 19675530 ↗
L5REVIEW_NARRATIVECited in: Diagnosis and Workup
[344]
Matsuo S, Imai E, Horio M et al.. “Revised equations for estimated GFR from serum creatinine in Japan.” American journal of kidney diseases : the official journal of the National Kidney Foundation (2009). PMID: 19339088 ↗
L2OTHERCited in: Diagnosis and Workup, Prognosis and Natural History
[345]
Delgado C, Baweja M, Crews DC et al.. “A Unifying Approach for GFR Estimation: Recommendations of the NKF-ASN Task Force on Reassessing the Inclusion of Race in Diagnosing Kidney Disease.” American journal of kidney diseases : the official journal of the National Kidney Foundation (2021). PMID: 34563581 ↗
L5REVIEW_NARRATIVECited in: Diagnosis and Workup
[346]
Blasco M, Quiroga B, García-Aznar JM et al.. “Genetic Characterization of Kidney Failure of Unknown Etiology in Spain: Findings From the GENSEN Study.” American journal of kidney diseases : the official journal of the National Kidney Foundation (2024). PMID: 38972501 ↗
L4OTHERCited in: Diagnosis and Workup, History and Evolution of Treatment
[347]
Hu EA, Coresh J, Anderson CAM et al.. “Adherence to Healthy Dietary Patterns and Risk of CKD Progression and All-Cause Mortality: Findings From the CRIC (Chronic Renal Insufficiency Cohort) Study.” American journal of kidney diseases : the official journal of the National Kidney Foundation (2020). PMID: 32768632 ↗
L2OTHERCited in: Diagnosis and Workup, Renal Replacement Therapy, Dialysis Access & Transplantation
[348]
McCoy IE, Yang J, Go AS et al.. “Complex Etiologies of the Discordance Between Cystatin C- and Creatinine-Based Estimated GFR and Its Adverse Associations: Findings From the CRIC Study.” American journal of kidney diseases : the official journal of the National Kidney Foundation (2025). PMID: 40373998 ↗
L2OTHERCited in: Diagnosis and Workup
[349]
Bostrom MA, Freedman BI. “The spectrum of MYH9-associated nephropathy.” Clinical journal of the American Society of Nephrology : CJASN (2010). PMID: 20299374 ↗
L5REVIEW_NARRATIVECited in: Diagnosis and Workup, Staging and Risk Stratification (KDIGO), Long-term and Definitive Management, Complications (Chronic Systemic Sequelae)
[350]
Lee J, Oh S, Kang H et al.. “Environment-Wide Association Study of CKD.” Clinical journal of the American Society of Nephrology : CJASN (2020). PMID: 32628126 ↗
L2OTHERCited in: Diagnosis and Workup, Staging and Risk Stratification (KDIGO), Prognosis and Natural History, Special Populations & Pregnancy
[351]
Shastri S, Tighiouart H, Katz R et al.. “Chronic kidney disease in octogenarians.” Clinical journal of the American Society of Nephrology : CJASN (2011). PMID: 21511839 ↗
L4OTHERCited in: Diagnosis and Workup, Staging and Risk Stratification (KDIGO), Prognosis and Natural History, Special Populations & Pregnancy
[352]
Bellomo R, Kellum JA, Ronco C. “Acute kidney injury.” Lancet (London, England) (2012). PMID: 22617274 ↗
L5REVIEW_NARRATIVECited in: Diagnosis and Workup, Acute Management, Renal Replacement Therapy, Dialysis Access & Transplantation
[353]
Ong ACM, Carriazo S, Ma BM et al.. “Autosomal dominant polycystic kidney disease.” Lancet (London, England) (2026). PMID: 41771281 ↗
L5REVIEW_NARRATIVECited in: Diagnosis and Workup
[354]
Judge P, Haynes R, Landray MJ et al.. “Neprilysin inhibition in chronic kidney disease.” Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association (2014). PMID: 25140014 ↗
L5REVIEW_NARRATIVECited in: Diagnosis and Workup, History and Evolution of Treatment, Prognosis and Natural History
[355]
Campbell VK, Gately RP, Krishnasamy R et al.. “Midkine and chronic kidney disease-associated multisystem organ dysfunctions.” Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association (2021). PMID: 32542315 ↗
L5REVIEW_NARRATIVECited in: Diagnosis and Workup
[356]
Milburn J, Jones R, Levy JB. “Renal effects of novel antiretroviral drugs.” Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association (2017). PMID: 27190354 ↗
L5REVIEW_NARRATIVECited in: Diagnosis and Workup
[357]
Özyilmaz A, de Jong PE, Gansevoort RT. “Screening for chronic kidney disease can be of help to prevent atherosclerotic end-organ damage.” Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association (2012). PMID: 23144071 ↗
L5REVIEW_NARRATIVECited in: Diagnosis and Workup, Prevention, Screening & Surveillance
[358]
Kongerud IC, Midtvedt K, Solbu MD et al.. “Can sodium-glucose cotransporter 2 (SGLT2) inhibition preserve renal structure and function in de novo kidney transplant recipients? Protocol for a randomised, double-blind, placebo-controlled trial assessing the efficacy of dapagliflozin on kidney structure, function and safety in kidney transplant recipients in Norway-the DEAK study.” BMJ open (2026). PMID: 42315275 ↗
L5TRIAL_NONRANDOMCited in: Diagnosis and Workup, Long-term and Definitive Management, Renal Replacement Therapy, Dialysis Access & Transplantation
[359]
Yang X, Okamura DM, Lu X et al.. “CD36 in chronic kidney disease: novel insights and therapeutic opportunities.” Nature reviews. Nephrology (2017). PMID: 28919632 ↗
L5REVIEW_NARRATIVECited in: Diagnosis and Workup
[360]
Vijayan A. “Tackling AKI: prevention, timing of dialysis and follow-up.” Nature reviews. Nephrology (2021). PMID: 33335277 ↗
L5REVIEW_NARRATIVECited in: Diagnosis and Workup, Acute Management, Fluid, Electrolyte & Acid-Base Disorders, Renal Replacement Therapy, Dialysis Access & Transplantation, Special Populations & Pregnancy
[361]
Barrera-Chimal J, Lima-Posada I, Bakris GL et al.. “Mineralocorticoid receptor antagonists in diabetic kidney disease - mechanistic and therapeutic effects.” Nature reviews. Nephrology (2021). PMID: 34675379 ↗
L5REVIEW_NARRATIVECited in: Diagnosis and Workup, Staging and Risk Stratification (KDIGO), Long-term and Definitive Management
[362]
Ataga KI, Saraf SL, Derebail VK. “The nephropathy of sickle cell trait and sickle cell disease.” Nature reviews. Nephrology (2022). PMID: 35190716 ↗
L5REVIEW_NARRATIVECited in: Diagnosis and Workup, Staging and Risk Stratification (KDIGO), History and Evolution of Treatment, Prognosis and Natural History
[363]
Chesnaye NC, Carrero JJ, Hecking M et al.. “Differences in the epidemiology, management and outcomes of kidney disease in men and women.” Nature reviews. Nephrology (2023). PMID: 37985869 ↗
L5REVIEW_NARRATIVECited in: Diagnosis and Workup, Renal Replacement Therapy, Dialysis Access & Transplantation
[364]
Cerda J, Kashani K, Ostermann M et al.. “The global epidemiology of acute kidney injury: challenges and opportunities.” Nature reviews. Nephrology (2025). PMID: 41350436 ↗
L5REVIEW_NARRATIVECited in: Diagnosis and Workup, Staging and Risk Stratification (KDIGO)
[365]
Elganyny MKE, Elganyni AKE, Maskji HA et al.. “Long-Term Safety and Renal Outcomes of Semaglutide in Non-Diabetic Obesity with Chronic Kidney Disease or Hypertension: A Systematic Review and Meta-Analysis.” La Clinica terapeutica (2026). PMID: 42340790 ↗
L1SR_OBSCited in: Diagnosis and Workup, Staging and Risk Stratification (KDIGO), Long-term and Definitive Management, Complications (Chronic Systemic Sequelae)
[366]
Eason JD, Gonwa TA, Davis CL et al.. “Proceedings of Consensus Conference on Simultaneous Liver Kidney Transplantation (SLK).” American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons (2008). PMID: 18808402 ↗
L5OTHERCited in: Diagnosis and Workup, Complications (Chronic Systemic Sequelae), Prognosis and Natural History
[367]
Halloran PF, Böhmig GA, Bromberg JS et al.. “Discovering novel injury features in kidney transplant biopsies associated with TCMR and donor aging.” American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons (2020). PMID: 33107191 ↗
L4OTHERCited in: Diagnosis and Workup
[368]
Gaillard F, Flamant M, Lemoine S et al.. “Estimated or Measured GFR in Living Kidney Donors Work-up?” American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons (2016). PMID: 27273845 ↗
L2OTHERCited in: Diagnosis and Workup
[369]
Martinelli J, Habes D, Majed L et al.. “Long-term outcome of liver transplantation in childhood: A study of 20-year survivors.” American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons (2018). PMID: 29247469 ↗
L4OTHERCited in: Diagnosis and Workup, Acute Management
[370]
Wang X, Wang Y, She J et al.. “Mortality prediction by quick Sequential Organ Failure Assessment, National Early Warning Score 2, Shock Index, and Modified Shock Index in suspected sepsis: A retrospective study.” The Journal of international medical research (2026). PMID: 42316959 ↗
L3COHORTCited in: Diagnosis and Workup, Staging and Risk Stratification (KDIGO)
[371]
Han R, Ouyang Y, Zhou S. “Endothelial Activation Stress Index and risk of all-cause and cardiovascular mortality in early-stage cardio-renal-metabolic syndrome: A nationwide retrospective cohort study.” Medicine (2026). PMID: 42299547 ↗
L2COHORTCited in: Diagnosis and Workup
[372]
Tang L, He Y, Qiao Z et al.. “Breaking the barrier: oral tacrolimus plus apremilast rescues acute generalized pustular psoriasis with severe comorbidities-a case report.” Frontiers in immunology (2026). PMID: 42344901 ↗
L4CASE_REPORTCited in: Diagnosis and Workup, Long-term and Definitive Management
[373]
Yin Y, Lin H, Gao Q et al.. “Finerenone in Treating a 12-Year-Old Boy Suffering Gitelman Syndrome Without Causing Gynecomastia.” Nephrology (Carlton, Vic.) (2026). PMID: 42337699 ↗
L4CASE_REPORTCited in: Diagnosis and Workup, Fluid, Electrolyte & Acid-Base Disorders
[374]
Boateng I, Phillips T, Harris S et al.. “The impact of multiple long-term conditions on mortality, progression to kidney failure and health-related quality of life among people with chronic kidney disease: a multicentre cohort study (NURTuRE-CKD).” Annals of medicine (2026). PMID: 42334309 ↗
L2COHORTCited in: Diagnosis and Workup
[375]
Zhang Y, Zhang M, Liu S et al.. “Gut microbiota biomarkers of chronic kidney disease progression identified by 16S rDNA sequencing and machine learning.” Renal failure (2026). PMID: 42425595 ↗
L3OTHERCited in: Diagnosis and Workup
[376]
Hu T, Chen X, Zhou Y et al.. “Visit-to-visit HbA1c variability and subsequent renal function decline in older adults with type 2 diabetes.” Frontiers in endocrinology (2026). PMID: 42416897 ↗
L2OTHERCited in: Diagnosis and Workup
[377]
Rizwan M, Naseem R, Khan MA et al.. “Explainable AI machine learning framework for chronic kidney disease prediction utilizing electronic health records.” BMC medical informatics and decision making (2026). PMID: 42399867 ↗
L3OTHERCited in: Diagnosis and Workup
[378]
Babitt JL, Berns JS, Bozkurt B et al.. “Executive Summary of the KDIGO 2026 Clinical Practice Guideline for the Management of Anemia in Chronic Kidney Disease (CKD).” Kidney international (2026). PMID: 41485807 ↗
L1GUIDELINECited in: Staging and Risk Stratification (KDIGO), History and Evolution of Treatment, Complications (Chronic Systemic Sequelae)
[379]
. “Erratum: Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Update Work Group. KDIGO 2017 Clinical Practice Guideline Update for the Diagnosis, Evaluation, Prevention, and Treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD). Kidney Int Suppl. 2017;7:1-59.” Kidney international supplements (2017). PMID: 30681074 ↗
L2GUIDELINECited in: Staging and Risk Stratification (KDIGO)
[380]
Navaneethan SD, Bansal N, Cavanaugh KL et al.. “KDOQI US Commentary on the KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of CKD.” American journal of kidney diseases : the official journal of the National Kidney Foundation (2024). PMID: 39556063 ↗
L5GUIDELINECited in: Staging and Risk Stratification (KDIGO)
[381]
Del Vecchio L, Cases A, Eisenga MF et al.. “KDIGO 2026 clinical practice guideline for Anemia in Chronic Kidney Disease (CKD): a commentary from the European Renal Best Practice (ERBP).” Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association (2026). PMID: 41604211 ↗
L5GUIDELINECited in: Staging and Risk Stratification (KDIGO)
[382]
Tonelli M, Wiebe N, Culleton B et al.. “Chronic kidney disease and mortality risk: a systematic review.” Journal of the American Society of Nephrology : JASN (2006). PMID: 16738019 ↗
L2SR_OBSCited in: Staging and Risk Stratification (KDIGO)
[383]
Appel LJ, Wright JT, Greene T et al.. “Intensive blood-pressure control in hypertensive chronic kidney disease.” The New England journal of medicine (2010). PMID: 20818902 ↗
L1RCTCited in: Staging and Risk Stratification (KDIGO)
[384]
Serra AL, Poster D, Kistler AD et al.. “Sirolimus and kidney growth in autosomal dominant polycystic kidney disease.” The New England journal of medicine (2010). PMID: 20581391 ↗
L1RCTCited in: Staging and Risk Stratification (KDIGO)
[385]
Torres VE, Abebe KZ, Chapman AB et al.. “Angiotensin blockade in late autosomal dominant polycystic kidney disease.” The New England journal of medicine (2014). PMID: 25399731 ↗
L1RCTCited in: Staging and Risk Stratification (KDIGO), Fluid, Electrolyte & Acid-Base Disorders
[386]
Baigent C, Landray MJ, Reith C et al.. “The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial.” Lancet (London, England) (2011). PMID: 21663949 ↗
L1RCTCited in: Staging and Risk Stratification (KDIGO), Acute Management, Renal Replacement Therapy, Dialysis Access & Transplantation, History and Evolution of Treatment, Special Populations & Pregnancy
[387]
Heerspink HJL, Cardona JF, Jolly S et al.. “Balcinrenone in combination with dapagliflozin compared with dapagliflozin alone in patients with chronic kidney disease and albuminuria: a randomised, active-controlled double-blind, phase 2b clinical trial.” Lancet (London, England) (2025). PMID: 41218621 ↗
L1RCTCited in: Staging and Risk Stratification (KDIGO), History and Evolution of Treatment
[388]
van Mil D, Kieneker LM, Evers-Roeten B et al.. “Participation rate and yield of two home-based screening methods to detect increased albuminuria in the general population in the Netherlands (THOMAS): a prospective, randomised, open-label implementation study.” Lancet (London, England) (2023). PMID: 37597522 ↗
L1RCTCited in: Staging and Risk Stratification (KDIGO)
[389]
Neuen BL, Tighiouart H, Heerspink HJL et al.. “Acute Treatment Effects on GFR in Randomized Clinical Trials of Kidney Disease Progression.” Journal of the American Society of Nephrology : JASN (2021). PMID: 34862238 ↗
L1SR_OBSCited in: Staging and Risk Stratification (KDIGO)
[390]
Shlipak MG, Matsushita K, Ärnlöv J et al.. “Cystatin C versus creatinine in determining risk based on kidney function.” The New England journal of medicine (2013). PMID: 24004120 ↗
L2SR_OBSCited in: Staging and Risk Stratification (KDIGO)
[391]
Mahmoodi BK, Matsushita K, Woodward M et al.. “Associations of kidney disease measures with mortality and end-stage renal disease in individuals with and without hypertension: a meta-analysis.” Lancet (London, England) (2012). PMID: 23013600 ↗
L2SR_OBSCited in: Staging and Risk Stratification (KDIGO)
[392]
Zeng G, Bidel Z, Yang Q et al.. “Pharmacological blood-pressure lowering for the prevention of cardiovascular disease and death across the full spectrum of chronic kidney disease severity: an individual-participant data meta-analysis.” Lancet (London, England) (2026). PMID: 42035778 ↗
L1SR_OBSCited in: Staging and Risk Stratification (KDIGO)
[393]
Dong L, Chen Y, Lin X et al.. “Risk prediction models for cognitive impairment in patients with chronic kidney disease: a systematic review.” Frontiers in public health (2026). PMID: 42368958 ↗
L2SR_OBSCited in: Staging and Risk Stratification (KDIGO), Complications (Chronic Systemic Sequelae)
[394]
Ricardo AC, Yang W, Sha D et al.. “Sex-Related Disparities in CKD Progression.” Journal of the American Society of Nephrology : JASN (2018). PMID: 30510134 ↗
L2OTHERCited in: Staging and Risk Stratification (KDIGO), Acute Management, Renal Replacement Therapy, Dialysis Access & Transplantation
[395]
Sumida K, Molnar MZ, Potukuchi PK et al.. “Constipation and Incident CKD.” Journal of the American Society of Nephrology : JASN (2016). PMID: 28122944 ↗
L2OTHERCited in: Staging and Risk Stratification (KDIGO)
[396]
Mitsnefes MM. “Cardiovascular disease in children with chronic kidney disease.” Journal of the American Society of Nephrology : JASN (2012). PMID: 22383696 ↗
L5REVIEW_NARRATIVECited in: Staging and Risk Stratification (KDIGO), Acute Management, Renal Replacement Therapy, Dialysis Access & Transplantation
[397]
Zanoli L, Lentini P, Briet M et al.. “Arterial Stiffness in the Heart Disease of CKD.” Journal of the American Society of Nephrology : JASN (2019). PMID: 31040188 ↗
L5REVIEW_NARRATIVECited in: Staging and Risk Stratification (KDIGO), Acute Management, Renal Replacement Therapy, Dialysis Access & Transplantation
[398]
Ma W, Wang J, Zhang J et al.. “An interpretable prediction model for severe sepsis-associated acute kidney injury in older ICU patients with sepsis: a prospective multicenter cohort study.” BMC geriatrics (2026). PMID: 42343250 ↗
L2COHORTCited in: Staging and Risk Stratification (KDIGO)
[399]
Jhee JH, Joo YS, Kee YK et al.. “Secondhand Smoke and CKD.” Clinical journal of the American Society of Nephrology : CJASN (2019). PMID: 30846462 ↗
L2OTHERCited in: Staging and Risk Stratification (KDIGO)
[400]
Rule AD, Krambeck AE, Lieske JC. “Chronic kidney disease in kidney stone formers.” Clinical journal of the American Society of Nephrology : CJASN (2011). PMID: 21784825 ↗
L5REVIEW_NARRATIVECited in: Staging and Risk Stratification (KDIGO), History and Evolution of Treatment, Prognosis and Natural History
[401]
Yabu JM, Winkelmayer WC. “Posttransplantation anemia: mechanisms and management.” Clinical journal of the American Society of Nephrology : CJASN (2011). PMID: 21734096 ↗
L5REVIEW_NARRATIVECited in: Staging and Risk Stratification (KDIGO), Complications (Chronic Systemic Sequelae)
[402]
Tin A, Köttgen A. “Genome-Wide Association Studies of CKD and Related Traits.” Clinical journal of the American Society of Nephrology : CJASN (2020). PMID: 32409295 ↗
L5REVIEW_NARRATIVECited in: Staging and Risk Stratification (KDIGO)
[403]
Xu H, Gasparini A, Ishigami J et al.. “eGFR and the Risk of Community-Acquired Infections.” Clinical journal of the American Society of Nephrology : CJASN (2017). PMID: 28818849 ↗
L2OTHERCited in: Staging and Risk Stratification (KDIGO)
[404]
Roberts NLS, Pierre JL, Rouzier V et al.. “Prevalence and Severity of Chronic Kidney Disease in Haiti.” Clinical journal of the American Society of Nephrology : CJASN (2023). PMID: 37081617 ↗
L4OTHERCited in: Staging and Risk Stratification (KDIGO)
[405]
Ortiz A, Lees JS, Torra R et al.. “The updated global burden of chronic kidney disease: one death every 20 seconds.” Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association (2026). PMID: 41739048 ↗
L5OTHERCited in: Staging and Risk Stratification (KDIGO)
[406]
Xipell M, Iraola M, Mirioglu S et al.. “Comparative Analysis of Lupus Nephritis Guidelines: ACR 2025, EULAR 2025, and Kdigo 2024.” Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association (2026). PMID: 42101868 ↗
L5OTHERCited in: Staging and Risk Stratification (KDIGO)
[407]
Rossing P. “HbA1c and beyond.” Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association (2023). PMID: 34383945 ↗
L5OTHERCited in: Staging and Risk Stratification (KDIGO)
[408]
Liu H, Xiong J. “A retrospective study on development and internal validation of cardiovascular disease risk prediction model for patients with chronic kidney disease stage 3-5 within 5 years.” PeerJ (2026). PMID: 42267085 ↗
L3COHORTCited in: Staging and Risk Stratification (KDIGO)
[409]
Kaur R, Singh A. “Efficacy and Safety of GLP-1 Receptor Agonists on Combined Cardiovascular and Renal Outcomes in Patients With Chronic Kidney Disease: A Systematic Review and Meta-Analysis.” Diabetes, obesity & metabolism (2026). PMID: 42337824 ↗
L1SR_OBSCited in: Staging and Risk Stratification (KDIGO), History and Evolution of Treatment
[410]
James MT, Bhatt M, Pannu N et al.. “Long-term outcomes of acute kidney injury and strategies for improved care.” Nature reviews. Nephrology (2020). PMID: 32051567 ↗
L5REVIEW_NARRATIVECited in: Staging and Risk Stratification (KDIGO)
[411]
Blum MF, Neuen BL, Grams ME. “Risk-directed management of chronic kidney disease.” Nature reviews. Nephrology (2025). PMID: 39885336 ↗
L5REVIEW_NARRATIVECited in: Staging and Risk Stratification (KDIGO)
[412]
Kooman JP, Kotanko P, Schols AM et al.. “Chronic kidney disease and premature ageing.” Nature reviews. Nephrology (2014). PMID: 25287433 ↗
L5REVIEW_NARRATIVECited in: Staging and Risk Stratification (KDIGO)
[413]
Cheung AK, Chang TI, Cushman WC et al.. “Executive summary of the KDIGO 2021 Clinical Practice Guideline for the Management of Blood Pressure in Chronic Kidney Disease.” Kidney international (2021). PMID: 33637203 ↗
L1GUIDELINECited in: Acute Management, Fluid, Electrolyte & Acid-Base Disorders, Renal Replacement Therapy, Dialysis Access & Transplantation
[414]
Yang C, Gao B, Wang F et al.. “Executive summary for the China Kidney Disease Network (CK-NET) 2017-2018 Annual Data Report.” Kidney international (2025). PMID: 40404261 ↗
L4GUIDELINECited in: Acute Management, Renal Replacement Therapy, Dialysis Access & Transplantation, Prevention, Screening & Surveillance
[415]
Wanner C, Tonelli M. “KDIGO Clinical Practice Guideline for Lipid Management in CKD: summary of recommendation statements and clinical approach to the patient.” Kidney international (2014). PMID: 24552851 ↗
L1GUIDELINECited in: Acute Management, Renal Replacement Therapy, Dialysis Access & Transplantation
[416]
Lok CE, Huber TS, Lee T et al.. “KDOQI Clinical Practice Guideline for Vascular Access: 2019 Update.” American journal of kidney diseases : the official journal of the National Kidney Foundation (2020). PMID: 32778223 ↗
L1GUIDELINECited in: Acute Management, Renal Replacement Therapy, Dialysis Access & Transplantation, History and Evolution of Treatment, Special Populations & Pregnancy
[417]
. “KDOQI Clinical Practice Guideline for Hemodialysis Adequacy: 2015 update.” American journal of kidney diseases : the official journal of the National Kidney Foundation (2015). PMID: 26498416 ↗
L1GUIDELINECited in: Acute Management, Renal Replacement Therapy, Dialysis Access & Transplantation, History and Evolution of Treatment, Special Populations & Pregnancy
[418]
See EJ, Jayasinghe K, Glassford N et al.. “Long-term risk of adverse outcomes after acute kidney injury: a systematic review and meta-analysis of cohort studies using consensus definitions of exposure.” Kidney international (2018). PMID: 30473140 ↗
L2SR_OBSCited in: Acute Management, Prognosis and Natural History
[419]
Fishbane S, Dember LM, Jadoul M et al.. “The randomized DIALIZE-Outcomes trial evaluated sodium zirconium cyclosilicate in hemodialysis.” Kidney international (2025). PMID: 40618849 ↗
L1RCTCited in: Acute Management, Fluid, Electrolyte & Acid-Base Disorders, Renal Replacement Therapy, Dialysis Access & Transplantation
[420]
Pyne L, Rossignol P, Giles C et al.. “Safety and efficacy of steroidal mineralocorticoid receptor antagonists in patients with kidney failure requiring dialysis: a systematic review and meta-analysis of randomised controlled trials.” Lancet (London, England) (2025). PMID: 40840478 ↗
L1SR_MA_RCTCited in: Acute Management, Renal Replacement Therapy, Dialysis Access & Transplantation
[421]
Xu C, Smith ER, Tiong MK et al.. “Interventions To Attenuate Vascular Calcification Progression in Chronic Kidney Disease: A Systematic Review of Clinical Trials.” Journal of the American Society of Nephrology : JASN (2022). PMID: 35232774 ↗
L2TRIAL_NONRANDOMCited in: Acute Management, Long-term and Definitive Management, Renal Replacement Therapy, Dialysis Access & Transplantation, Special Populations & Pregnancy
[422]
Drube J, Wan M, Bonthuis M et al.. “Clinical practice recommendations for growth hormone treatment in children with chronic kidney disease.” Nature reviews. Nephrology (2019). PMID: 31197263 ↗
L1GUIDELINECited in: Acute Management, Renal Replacement Therapy, Dialysis Access & Transplantation, History and Evolution of Treatment, Special Populations & Pregnancy
[423]
Toka HR, Bernardo M, Burke SK et al.. “Vadadustat Three Times Weekly in Patients With Anemia Due to Dialysis-Dependent CKD.” American journal of kidney diseases : the official journal of the National Kidney Foundation (2024). PMID: 39521398 ↗
L1RCTCited in: Acute Management, Renal Replacement Therapy, Dialysis Access & Transplantation, History and Evolution of Treatment, Special Populations & Pregnancy
[424]
Chen K, Didsbury M, van Zwieten A et al.. “Neurocognitive and Educational Outcomes in Children and Adolescents with CKD: A Systematic Review and Meta-Analysis.” Clinical journal of the American Society of Nephrology : CJASN (2018). PMID: 29472306 ↗
L2SR_OBSCited in: Acute Management
[425]
Fishbane S, Pollock CA, El-Shahawy M et al.. “Roxadustat Versus Epoetin Alfa for Treating Anemia in Patients with Chronic Kidney Disease on Dialysis: Results from the Randomized Phase 3 ROCKIES Study.” Journal of the American Society of Nephrology : JASN (2022). PMID: 35361724 ↗
L1RCTCited in: Acute Management, Long-term and Definitive Management, Renal Replacement Therapy, Dialysis Access & Transplantation, History and Evolution of Treatment, Complications (Chronic Systemic Sequelae), Special Populations & Pregnancy
[426]
Pergola PE, Devalaraja M, Fishbane S et al.. “Ziltivekimab for Treatment of Anemia of Inflammation in Patients on Hemodialysis: Results from a Phase 1/2 Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial.” Journal of the American Society of Nephrology : JASN (2020). PMID: 33272965 ↗
L1RCTCited in: Acute Management, Renal Replacement Therapy, Dialysis Access & Transplantation
[427]
Singh AK, Carroll K, Perkovic V et al.. “Daprodustat for the Treatment of Anemia in Patients Undergoing Dialysis.” The New England journal of medicine (2021). PMID: 34739194 ↗
L1RCTCited in: Acute Management, Renal Replacement Therapy, Dialysis Access & Transplantation
[428]
Eckardt KU, Agarwal R, Aswad A et al.. “Safety and Efficacy of Vadadustat for Anemia in Patients Undergoing Dialysis.” The New England journal of medicine (2021). PMID: 33913638 ↗
L1RCTCited in: Acute Management, Renal Replacement Therapy, Dialysis Access & Transplantation
[429]
Vazquez MA, Oliver G, Amarasingham R et al.. “Pragmatic Trial of Hospitalization Rate in Chronic Kidney Disease.” The New England journal of medicine (2024). PMID: 38598574 ↗
L2RCTCited in: Acute Management, Renal Replacement Therapy, Dialysis Access & Transplantation
[430]
Weir MR, Bakris GL, Bushinsky DA et al.. “Patiromer in patients with kidney disease and hyperkalemia receiving RAAS inhibitors.” The New England journal of medicine (2014). PMID: 25415805 ↗
L4RCTCited in: Acute Management, Fluid, Electrolyte & Acid-Base Disorders
[431]
Fishbane S, Schiller B, Locatelli F et al.. “Peginesatide in patients with anemia undergoing hemodialysis.” The New England journal of medicine (2013). PMID: 23343061 ↗
L1RCTCited in: Acute Management, Renal Replacement Therapy, Dialysis Access & Transplantation
[432]
Drüeke TB, Locatelli F, Clyne N et al.. “Normalization of hemoglobin level in patients with chronic kidney disease and anemia.” The New England journal of medicine (2006). PMID: 17108342 ↗
L1RCTCited in: Acute Management
[433]
Jamal SA, Vandermeer B, Raggi P et al.. “Effect of calcium-based versus non-calcium-based phosphate binders on mortality in patients with chronic kidney disease: an updated systematic review and meta-analysis.” Lancet (London, England) (2013). PMID: 23870817 ↗
L1SR_OBSCited in: Acute Management, Renal Replacement Therapy, Dialysis Access & Transplantation
[434]
Macdougall IC, Bock AH, Carrera F et al.. “FIND-CKD: a randomized trial of intravenous ferric carboxymaltose versus oral iron in patients with chronic kidney disease and iron deficiency anaemia.” Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association (2014). PMID: 24891437 ↗
L1RCTCited in: Acute Management, Renal Replacement Therapy, Dialysis Access & Transplantation, History and Evolution of Treatment, Complications (Chronic Systemic Sequelae), Special Populations & Pregnancy
[435]
Sarnak MJ, Agarwal R, Boudville N et al.. “Vadadustat for treatment of anemia in patients with dialysis-dependent chronic kidney disease receiving peritoneal dialysis.” Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association (2023). PMID: 37096396 ↗
L1RCTCited in: Acute Management, History and Evolution of Treatment
[436]
Agarwal AK. “Central vein stenosis.” American journal of kidney diseases : the official journal of the National Kidney Foundation (2013). PMID: 23291234 ↗
L5CASE_REPORTCited in: Acute Management
[437]
Rosner MH, Husain-Syed F, Reis T et al.. “Uremic encephalopathy.” Kidney international (2021). PMID: 34736971 ↗
L5REVIEW_NARRATIVECited in: Acute Management, Renal Replacement Therapy, Dialysis Access & Transplantation, Complications (Chronic Systemic Sequelae), Special Populations & Pregnancy
[438]
Griffin BR, Liu KD, Teixeira JP. “Critical Care Nephrology: Core Curriculum 2020.” American journal of kidney diseases : the official journal of the National Kidney Foundation (2020). PMID: 31982214 ↗
L5REVIEW_NARRATIVECited in: Acute Management, Renal Replacement Therapy, Dialysis Access & Transplantation
[439]
Yarandi N, Shirali AC. “Onconephrology: Core Curriculum 2023.” American journal of kidney diseases : the official journal of the National Kidney Foundation (2023). PMID: 37855786 ↗
L5REVIEW_NARRATIVECited in: Acute Management, Long-term and Definitive Management
[440]
Navaneethan SD, Schold JD, Arrigain S et al.. “Cause-Specific Deaths in Non-Dialysis-Dependent CKD.” Journal of the American Society of Nephrology : JASN (2015). PMID: 26045089 ↗
L2OTHERCited in: Acute Management, Renal Replacement Therapy, Dialysis Access & Transplantation
[441]
Matsushita K, Mori K, Saritas T et al.. “Cilastatin Ameliorates Rhabdomyolysis-induced AKI in Mice.” Journal of the American Society of Nephrology : JASN (2021). PMID: 34341182 ↗
L5OTHERCited in: Acute Management
[442]
Tang JM, Kuo LW, Huang JF et al.. “Comparative long-term risks of chronic kidney disease and dialysis following conservative treatment, renal artery embolization, or nephrectomy in patients with blunt kidney injuries: retrospective cohort study.” BJS open (2026). PMID: 42224098 ↗
L2COHORTCited in: Acute Management, Renal Replacement Therapy, Dialysis Access & Transplantation
[443]
Silver SA, Harel Z, McQuillan R et al.. “How to Begin a Quality Improvement Project.” Clinical journal of the American Society of Nephrology : CJASN (2016). PMID: 27016497 ↗
L5OTHERCited in: Acute Management, Renal Replacement Therapy, Dialysis Access & Transplantation, Special Populations & Pregnancy
[444]
Renaghan AD, Jaimes EA, Malyszko J et al.. “Acute Kidney Injury and CKD Associated with Hematopoietic Stem Cell Transplantation.” Clinical journal of the American Society of Nephrology : CJASN (2019). PMID: 31836598 ↗
L5REVIEW_NARRATIVECited in: Acute Management
[445]
Perico N, Cattaneo D, Bikbov B et al.. “Hepatitis C infection and chronic renal diseases.” Clinical journal of the American Society of Nephrology : CJASN (2009). PMID: 19129320 ↗
L5REVIEW_NARRATIVECited in: Acute Management, Renal Replacement Therapy, Dialysis Access & Transplantation
[446]
Whittaker CF, Miklich MA, Patel RS et al.. “Medication Safety Principles and Practice in CKD.” Clinical journal of the American Society of Nephrology : CJASN (2018). PMID: 29915131 ↗
L5REVIEW_NARRATIVECited in: Acute Management, Fluid, Electrolyte & Acid-Base Disorders, Renal Replacement Therapy, Dialysis Access & Transplantation
[447]
Glassock RJ, Pecoits-Filho R, Barberato SH. “Left ventricular mass in chronic kidney disease and ESRD.” Clinical journal of the American Society of Nephrology : CJASN (2009). PMID: 19996010 ↗
L5REVIEW_NARRATIVECited in: Acute Management, Renal Replacement Therapy, Dialysis Access & Transplantation
[448]
Bishu K, Agarwal R. “Acute injury with intravenous iron and concerns regarding long-term safety.” Clinical journal of the American Society of Nephrology : CJASN (2006). PMID: 17699372 ↗
L5REVIEW_NARRATIVECited in: Acute Management
[449]
Mignani R, Feriozzi S, Schaefer RM et al.. “Dialysis and transplantation in Fabry disease: indications for enzyme replacement therapy.” Clinical journal of the American Society of Nephrology : CJASN (2010). PMID: 20056752 ↗
L5REVIEW_NARRATIVECited in: Acute Management
[450]
Uno C, Nishioka S, Tsuchida Y et al.. “Combination effect of nutrition and exercise intervention in patients with maintenance dialysis: A systematic review and meta-analysis.” Clinical nutrition ESPEN (2026). PMID: 42285222 ↗
L1SR_OBSCited in: Acute Management, Renal Replacement Therapy, Dialysis Access & Transplantation
[451]
Carbognin SJ, Solomon NM, Yeo FE et al.. “Acute renal allograft rejection following pegylated IFN-alpha treatment for chronic HCV in a repeat allograft recipient on hemodialysis: a case report.” American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons (2006). PMID: 16827881 ↗
L4CASE_REPORTCited in: Acute Management
[452]
Jørgensen HS, Vervloet M, Cavalier E et al.. “The role of nutritional vitamin D in chronic kidney disease-mineral and bone disorder in children and adults with chronic kidney disease, on dialysis, and after kidney transplantation-a European consensus statement.” Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association (2025). PMID: 39875204 ↗
L1OTHERCited in: Acute Management, Renal Replacement Therapy, Dialysis Access & Transplantation, Special Populations & Pregnancy
[453]
Locatelli F, Canaud B. “Dialysis adequacy today: a European perspective.” Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association (2012). PMID: 22743335 ↗
L5REVIEW_NARRATIVECited in: Acute Management, Renal Replacement Therapy, Dialysis Access & Transplantation, Special Populations & Pregnancy
[454]
Corte-Iglesias V, Saiz ML, Andrade-Lopez AC et al.. “Propionate and butyrate counteract renal damage and progression to chronic kidney disease.” Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association (2024). PMID: 38794880 ↗
L4OTHERCited in: Acute Management, Prevention, Screening & Surveillance
[455]
Evenepoel P, Jørgensen HS, Bover J et al.. “Recommended calcium intake in adults and children with chronic kidney disease-a European consensus statement.” Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association (2024). PMID: 37697718 ↗
L1OTHERCited in: Acute Management, Renal Replacement Therapy, Dialysis Access & Transplantation, Special Populations & Pregnancy
[456]
Bataille S, Chauveau P, Fouque D et al.. “Myostatin and muscle atrophy during chronic kidney disease.” Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association (2021). PMID: 32974666 ↗
L5REVIEW_NARRATIVECited in: Acute Management, Fluid, Electrolyte & Acid-Base Disorders, Renal Replacement Therapy, Dialysis Access & Transplantation
[457]
Ermer T, Nazzal L, Tio MC et al.. “Oxalate homeostasis.” Nature reviews. Nephrology (2022). PMID: 36329260 ↗
L5REVIEW_NARRATIVECited in: Acute Management, Long-term and Definitive Management, Renal Replacement Therapy, Dialysis Access & Transplantation, Complications (Chronic Systemic Sequelae), Special Populations & Pregnancy
[458]
Kishi S, Kadoya H, Kashihara N. “Treatment of chronic kidney disease in older populations.” Nature reviews. Nephrology (2024). PMID: 38977884 ↗
L5REVIEW_NARRATIVECited in: Acute Management, Long-term and Definitive Management, Renal Replacement Therapy, Dialysis Access & Transplantation, Special Populations & Pregnancy
[459]
McIntyre CW, Jain A. “Dialysis and cognitive impairment.” Nature reviews. Nephrology (2025). PMID: 40275017 ↗
L5REVIEW_NARRATIVECited in: Acute Management, Renal Replacement Therapy, Dialysis Access & Transplantation, Prognosis and Natural History, Special Populations & Pregnancy
[460]
Bishop NC, Burton JO, Graham-Brown MPM et al.. “Exercise and chronic kidney disease: potential mechanisms underlying the physiological benefits.” Nature reviews. Nephrology (2023). PMID: 36650232 ↗
L5REVIEW_NARRATIVECited in: Acute Management, Renal Replacement Therapy, Dialysis Access & Transplantation, Special Populations & Pregnancy
[461]
Carrero JJ, González-Ortiz A, Avesani CM et al.. “Plant-based diets to manage the risks and complications of chronic kidney disease.” Nature reviews. Nephrology (2020). PMID: 32528189 ↗
L5REVIEW_NARRATIVECited in: Acute Management, Fluid, Electrolyte & Acid-Base Disorders, Renal Replacement Therapy, Dialysis Access & Transplantation, Prognosis and Natural History
[462]
Husain SA, Brennan C, Michelson A et al.. “Patients prioritize waitlist over posttransplant outcomes when evaluating kidney transplant centers.” American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons (2018). PMID: 29945305 ↗
L4OTHERCited in: Acute Management
[463]
Hippen BE, Maddux FW. “Integrating kidney transplantation into value-based care for people with renal failure.” American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons (2017). PMID: 28898574 ↗
L5OTHERCited in: Acute Management
[464]
Kutner NG, Johansen KL, Zhang R et al.. “Perspectives on the new kidney disease education benefit: early awareness, race and kidney transplant access in a USRDS study.” American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons (2012). PMID: 22226386 ↗
L2OTHERCited in: Acute Management
[465]
Alam A, Badovinac K, Ivis F et al.. “The outcome of heart transplant recipients following the development of end-stage renal disease: analysis of the Canadian Organ Replacement Register (CORR).” American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons (2007). PMID: 17283490 ↗
L2OTHERCited in: Acute Management, Long-term and Definitive Management
[466]
Yan Y, Liu J, Liu G. “Association of continuity of care with treatment adherence and quality of life in patients with chronic kidney disease and hyperkalemia: A retrospective study.” Medicine (2026). PMID: 42410769 ↗
L4COHORTCited in: Acute Management, Fluid, Electrolyte & Acid-Base Disorders, Complications (Chronic Systemic Sequelae)
[467]
Parizad R, Batta A, Hatwal J et al.. “Sudden cardiac arrest in young adults: A comprehensive systematic review of epidemiology, aetiology and preventive strategies.” Heart international (2026). PMID: 42293057 ↗
L5SR_OBSCited in: Acute Management
[468]
Nicolescu O, Mitache MM, Mitache A et al.. “Healthcare costs of COVID-19 hospitalization in maintenance hemodialysis patients during the first two pandemic waves in Romania: a retrospective cohort study.” Journal of medicine and life (2026). PMID: 42282232 ↗
L2COHORTCited in: Acute Management, Renal Replacement Therapy, Dialysis Access & Transplantation
[469]
Zhang HD, Gao Y, Zhang ZY et al.. “The Effect of Dexmedetomidine on Postoperative Acute Kidney Injury in High-Risk Partial Nephrectomy Patients: A Retrospective Cohort Study.” Drug design, development and therapy (2026). PMID: 42238708 ↗
L2COHORTCited in: Acute Management
[470]
Mohamadizadeh M, Sharifi S, Motamed N et al.. “Effect of intra-dialytic pedaling exercise on dialysis adequacy: A randomized controlled trial.” PloS one (2026). PMID: 42139306 ↗
L1RCTCited in: Acute Management, Renal Replacement Therapy, Dialysis Access & Transplantation
[471]
Aslan Başbulut E, Yavuz D, Demir T. “Anti-Borrelia IgG Seropositivity Among Hemodialysis Patients with Chronic Kidney Disease of Unknown Etiology: A Preliminary Case-Control Study from Northern Türkiye.” Pathogens (Basel, Switzerland) (2026). PMID: 42347267 ↗
L3CASE_CONTROLCited in: Acute Management, Renal Replacement Therapy, Dialysis Access & Transplantation
[472]
Kilonzo GN, Githinji EM, Makworo D et al.. “Impact of a nurse-led educational intervention on knowledge and adherence to hemodialysis in Kiambu County, Kenya: a quasi-experimental study.” Frontiers in public health (2026). PMID: 42422671 ↗
L2OTHERCited in: Acute Management, Renal Replacement Therapy, Dialysis Access & Transplantation
[473]
Lian R, Rao S, Zheng Z et al.. “Finerenone attenuates chronic fibrotic remodeling during the AKI-CKD transition in an ischemia-reperfusion-induced acute kidney injury mouse model.” Renal failure (2026). PMID: 42414246 ↗
L4OTHERCited in: Acute Management
[474]
Wang J, Jin H, Chai Y et al.. “Development and Validation of a Multivariable Nomogram Predictive of Kidney Function after Cardiopulmonary Resuscitation.” Kidney diseases (Basel, Switzerland) (2026). PMID: 42375137 ↗
L4OTHERCited in: Acute Management
[475]
Weiner DE, Liu CK, Miao S et al.. “Effect of Long-term Exercise Training on Physical Performance and Cardiorespiratory Function in Adults With CKD: A Randomized Controlled Trial.” American journal of kidney diseases : the official journal of the National Kidney Foundation (2022). PMID: 35944747 ↗
L1RCTCited in: Long-term and Definitive Management, History and Evolution of Treatment
[476]
Yang TY, Lin HM, Wang HY et al.. “Sodium Bicarbonate Treatment and Clinical Outcomes in Chronic Kidney Disease with Metabolic Acidosis: A Meta-Analysis.” Clinical journal of the American Society of Nephrology : CJASN (2024). PMID: 38980732 ↗
L1SR_OBSCited in: Long-term and Definitive Management, Fluid, Electrolyte & Acid-Base Disorders
[477]
Zhang JJ, Ma XX, Hao L et al.. “A Systematic Review and Meta-Analysis of Outcomes of Pregnancy in CKD and CKD Outcomes in Pregnancy.” Clinical journal of the American Society of Nephrology : CJASN (2015). PMID: 26487769 ↗
L2SR_OBSCited in: Long-term and Definitive Management, Complications (Chronic Systemic Sequelae), Special Populations & Pregnancy
[478]
Fishbane S, El-Shahawy MA, Pecoits-Filho R et al.. “Roxadustat for Treating Anemia in Patients with CKD Not on Dialysis: Results from a Randomized Phase 3 Study.” Journal of the American Society of Nephrology : JASN (2021). PMID: 33568383 ↗
L1RCTCited in: Long-term and Definitive Management, History and Evolution of Treatment, Complications (Chronic Systemic Sequelae), Special Populations & Pregnancy
[479]
Perico N, Remuzzi G, Griffin MD et al.. “Safety and Preliminary Efficacy of Mesenchymal Stromal Cell (ORBCEL-M) Therapy in Diabetic Kidney Disease: A Randomized Clinical Trial (NEPHSTROM).” Journal of the American Society of Nephrology : JASN (2023). PMID: 37560967 ↗
L1RCTCited in: Long-term and Definitive Management, History and Evolution of Treatment, Complications (Chronic Systemic Sequelae), Prognosis and Natural History
[480]
Husain M, Birkenfeld AL, Donsmark M et al.. “Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes.” The New England journal of medicine (2019). PMID: 31185157 ↗
L1RCTCited in: Long-term and Definitive Management, History and Evolution of Treatment, Complications (Chronic Systemic Sequelae), Special Populations & Pregnancy
[481]
Ridker PM, Devalaraja M, Baeres FMM et al.. “IL-6 inhibition with ziltivekimab in patients at high atherosclerotic risk (RESCUE): a double-blind, randomised, placebo-controlled, phase 2 trial.” Lancet (London, England) (2021). PMID: 34015342 ↗
L1RCTCited in: Long-term and Definitive Management, History and Evolution of Treatment, Special Populations & Pregnancy
[482]
Tuttle KR, Hauske SJ, Canziani ME et al.. “Efficacy and safety of aldosterone synthase inhibition with and without empagliflozin for chronic kidney disease: a randomised, controlled, phase 2 trial.” Lancet (London, England) (2023). PMID: 38109916 ↗
L1RCTCited in: Long-term and Definitive Management, Fluid, Electrolyte & Acid-Base Disorders, History and Evolution of Treatment, Special Populations & Pregnancy
[483]
Mayne KJ, Sardell RJ, Staplin N et al.. “Empagliflozin lowers serum uric acid in chronic kidney disease: exploratory analyses from the EMPA-KIDNEY trial.” Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association (2025). PMID: 39277784 ↗
L1RCTCited in: Long-term and Definitive Management, History and Evolution of Treatment
[484]
Green JB, Mottl AK, Bakris G et al.. “Design of the COmbinatioN effect of FInerenone anD EmpaglifloziN in participants with chronic kidney disease and type 2 diabetes using a UACR Endpoint study (CONFIDENCE).” Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association (2023). PMID: 35700142 ↗
L5TRIAL_NONRANDOMCited in: Long-term and Definitive Management, Fluid, Electrolyte & Acid-Base Disorders
[485]
Masetti M, Montalti R, Rompianesi G et al.. “Early withdrawal of calcineurin inhibitors and everolimus monotherapy in de novo liver transplant recipients preserves renal function.” American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons (2010). PMID: 20486905 ↗
L1RCTCited in: Long-term and Definitive Management, History and Evolution of Treatment
[486]
Pestana JO, Grinyo JM, Vanrenterghem Y et al.. “Three-year outcomes from BENEFIT-EXT: a phase III study of belatacept versus cyclosporine in recipients of extended criteria donor kidneys.” American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons (2012). PMID: 22300431 ↗
L1RCTCited in: Long-term and Definitive Management, History and Evolution of Treatment
[487]
Tuttle KR, Agarwal R, Alpers CE et al.. “Molecular mechanisms and therapeutic targets for diabetic kidney disease.” Kidney international (2022). PMID: 35661785 ↗
L5REVIEW_NARRATIVECited in: Long-term and Definitive Management, Complications (Chronic Systemic Sequelae)
[488]
Floege J, Bernier-Jean A, Barratt J et al.. “Treatment of patients with IgA nephropathy: a call for a new paradigm.” Kidney international (2025). PMID: 39894081 ↗
L5REVIEW_NARRATIVECited in: Long-term and Definitive Management
[489]
Rayego-Mateos S, Rodrigues-Diez RR, Fernandez-Fernandez B et al.. “Targeting inflammation to treat diabetic kidney disease: the road to 2030.” Kidney international (2022). PMID: 36470394 ↗
L5REVIEW_NARRATIVECited in: Long-term and Definitive Management, History and Evolution of Treatment
[490]
Heerspink HJL, Kosiborod M, Inzucchi SE et al.. “Renoprotective effects of sodium-glucose cotransporter-2 inhibitors.” Kidney international (2018). PMID: 29735306 ↗
L5REVIEW_NARRATIVECited in: Long-term and Definitive Management, Complications (Chronic Systemic Sequelae)
[491]
Zhu D, Judge PK, Wanner C et al.. “The prevention and management of chronic kidney disease among patients with metabolic syndrome.” Kidney international (2025). PMID: 39986466 ↗
L5REVIEW_NARRATIVECited in: Long-term and Definitive Management
[492]
Novak JE, Ellison DH. “Diuretics in States of Volume Overload: Core Curriculum 2022.” American journal of kidney diseases : the official journal of the National Kidney Foundation (2022). PMID: 35190215 ↗
L5REVIEW_NARRATIVECited in: Long-term and Definitive Management, Fluid, Electrolyte & Acid-Base Disorders, Complications (Chronic Systemic Sequelae)
[493]
Epstein M, Kovesdy CP, Clase CM et al.. “Aldosterone, Mineralocorticoid Receptor Activation, and CKD: A Review of Evolving Treatment Paradigms.” American journal of kidney diseases : the official journal of the National Kidney Foundation (2022). PMID: 36057467 ↗
L5REVIEW_NARRATIVECited in: Long-term and Definitive Management, Fluid, Electrolyte & Acid-Base Disorders
[494]
Ostrowski RA. “Gout Management in Patients With CKD: A Review.” American journal of kidney diseases : the official journal of the National Kidney Foundation (2025). PMID: 40609855 ↗
L5REVIEW_NARRATIVECited in: Long-term and Definitive Management
[495]
Abudoureheman W, Zhang F, Huang L et al.. “Association between HbA1c variability and disease prognosis in chronic kidney disease patients: a systematic review and meta-analysis.” Diabetes research and clinical practice (2026). PMID: 42251946 ↗
L2SR_OBSCited in: Long-term and Definitive Management
[496]
Costa TA, de Sousa LMT, Nogueira A et al.. “Association between SGLT2 inhibitors and outcomes after heart transplant in patients with type 2 diabetes: A systematic review and meta-analysis.” Heart failure reviews (2026). PMID: 42249978 ↗
L2SR_OBSCited in: Long-term and Definitive Management
[497]
Peacock M. “Calcium metabolism in health and disease.” Clinical journal of the American Society of Nephrology : CJASN (2010). PMID: 20089499 ↗
L5REVIEW_NARRATIVECited in: Long-term and Definitive Management, Fluid, Electrolyte & Acid-Base Disorders
[498]
Lu J, Sun S, Shang X et al.. “Genetic Evidence for the Benefits and Risks of Glucose-Lowering Drugs on Cardiovascular-Kidney-Metabolic Syndrome: A Drug-Target Mendelian Randomization Study.” International journal of medical sciences (2026). PMID: 42328113 ↗
L2SR_OBSCited in: Long-term and Definitive Management
[499]
Benyahia R, Huart A, Javaugue V et al.. “Recurrence of light chain crystalline podocytopathy and tubulopathy after kidney transplantation achieving remission with an antimyeloma regimen.” American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons (2025). PMID: 41456771 ↗
L4CASE_REPORTCited in: Long-term and Definitive Management
[500]
Thiem U, Buxhofer-Ausch V, Kranewitter W et al.. “Successful kidney transplantation in a patient with pre-existing chronic myeloid leukemia treated with imatinib.” American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons (2020). PMID: 32654389 ↗
L4CASE_REPORTCited in: Long-term and Definitive Management
[501]
Mujtaba MA, Sharfuddin AA, Taber T et al.. “Conversion from tacrolimus to belatacept to prevent the progression of chronic kidney disease in pancreas transplantation: case report of two patients.” American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons (2014). PMID: 25179306 ↗
L4CASE_REPORTCited in: Long-term and Definitive Management, History and Evolution of Treatment
[502]
Kalantar-Zadeh K, Jafar TH, Nitsch D et al.. “Chronic kidney disease.” Lancet (London, England) (2021). PMID: 34175022 ↗
L5REVIEW_NARRATIVECited in: Long-term and Definitive Management
[503]
Brown E, Heerspink HJL, Cuthbertson DJ et al.. “SGLT2 inhibitors and GLP-1 receptor agonists: established and emerging indications.” Lancet (London, England) (2021). PMID: 34216571 ↗
L5REVIEW_NARRATIVECited in: Long-term and Definitive Management, History and Evolution of Treatment
[504]
Azizi M, Tuttle KR, Brown JM et al.. “New drug therapies for hypertension.” Lancet (London, England) (2026). PMID: 41687677 ↗
L5REVIEW_NARRATIVECited in: Long-term and Definitive Management
[505]
Nakao Y, Mori M, Mori Y et al.. “SGLT2 inhibitors and acute kidney injury.” Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association (2026). PMID: 40736512 ↗
L5REVIEW_NARRATIVECited in: Long-term and Definitive Management, Prevention, Screening & Surveillance
[506]
Alicic RZ, Neumiller JJ, Tuttle KR. “Combination therapy: an upcoming paradigm to improve kidney and cardiovascular outcomes in chronic kidney disease.” Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association (2025). PMID: 39907543 ↗
L5REVIEW_NARRATIVECited in: Long-term and Definitive Management
[507]
Müller RU, Guerrot D, Chonchol M et al.. “SGLT2 inhibition for patients with ADPKD - closing the evidence gap.” Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association (2025). PMID: 40199734 ↗
L5REVIEW_NARRATIVECited in: Long-term and Definitive Management, History and Evolution of Treatment
[508]
Romagnani P. “SGLT2 inhibitors in CKD: are they really effective in all patients?” Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association (2025). PMID: 40053507 ↗
L5REVIEW_NARRATIVECited in: Long-term and Definitive Management, Complications (Chronic Systemic Sequelae)
[509]
Chuang MH, Wang HY, Kan WC et al.. “Cardio-kidney outcomes for combined versus monotherapy with finerenone or SGLT2 inhibitors in patients with CKD.” Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association (2025). PMID: 40199739 ↗
L3OTHERCited in: Long-term and Definitive Management, Fluid, Electrolyte & Acid-Base Disorders, Prognosis and Natural History
[510]
Agarwal R, Verma A, Georgianos PI. “Diuretics in patients with chronic kidney disease.” Nature reviews. Nephrology (2025). PMID: 39775051 ↗
L5REVIEW_NARRATIVECited in: Long-term and Definitive Management, Complications (Chronic Systemic Sequelae)
[511]
Tang C, Livingston MJ, Safirstein R et al.. “Cisplatin nephrotoxicity: new insights and therapeutic implications.” Nature reviews. Nephrology (2022). PMID: 36229672 ↗
L5REVIEW_NARRATIVECited in: Long-term and Definitive Management
[512]
Sato Y, Silina K, van den Broek M et al.. “The roles of tertiary lymphoid structures in chronic diseases.” Nature reviews. Nephrology (2023). PMID: 37046081 ↗
L5REVIEW_NARRATIVECited in: Long-term and Definitive Management, Complications (Chronic Systemic Sequelae), Prognosis and Natural History
[513]
Abbad L, Esteve E, Chatziantoniou C. “Advances and challenges in kidney fibrosis therapeutics.” Nature reviews. Nephrology (2025). PMID: 39934355 ↗
L5REVIEW_NARRATIVECited in: Long-term and Definitive Management
[514]
van Raalte DH, Bjornstad P, Cherney DZI et al.. “Combination therapy for kidney disease in people with diabetes mellitus.” Nature reviews. Nephrology (2024). PMID: 38570632 ↗
L5REVIEW_NARRATIVECited in: Long-term and Definitive Management
[515]
Wagner CA, Unwin R, Lopez-Garcia SC et al.. “The pathophysiology of distal renal tubular acidosis.” Nature reviews. Nephrology (2023). PMID: 37016093 ↗
L5REVIEW_NARRATIVECited in: Long-term and Definitive Management, Fluid, Electrolyte & Acid-Base Disorders
[516]
van der Aart-van der Beek AB, de Boer RA, Heerspink HJL. “Kidney and heart failure outcomes associated with SGLT2 inhibitor use.” Nature reviews. Nephrology (2022). PMID: 35145275 ↗
L5REVIEW_NARRATIVECited in: Long-term and Definitive Management
[517]
Smeijer JD, Kohan DE, Dhaun N et al.. “Endothelin receptor antagonists in chronic kidney disease.” Nature reviews. Nephrology (2024). PMID: 39643698 ↗
L5REVIEW_NARRATIVECited in: Long-term and Definitive Management
[518]
Li M, Cheang I, Xu M et al.. “Sex-Specific Outcomes and Treatment Responses in Elderly Patients With Heart Failure With Preserved Ejection Fraction: A Comprehensive Single-Center Retrospective Study.” Journal of the American Heart Association (2026). PMID: 42261950 ↗
L3COHORTCited in: Long-term and Definitive Management
[519]
Raven LM, Brinker L, Sideris K et al.. “Sodium glucose cotransporter 2 inhibitor use after heart transplant: Current knowledge and potential applications.” American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons (2025). PMID: 40835110 ↗
L5REVIEW_NARRATIVECited in: Long-term and Definitive Management, Complications (Chronic Systemic Sequelae), Prognosis and Natural History
[520]
Pallet N, Rabant M, Legendre C et al.. “The nephroprotective properties of recombinant human erythropoietin in kidney transplantation: experimental facts and clinical proofs.” American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons (2012). PMID: 23057777 ↗
L5REVIEW_NARRATIVECited in: Long-term and Definitive Management, Renal Replacement Therapy, Dialysis Access & Transplantation
[521]
Wali RK, Mohanlal V, Ramos E et al.. “Early withdrawal of calcineurin inhibitors and rescue immunosuppression with sirolimus-based therapy in renal transplant recipients with moderate to severe renal dysfunction.” American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons (2007). PMID: 17511682 ↗
L4OTHERCited in: Long-term and Definitive Management
[522]
Kido R, Shibagaki Y, Iwadoh K et al.. “Persistent glomerular hematuria in living kidney donors confers a risk of progressive kidney disease in donors after heminephrectomy.” American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons (2010). PMID: 20353466 ↗
L3OTHERCited in: Long-term and Definitive Management
[523]
Wisel SA, Gardner JM, Roll GR et al.. “Pancreas-After-Islet Transplantation in Nonuremic Type 1 Diabetes: A Strategy for Restoring Durable Insulin Independence.” American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons (2017). PMID: 28489277 ↗
L4OTHERCited in: Long-term and Definitive Management
[524]
Hewapathiranage S, Pushpakumara N, Sonnadara T et al.. “A retrospective study of CKDu progression in Sri Lanka: analysis of kidney biopsies and association with risk factors.” BMC nephrology (2026). PMID: 42251320 ↗
L3COHORTCited in: Long-term and Definitive Management
[525]
Pavlov V N, Vorobev V A, Ananyev V A. “[Treatment, outcomes, and management strategy for purulent pyelonephritis: a systematic review and meta-analysis. Part II].” Urologiia (Moscow, Russia : 1999) (2025). PMID: 42417339 ↗
L1SR_OBSCited in: Long-term and Definitive Management
[526]
Putri AA, Shandrianti A, Liberty IA. “The Role of SGLT2 Inhibitors in Preventing the Progression of Chronic Kidney Disease in Patients with Type 2 DM: A Systematic Review.” Journal of preventive medicine and hygiene (2026). PMID: 42256478 ↗
L5SR_OBSCited in: Long-term and Definitive Management
[527]
Wanyan X, Xu J. “Clinical Efficacy of Vitamin D Supplements for the Treatment of Anemia in Patients With Chronic Kidney Disease: A Systematic Review and Meta-Analysis.” Hemodialysis international. International Symposium on Home Hemodialysis (2026). PMID: 42252089 ↗
L1SR_OBSCited in: Long-term and Definitive Management
[528]
Leon SJ, Whitlock R, Rigatto C et al.. “Hyperkalemia-Related Discontinuation of Renin-Angiotensin-Aldosterone System Inhibitors and Clinical Outcomes in CKD: A Population-Based Cohort Study.” American journal of kidney diseases : the official journal of the National Kidney Foundation (2022). PMID: 35085685 ↗
L2COHORTCited in: Fluid, Electrolyte & Acid-Base Disorders
[529]
Chen N, Hao C, Peng X et al.. “Roxadustat for Anemia in Patients with Kidney Disease Not Receiving Dialysis.” The New England journal of medicine (2019). PMID: 31340089 ↗
L1RCTCited in: Fluid, Electrolyte & Acid-Base Disorders
[530]
Parving HH, Brenner BM, McMurray JJ et al.. “Cardiorenal end points in a trial of aliskiren for type 2 diabetes.” The New England journal of medicine (2012). PMID: 23121378 ↗
L1RCTCited in: Fluid, Electrolyte & Acid-Base Disorders
[531]
Pergola PE, Raskin P, Toto RD et al.. “Bardoxolone methyl and kidney function in CKD with type 2 diabetes.” The New England journal of medicine (2011). PMID: 21699484 ↗
L1RCTCited in: Fluid, Electrolyte & Acid-Base Disorders
[532]
Chertow GM, Block GA, Correa-Rotter R et al.. “Effect of cinacalcet on cardiovascular disease in patients undergoing dialysis.” The New England journal of medicine (2012). PMID: 23121374 ↗
L1RCTCited in: Fluid, Electrolyte & Acid-Base Disorders
[533]
Albakr RB, Sridhar VS, Cherney DZI. “Novel Therapies in Diabetic Kidney Disease and Risk of Hyperkalemia: A Review of the Evidence From Clinical Trials.” American journal of kidney diseases : the official journal of the National Kidney Foundation (2023). PMID: 37517546 ↗
L5TRIAL_NONRANDOMCited in: Fluid, Electrolyte & Acid-Base Disorders
[534]
Mohebbi N, Ritter A, Wiegand A et al.. “Sodium bicarbonate for kidney transplant recipients with metabolic acidosis in Switzerland: a multicentre, randomised, single-blind, placebo-controlled, phase 3 trial.” Lancet (London, England) (2023). PMID: 36708734 ↗
L1RCTCited in: Fluid, Electrolyte & Acid-Base Disorders, Renal Replacement Therapy, Dialysis Access & Transplantation
[535]
Agarwal R, Rossignol P, Romero A et al.. “Patiromer versus placebo to enable spironolactone use in patients with resistant hypertension and chronic kidney disease (AMBER): a phase 2, randomised, double-blind, placebo-controlled trial.” Lancet (London, England) (2019). PMID: 31533906 ↗
L1RCTCited in: Fluid, Electrolyte & Acid-Base Disorders, History and Evolution of Treatment, Special Populations & Pregnancy
[536]
Wesson DE, Mathur V, Tangri N et al.. “Veverimer versus placebo in patients with metabolic acidosis associated with chronic kidney disease: a multicentre, randomised, double-blind, controlled, phase 3 trial.” Lancet (London, England) (2019). PMID: 30857647 ↗
L1RCTCited in: Fluid, Electrolyte & Acid-Base Disorders
[537]
Wesson DE, Mathur V, Tangri N et al.. “Long-term safety and efficacy of veverimer in patients with metabolic acidosis in chronic kidney disease: a multicentre, randomised, blinded, placebo-controlled, 40-week extension.” Lancet (London, England) (2019). PMID: 31248662 ↗
L1RCTCited in: Fluid, Electrolyte & Acid-Base Disorders
[538]
Whitlock RH, Ferguson TW, Komenda P et al.. “Metabolic acidosis is undertreated and underdiagnosed: a retrospective cohort study.” Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association (2023). PMID: 36323446 ↗
L2COHORTCited in: Fluid, Electrolyte & Acid-Base Disorders
[539]
Jalal DI, Bansal N, Cho ME et al.. “KDOQI US Commentary on the KDIGO 2026 Clinical Practice Guideline for the Management of Anemia in CKD.” American journal of kidney diseases : the official journal of the National Kidney Foundation (2026). PMID: 42095795 ↗
L5GUIDELINECited in: Fluid, Electrolyte & Acid-Base Disorders
[540]
Shah MK, Mandayam S, Adrogué HJ. “Osmotic Demyelination Unrelated to Hyponatremia.” American journal of kidney diseases : the official journal of the National Kidney Foundation (2017). PMID: 29277507 ↗
L4CASE_REPORTCited in: Fluid, Electrolyte & Acid-Base Disorders
[541]
Raphael KL. “Metabolic Acidosis in CKD: Core Curriculum 2019.” American journal of kidney diseases : the official journal of the National Kidney Foundation (2019). PMID: 31036389 ↗
L5CASE_REPORTCited in: Fluid, Electrolyte & Acid-Base Disorders
[542]
Ikizler TA, Cano NJ, Franch H et al.. “Prevention and treatment of protein energy wasting in chronic kidney disease patients: a consensus statement by the International Society of Renal Nutrition and Metabolism.” Kidney international (2013). PMID: 23698226 ↗
L5REVIEW_NARRATIVECited in: Fluid, Electrolyte & Acid-Base Disorders, Renal Replacement Therapy, Dialysis Access & Transplantation
[543]
Bakris GL, Ruilope LM, Anker SD et al.. “A prespecified exploratory analysis from FIDELITY examined finerenone use and kidney outcomes in patients with chronic kidney disease and type 2 diabetes.” Kidney international (2022). PMID: 36367466 ↗
L1OTHERCited in: Fluid, Electrolyte & Acid-Base Disorders
[544]
Bushinsky DA, Krieger NS. “Effects of acid on bone.” Kidney international (2022). PMID: 35351460 ↗
L5REVIEW_NARRATIVECited in: Fluid, Electrolyte & Acid-Base Disorders
[545]
Fu EL, Mastrorilli J, Bykov K et al.. “A population-based cohort defined risk of hyperkalemia after initiating SGLT-2 inhibitors, GLP1 receptor agonists or DPP-4 inhibitors to patients with chronic kidney disease and type 2 diabetes.” Kidney international (2023). PMID: 38101515 ↗
L2OTHERCited in: Fluid, Electrolyte & Acid-Base Disorders
[546]
Georgianos PI, Agarwal R. “Revisiting RAAS blockade in CKD with newer potassium-binding drugs.” Kidney international (2017). PMID: 29276100 ↗
L5REVIEW_NARRATIVECited in: Fluid, Electrolyte & Acid-Base Disorders
[547]
Bhan I, Shah A, Holmes J et al.. “Post-transplant hypophosphatemia: Tertiary 'Hyper-Phosphatoninism'?” Kidney international (2006). PMID: 16941023 ↗
L5OTHERCited in: Fluid, Electrolyte & Acid-Base Disorders
[548]
O'Neill WC. “Targeting serum calcium in chronic kidney disease and end-stage renal disease: is normal too high?” Kidney international (2016). PMID: 26759046 ↗
L5REVIEW_NARRATIVECited in: Fluid, Electrolyte & Acid-Base Disorders
[549]
Basile C, Rossi L, Lomonte C. “The choice of dialysate bicarbonate: do different concentrations make a difference?” Kidney international (2016). PMID: 26924048 ↗
L5REVIEW_NARRATIVECited in: Fluid, Electrolyte & Acid-Base Disorders
[550]
Zaritsky JJ, Salusky IB. “Ironing out the phosphorus problem.” Kidney international (2010). PMID: 20431575 ↗
L5REVIEW_NARRATIVECited in: Fluid, Electrolyte & Acid-Base Disorders
[551]
Murtafa KM, Khanday SS, Vondivillu Srinivasan R et al.. “Efficacy and safety of non-steroidal mineralocorticoid receptor antagonist and SGLT2 inhibitor combination therapy versus SGLT2-inhibitor monotherapy in patients with chronic kidney disease with albuminuria: a systematic review and meta-analysis of randomized controlled trials.” International urology and nephrology (2026). PMID: 42154418 ↗
L1SR_MA_RCTCited in: Fluid, Electrolyte & Acid-Base Disorders
[552]
Kovesdy CP. “Epidemiology of hyperkalemia: an update.” Kidney international supplements (2016). PMID: 30675413 ↗
L5REVIEW_NARRATIVECited in: Fluid, Electrolyte & Acid-Base Disorders
[553]
Rossing P. “Clinical perspective-evolving evidence of mineralocorticoid receptor antagonists in patients with chronic kidney disease and type 2 diabetes.” Kidney international supplements (2022). PMID: 35529090 ↗
L5REVIEW_NARRATIVECited in: Fluid, Electrolyte & Acid-Base Disorders
[554]
Weir MR. “Current and future treatment options for managing hyperkalemia.” Kidney international supplements (2016). PMID: 30675417 ↗
L5REVIEW_NARRATIVECited in: Fluid, Electrolyte & Acid-Base Disorders
[555]
Drawz PE, Rosenberg ME. “Slowing progression of chronic kidney disease.” Kidney international supplements (2013). PMID: 25019022 ↗
L5OTHERCited in: Fluid, Electrolyte & Acid-Base Disorders
[556]
Epstein M. “Hyperkalemia constitutes a constraint for implementing renin-angiotensin-aldosterone inhibition: the widening gap between mandated treatment guidelines and the real-world clinical arena.” Kidney international supplements (2016). PMID: 30675416 ↗
L3REVIEW_NARRATIVECited in: Fluid, Electrolyte & Acid-Base Disorders, History and Evolution of Treatment
[557]
Becerra LA, Mansour SG. “Exercise and Kidney Health: Core Curriculum 2026.” American journal of kidney diseases : the official journal of the National Kidney Foundation (2025). PMID: 41389078 ↗
L5REVIEW_NARRATIVECited in: Fluid, Electrolyte & Acid-Base Disorders, Prevention, Screening & Surveillance
[558]
Bouquegneau A, Dubois BE, Krzesinski JM et al.. “Anorexia nervosa and the kidney.” American journal of kidney diseases : the official journal of the National Kidney Foundation (2012). PMID: 22609034 ↗
L5REVIEW_NARRATIVECited in: Fluid, Electrolyte & Acid-Base Disorders
[559]
Kraut JA, Madias NE. “Metabolic Acidosis of CKD: An Update.” American journal of kidney diseases : the official journal of the National Kidney Foundation (2015). PMID: 26477665 ↗
L5REVIEW_NARRATIVECited in: Fluid, Electrolyte & Acid-Base Disorders
[560]
Wen CF, Chuang MH, Wu VC et al.. “Efficacy of combined sodium-glucose cotransporter 2 inhibitors and finerenone in chronic kidney disease: a systematic review and meta-analysis.” Frontiers in pharmacology (2026). PMID: 42212277 ↗
L2SR_OBSCited in: Fluid, Electrolyte & Acid-Base Disorders
[561]
Dwyer JP, Maklad N, Vedin O et al.. “Efficacy and Safety of Baxdrostat in Participants with CKD and Uncontrolled Hypertension: A Randomized, Double-Blind, Placebo-Controlled Trial.” Journal of the American Society of Nephrology : JASN (2025). PMID: 40913594 ↗
L1OTHERCited in: Fluid, Electrolyte & Acid-Base Disorders
[562]
Raphael KL. “Metabolic Acidosis and Subclinical Metabolic Acidosis in CKD.” Journal of the American Society of Nephrology : JASN (2017). PMID: 29030467 ↗
L5REVIEW_NARRATIVECited in: Fluid, Electrolyte & Acid-Base Disorders
[563]
Wesson DE, Buysse JM, Bushinsky DA. “Mechanisms of Metabolic Acidosis-Induced Kidney Injury in Chronic Kidney Disease.” Journal of the American Society of Nephrology : JASN (2020). PMID: 31988269 ↗
L5OTHERCited in: Fluid, Electrolyte & Acid-Base Disorders
[564]
Viering D, Schlingmann KP, Hureaux M et al.. “Gitelman-Like Syndrome Caused by Pathogenic Variants in mtDNA.” Journal of the American Society of Nephrology : JASN (2021). PMID: 34607911 ↗
L4OTHERCited in: Fluid, Electrolyte & Acid-Base Disorders
[565]
Gritter M, Wouda RD, Yeung SMH et al.. “Effects of Short-Term Potassium Chloride Supplementation in Patients with CKD.” Journal of the American Society of Nephrology : JASN (2022). PMID: 35609996 ↗
L4OTHERCited in: Fluid, Electrolyte & Acid-Base Disorders
[566]
Johnson RJ, Stenvinkel P, Jensen T et al.. “Metabolic and Kidney Diseases in the Setting of Climate Change, Water Shortage, and Survival Factors.” Journal of the American Society of Nephrology : JASN (2016). PMID: 27283495 ↗
L5OTHERCited in: Fluid, Electrolyte & Acid-Base Disorders
[567]
Moranne O, Froissart M, Rossert J et al.. “Timing of onset of CKD-related metabolic complications.” Journal of the American Society of Nephrology : JASN (2008). PMID: 19005010 ↗
L2OTHERCited in: Fluid, Electrolyte & Acid-Base Disorders
[568]
Seys E, Andrini O, Keck M et al.. “Clinical and Genetic Spectrum of Bartter Syndrome Type 3.” Journal of the American Society of Nephrology : JASN (2017). PMID: 28381550 ↗
L4OTHERCited in: Fluid, Electrolyte & Acid-Base Disorders
[569]
Raphael KL, Carroll DJ, Murray J et al.. “Urine Ammonium Predicts Clinical Outcomes in Hypertensive Kidney Disease.” Journal of the American Society of Nephrology : JASN (2017). PMID: 28385806 ↗
L2OTHERCited in: Fluid, Electrolyte & Acid-Base Disorders
[570]
Peng W, Shang X, Zhang C et al.. “Long-term efficacy and renal safety of SGLT2 inhibitors in patients with heart failure and advanced chronic kidney disease (stage 4): a propensity score-matched retrospective cohort study.” Frontiers in cardiovascular medicine (2026). PMID: 42389639 ↗
L3COHORTCited in: Fluid, Electrolyte & Acid-Base Disorders, History and Evolution of Treatment
[571]
Weisinger JR, Carlini RG, Rojas E et al.. “Bone disease after renal transplantation.” Clinical journal of the American Society of Nephrology : CJASN (2006). PMID: 17699362 ↗
L5REVIEW_NARRATIVECited in: Fluid, Electrolyte & Acid-Base Disorders, Renal Replacement Therapy, Dialysis Access & Transplantation, Special Populations & Pregnancy
[572]
Mutig K, Bachmann S. “Hyperkalemia and blood pressure regulation.” Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association (2019). PMID: 31800077 ↗
L5REVIEW_NARRATIVECited in: Fluid, Electrolyte & Acid-Base Disorders
[573]
Chauveau P, Koppe L, Combe C et al.. “Vegetarian diets and chronic kidney disease.” Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association (2019). PMID: 29982610 ↗
L5REVIEW_NARRATIVECited in: Fluid, Electrolyte & Acid-Base Disorders, Complications (Chronic Systemic Sequelae)
[574]
Sasai F, Roncal-Jimenez C, Rogers K et al.. “Climate change and nephrology.” Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association (2023). PMID: 34473287 ↗
L5OTHERCited in: Fluid, Electrolyte & Acid-Base Disorders
[575]
Imenez Silva PH, Unwin R, Hoorn EJ et al.. “Acidosis, cognitive dysfunction and motor impairments in patients with kidney disease.” Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association (2021). PMID: 34718761 ↗
L5REVIEW_NARRATIVECited in: Fluid, Electrolyte & Acid-Base Disorders
[576]
Fahal IH. “Uraemic sarcopenia: aetiology and implications.” Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association (2013). PMID: 23625972 ↗
L5REVIEW_NARRATIVECited in: Fluid, Electrolyte & Acid-Base Disorders
[577]
Giaccari M, Veligratli F, Hayes W et al.. “The European distal renal tubular acidosis registry: a five-year analysis.” Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association (2026). PMID: 41790493 ↗
L4OTHERCited in: Fluid, Electrolyte & Acid-Base Disorders
[578]
Zhou M, Ruessmann D, Ficociello LH et al.. “Real-world effectiveness of patiromer among hemodialysis patients: a one-year retrospective cohort study.” BMC nephrology (2026). PMID: 42363136 ↗
L2COHORTCited in: Fluid, Electrolyte & Acid-Base Disorders
[579]
Hashimoto N, Sakaguchi Y, Naito M et al.. “Hyperkalemia risk and potassium trajectory after finerenone initiation: a real-world cohort study.” Clinical and experimental nephrology (2026). PMID: 42258056 ↗
L4COHORTCited in: Fluid, Electrolyte & Acid-Base Disorders
[580]
Tian G, Lin Z, Chen Z et al.. “Association between renal replacement therapy and in-hospital mortality in patients with severe acute kidney injury: a retrospective cohort study based on MIMIC-IV database.” BMC urology (2026). PMID: 42226256 ↗
L2COHORTCited in: Fluid, Electrolyte & Acid-Base Disorders
[581]
Grünfeld JP, Rossier BC. “Lithium nephrotoxicity revisited.” Nature reviews. Nephrology (2009). PMID: 19384328 ↗
L5REVIEW_NARRATIVECited in: Fluid, Electrolyte & Acid-Base Disorders
[582]
Hoorn EJ, Subramanya AR, Boyd-Shiwarski CR. “Potassium and the kidney.” Nature reviews. Nephrology (2026). PMID: 41611896 ↗
L5REVIEW_NARRATIVECited in: Fluid, Electrolyte & Acid-Base Disorders
[583]
Johnson RJ, Rodriguez-Iturbe B, Roncal-Jimenez C et al.. “Hyperosmolarity drives hypertension and CKD--water and salt revisited.” Nature reviews. Nephrology (2014). PMID: 24802066 ↗
L5REVIEW_NARRATIVECited in: Fluid, Electrolyte & Acid-Base Disorders
[584]
Wang XH, Mitch WE. “Mechanisms of muscle wasting in chronic kidney disease.” Nature reviews. Nephrology (2014). PMID: 24981816 ↗
L5REVIEW_NARRATIVECited in: Fluid, Electrolyte & Acid-Base Disorders
[585]
Wang XH, Mitch WE, Price SR. “Pathophysiological mechanisms leading to muscle loss in chronic kidney disease.” Nature reviews. Nephrology (2021). PMID: 34750550 ↗
L5REVIEW_NARRATIVECited in: Fluid, Electrolyte & Acid-Base Disorders
[586]
Kovesdy CP. “Management of hyperkalaemia in chronic kidney disease.” Nature reviews. Nephrology (2014). PMID: 25223988 ↗
L5REVIEW_NARRATIVECited in: Fluid, Electrolyte & Acid-Base Disorders
[587]
Sica DA. “Diuretic use in renal disease.” Nature reviews. Nephrology (2011). PMID: 22183505 ↗
L5REVIEW_NARRATIVECited in: Fluid, Electrolyte & Acid-Base Disorders
[588]
Silver J, Naveh-Many T. “FGF-23 and secondary hyperparathyroidism in chronic kidney disease.” Nature reviews. Nephrology (2013). PMID: 23877588 ↗
L5REVIEW_NARRATIVECited in: Fluid, Electrolyte & Acid-Base Disorders
[589]
Hebert LA, Parikh S. “Chronic kidney disease: fluid in chronic kidney disease-how much is too much?” Nature reviews. Nephrology (2013). PMID: 24042464 ↗
L5OTHERCited in: Fluid, Electrolyte & Acid-Base Disorders
[590]
Biswas S, Qammar B, Srivastava Y et al.. “Electrolyte abnormalities and clinical outcomes in heart failure patients: a retrospective cohort study using MIMIC-IV database.” Scientific reports (2026). PMID: 42236834 ↗
L2COHORTCited in: Fluid, Electrolyte & Acid-Base Disorders
[591]
Al-Kindi S, Chen Z, Dazard JE et al.. “Impact of air pollution exposure on chronic kidney disease and type 2 diabetes: A FIDELITY analysis.” American journal of preventive cardiology (2026). PMID: 42403440 ↗
L2OTHERCited in: Fluid, Electrolyte & Acid-Base Disorders
[592]
Rose M, Fischer FH, Liegl G et al.. “The CONVINCE randomized trial found positive effects on quality of life for patients with chronic kidney disease treated with hemodiafiltration.” Kidney international (2024). PMID: 39089577 ↗
L1RCTCited in: Renal Replacement Therapy, Dialysis Access & Transplantation
[593]
Rico-Fontalvo J, Ciudin A, Correa-Rotter R et al.. “S.E.N., SLANH, and SEEDO consensus report on obesity-related kidney disease: proposal for a new classification.” Kidney international (2025). PMID: 40617478 ↗
L5OTHERCited in: Renal Replacement Therapy, Dialysis Access & Transplantation
[594]
Fouque D, Pelletier S, Mafra D et al.. “Nutrition and chronic kidney disease.” Kidney international (2011). PMID: 21562470 ↗
L5REVIEW_NARRATIVECited in: Renal Replacement Therapy, Dialysis Access & Transplantation
[595]
Komaba H, Fukagawa M. “Phosphate-a poison for humans?” Kidney international (2016). PMID: 27282935 ↗
L5REVIEW_NARRATIVECited in: Renal Replacement Therapy, Dialysis Access & Transplantation
[596]
Brown EA, Zhao J, McCullough K et al.. “Burden of Kidney Disease, Health-Related Quality of Life, and Employment Among Patients Receiving Peritoneal Dialysis and In-Center Hemodialysis: Findings From the DOPPS Program.” American journal of kidney diseases : the official journal of the National Kidney Foundation (2021). PMID: 33872688 ↗
L2OTHERCited in: Renal Replacement Therapy, Dialysis Access & Transplantation, History and Evolution of Treatment
[597]
Lu E, Schell JO, Koncicki HM. “Opioid Management in CKD.” American journal of kidney diseases : the official journal of the National Kidney Foundation (2020). PMID: 33500128 ↗
L5REVIEW_NARRATIVECited in: Renal Replacement Therapy, Dialysis Access & Transplantation, History and Evolution of Treatment
[598]
Tang J, Zheng Y, Pan L et al.. “Thrombotic outcomes and mortality with roxadustat for anemia in chronic kidney disease: a systematic review and meta-analysis of randomized trials.” Frontiers in pharmacology (2026). PMID: 42358369 ↗
L1SR_OBSCited in: Renal Replacement Therapy, Dialysis Access & Transplantation, Prevention, Screening & Surveillance
[599]
Jotwani V, Atta MG, Estrella MM. “Kidney Disease in HIV: Moving beyond HIV-Associated Nephropathy.” Journal of the American Society of Nephrology : JASN (2017). PMID: 28784698 ↗
L5REVIEW_NARRATIVECited in: Renal Replacement Therapy, Dialysis Access & Transplantation
[600]
Ladino M, Pedraza F, Roth D. “Hepatitis C Virus Infection in Chronic Kidney Disease.” Journal of the American Society of Nephrology : JASN (2016). PMID: 27095799 ↗
L5REVIEW_NARRATIVECited in: Renal Replacement Therapy, Dialysis Access & Transplantation
[601]
Denic A, Mathew J, Lerman LO et al.. “Single-Nephron Glomerular Filtration Rate in Healthy Adults.” The New England journal of medicine (2017). PMID: 28614683 ↗
L4OTHERCited in: Renal Replacement Therapy, Dialysis Access & Transplantation
[602]
Olesen JB, Lip GY, Kamper AL et al.. “Stroke and bleeding in atrial fibrillation with chronic kidney disease.” The New England journal of medicine (2012). PMID: 22894575 ↗
L2OTHERCited in: Renal Replacement Therapy, Dialysis Access & Transplantation
[603]
Allon M, Lok CE. “Dialysis fistula or graft: the role for randomized clinical trials.” Clinical journal of the American Society of Nephrology : CJASN (2010). PMID: 21030576 ↗
L5REVIEW_NARRATIVECited in: Renal Replacement Therapy, Dialysis Access & Transplantation
[604]
Devuyst O, Knoers NV, Remuzzi G et al.. “Rare inherited kidney diseases: challenges, opportunities, and perspectives.” Lancet (London, England) (2014). PMID: 24856029 ↗
L5REVIEW_NARRATIVECited in: Renal Replacement Therapy, Dialysis Access & Transplantation
[605]
Tonelli M, Kalyesubula R, Tungsanga S et al.. “Implementing the commitments of the World Health Assembly kidney health resolution: a key opportunity to improve health for millions.” Lancet (London, England) (2026). PMID: 42155504 ↗
L5REVIEW_NARRATIVECited in: Renal Replacement Therapy, Dialysis Access & Transplantation, Prevention, Screening & Surveillance
[606]
Vinke JSJ, Francke MI, Eisenga MF et al.. “Iron deficiency after kidney transplantation.” Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association (2021). PMID: 32910168 ↗
L5OTHERCited in: Renal Replacement Therapy, Dialysis Access & Transplantation
[607]
Evans M, Lopau K. “The transition clinic in chronic kidney disease care.” Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association (2020). PMID: 32162667 ↗
L5REVIEW_NARRATIVECited in: Renal Replacement Therapy, Dialysis Access & Transplantation
[608]
Cobo G, Lindholm B, Stenvinkel P. “Chronic inflammation in end-stage renal disease and dialysis.” Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association (2018). PMID: 30281126 ↗
L5REVIEW_NARRATIVECited in: Renal Replacement Therapy, Dialysis Access & Transplantation
[609]
Carrero JJ, Hecking M, Chesnaye NC et al.. “Sex and gender disparities in the epidemiology and outcomes of chronic kidney disease.” Nature reviews. Nephrology (2018). PMID: 29355169 ↗
L5REVIEW_NARRATIVECited in: Renal Replacement Therapy, Dialysis Access & Transplantation
[610]
Liu ZH. “Nephrology in china.” Nature reviews. Nephrology (2013). PMID: 23877587 ↗
L5REVIEW_NARRATIVECited in: Renal Replacement Therapy, Dialysis Access & Transplantation, Prevention, Screening & Surveillance
[611]
Sever MS, Luyckx V, Tonelli M et al.. “Disasters and kidney care: pitfalls and solutions.” Nature reviews. Nephrology (2023). PMID: 37479903 ↗
L5REVIEW_NARRATIVECited in: Renal Replacement Therapy, Dialysis Access & Transplantation
[612]
Trionfini P, Benigni A, Remuzzi G. “MicroRNAs in kidney physiology and disease.” Nature reviews. Nephrology (2014). PMID: 25385286 ↗
L5REVIEW_NARRATIVECited in: Renal Replacement Therapy, Dialysis Access & Transplantation
[613]
Heylen L, Thienpont B, Naesens M et al.. “The Emerging Role of DNA Methylation in Kidney Transplantation: A Perspective.” American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons (2016). PMID: 26780242 ↗
L5REVIEW_NARRATIVECited in: Renal Replacement Therapy, Dialysis Access & Transplantation, Special Populations & Pregnancy
[614]
Zolty R, Hynes PJ, Vittorio TJ. “Severe left ventricular systolic dysfunction may reverse with renal transplantation: uremic cardiomyopathy and cardiorenal syndrome.” American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons (2008). PMID: 18808406 ↗
L5REVIEW_NARRATIVECited in: Renal Replacement Therapy, Dialysis Access & Transplantation, Complications (Chronic Systemic Sequelae), Special Populations & Pregnancy
[615]
LaPointe Rudow D, Hays R, Baliga P et al.. “Consensus conference on best practices in live kidney donation: recommendations to optimize education, access, and care.” American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons (2015). PMID: 25648884 ↗
L5OTHERCited in: Renal Replacement Therapy, Dialysis Access & Transplantation
[616]
Birgün A, Çelik MC, Karaarslan O et al.. “Bailout Endovascular Retrieval of a Severely Kinked Guiding Catheter During Primary PCI for Inferior STEMI.” Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions (2026). PMID: 42402802 ↗
L4CASE_REPORTCited in: Renal Replacement Therapy, Dialysis Access & Transplantation
[617]
Fang W, Deng J, Hu R et al.. “Optimization of blood sampling strategy to avoid spurious PTH elevation in patients with forearm parathyroid autotransplantation and arteriovenous fistula.” Clinica chimica acta; international journal of clinical chemistry (2026). PMID: 42269742 ↗
L4CASE_REPORTCited in: Renal Replacement Therapy, Dialysis Access & Transplantation
[618]
Dobrijevic E, van Zwieten A, Jaure A et al.. “Establishing a core outcome measure for cancer in trials in kidney transplantation: a standardized outcomes in nephrology-kidney transplantation consensus workshop report.” Transplant international : official journal of the European Society for Organ Transplantation (2026). PMID: 42367326 ↗
L5OTHERCited in: Renal Replacement Therapy, Dialysis Access & Transplantation
[619]
El Wadia H, Beauregard N, Silver SA et al.. “Severity of Chronic Kidney Disease and Outcomes After Admission to the Intensive Care Unit.” JAMA network open (2026). PMID: 42348209 ↗
L2OTHERCited in: Renal Replacement Therapy, Dialysis Access & Transplantation
[620]
Cuevas-Budhart MA, Becerra-Barrera JS, Silva-Rueda RI et al.. “Glycemic Patterns Revealed by Continuous Glucose Monitoring in Patients with Type 2 Diabetes Undergoing Intermittent Hemodialysis: A Pilot Study.” Medical sciences (Basel, Switzerland) (2026). PMID: 42346863 ↗
L4OTHERCited in: Renal Replacement Therapy, Dialysis Access & Transplantation
[621]
Ikizler TA, Burrowes JD, Byham-Gray LD et al.. “KDOQI Clinical Practice Guideline for Nutrition in CKD: 2020 Update.” American journal of kidney diseases : the official journal of the National Kidney Foundation (2020). PMID: 32829751 ↗
L1GUIDELINECited in: History and Evolution of Treatment
[622]
Torra R, Lipska-Zietkiewicz B, Acke F et al.. “Diagnosis, management and treatment of the Alport syndrome - 2024 guideline on behalf of ERKNet, ERA and ESPN.” Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association (2025). PMID: 39673454 ↗
L1GUIDELINECited in: History and Evolution of Treatment
[623]
Kasiske B, Cosio FG, Beto J et al.. “Clinical practice guidelines for managing dyslipidemias in kidney transplant patients: a report from the Managing Dyslipidemias in Chronic Kidney Disease Work Group of the National Kidney Foundation Kidney Disease Outcomes Quality Initiative.” American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons (2004). PMID: 15027968 ↗
L1GUIDELINECited in: History and Evolution of Treatment
[624]
Lunyera J, Mohottige D, Von Isenburg M et al.. “CKD of Uncertain Etiology: A Systematic Review.” Clinical journal of the American Society of Nephrology : CJASN (2015). PMID: 26712810 ↗
L2SR_OBSCited in: History and Evolution of Treatment
[625]
Nevis IF, Reitsma A, Dominic A et al.. “Pregnancy outcomes in women with chronic kidney disease: a systematic review.” Clinical journal of the American Society of Nephrology : CJASN (2011). PMID: 21940842 ↗
L2SR_OBSCited in: History and Evolution of Treatment
[626]
Heerspink HJL, Stack AG, Terkeltaub R et al.. “Combination Treatment with Verinurad and Allopurinol in CKD: A Randomized Placebo and Active Controlled Trial.” Journal of the American Society of Nephrology : JASN (2024). PMID: 38564654 ↗
L1RCTCited in: History and Evolution of Treatment
[627]
Piccini JP, Caso V, Connolly SJ et al.. “Safety of the oral factor XIa inhibitor asundexian compared with apixaban in patients with atrial fibrillation (PACIFIC-AF): a multicentre, randomised, double-blind, double-dummy, dose-finding phase 2 study.” Lancet (London, England) (2022). PMID: 35385695 ↗
L1RCTCited in: History and Evolution of Treatment
[628]
Sun Y, Mu J, Wang DW et al.. “A village doctor-led multifaceted intervention for blood pressure control in rural China: an open, cluster randomised trial.” Lancet (London, England) (2022). PMID: 35500594 ↗
L1RCTCited in: History and Evolution of Treatment
[629]
Wheeler DC, Jongs N, Stefansson BV et al.. “Safety and efficacy of dapagliflozin in patients with focal segmental glomerulosclerosis: a prespecified analysis of the dapagliflozin and prevention of adverse outcomes in chronic kidney disease (DAPA-CKD) trial.” Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association (2022). PMID: 34850160 ↗
L2RCTCited in: History and Evolution of Treatment
[630]
Koshino A, Heerspink HJL, Jongs N et al.. “Canagliflozin and iron metabolism in the CREDENCE trial.” Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association (2025). PMID: 39304530 ↗
L2RCTCited in: History and Evolution of Treatment
[631]
Eddy AA. “Overview of the cellular and molecular basis of kidney fibrosis.” Kidney international supplements (2014). PMID: 25401038 ↗
L5REVIEW_NARRATIVECited in: History and Evolution of Treatment
[632]
Anders HJ. “Of Inflammasomes and Alarmins: IL-1β and IL-1α in Kidney Disease.” Journal of the American Society of Nephrology : JASN (2016). PMID: 27516236 ↗
L5REVIEW_NARRATIVECited in: History and Evolution of Treatment
[633]
Ramirez SP. “Chronic kidney disease prevention in Singapore.” Clinical journal of the American Society of Nephrology : CJASN (2008). PMID: 18184881 ↗
L4REVIEW_NARRATIVECited in: History and Evolution of Treatment, Prevention, Screening & Surveillance
[634]
Imai E, Yamagata K, Iseki K et al.. “Kidney disease screening program in Japan: history, outcome, and perspectives.” Clinical journal of the American Society of Nephrology : CJASN (2007). PMID: 17942780 ↗
L4REVIEW_NARRATIVECited in: History and Evolution of Treatment, Prevention, Screening & Surveillance
[635]
Bruggeman LA. “Viral subversion mechanisms in chronic kidney disease pathogenesis.” Clinical journal of the American Society of Nephrology : CJASN (2007). PMID: 17699505 ↗
L5REVIEW_NARRATIVECited in: History and Evolution of Treatment
[636]
Kovesdy CP, Mehrotra R, Kalantar-Zadeh K. “Battleground: chronic kidney disorders mineral and bone disease--calcium obsession, vitamin d, and binder confusion.” Clinical journal of the American Society of Nephrology : CJASN (2007). PMID: 18045858 ↗
L5REVIEW_NARRATIVECited in: History and Evolution of Treatment
[637]
Podymow T, Turnbull J. “Management of chronic kidney disease and dialysis in homeless persons.” Kidney international supplements (2013). PMID: 25018988 ↗
L4OTHERCited in: History and Evolution of Treatment
[638]
Collins AJ, Foley RN, Gilbertson DT et al.. “United States Renal Data System public health surveillance of chronic kidney disease and end-stage renal disease.” Kidney international supplements (2015). PMID: 26097778 ↗
L4OTHERCited in: History and Evolution of Treatment, Prognosis and Natural History
[639]
Kazancioğlu R. “Risk factors for chronic kidney disease: an update.” Kidney international supplements (2013). PMID: 25019021 ↗
L5OTHERCited in: History and Evolution of Treatment
[640]
Ecder T. “Early diagnosis saves lives: focus on patients with chronic kidney disease.” Kidney international supplements (2013). PMID: 25019015 ↗
L5OTHERCited in: History and Evolution of Treatment
[641]
Hamano T, Nakano C, Obi Y et al.. “Fibroblast growth factor 23 and 25-hydroxyvitamin D levels are associated with estimated glomerular filtration rate decline.” Kidney international supplements (2013). PMID: 25019032 ↗
L2OTHERCited in: History and Evolution of Treatment
[642]
Nakazawa D, Masuda S, Nishibata Y et al.. “Neutrophils and NETs in kidney disease.” Nature reviews. Nephrology (2025). PMID: 40102634 ↗
L5REVIEW_NARRATIVECited in: History and Evolution of Treatment
[643]
Yamamoto T, Isaka Y. “Pathological mechanisms of kidney disease in ageing.” Nature reviews. Nephrology (2024). PMID: 39025993 ↗
L5REVIEW_NARRATIVECited in: History and Evolution of Treatment
[644]
Khan A, Kiryluk K. “Polygenic scores and their applications in kidney disease.” Nature reviews. Nephrology (2024). PMID: 39271761 ↗
L5REVIEW_NARRATIVECited in: History and Evolution of Treatment
[645]
Davin JC, Coppo R. “Henoch-Schönlein purpura nephritis in children.” Nature reviews. Nephrology (2014). PMID: 25072122 ↗
L5REVIEW_NARRATIVECited in: History and Evolution of Treatment
[646]
Lu R, Kiernan MC, Murray A et al.. “Kidney-brain crosstalk in the acute and chronic setting.” Nature reviews. Nephrology (2015). PMID: 26281892 ↗
L5REVIEW_NARRATIVECited in: History and Evolution of Treatment
[647]
Adeyemo AA, Shriner D, Bentley AR et al.. “Evolutionary genetics and acclimatization in nephrology.” Nature reviews. Nephrology (2021). PMID: 34584272 ↗
L5REVIEW_NARRATIVECited in: History and Evolution of Treatment
[648]
Vaziri ND. “HDL abnormalities in nephrotic syndrome and chronic kidney disease.” Nature reviews. Nephrology (2015). PMID: 26568191 ↗
L5REVIEW_NARRATIVECited in: History and Evolution of Treatment
[649]
Mallawaarachchi AC, Fowles L, Wardrop L et al.. “Genomic Testing in Patients with Kidney Failure of an Unknown Cause: A National Australian Study.” Clinical journal of the American Society of Nephrology : CJASN (2024). PMID: 38861662 ↗
L4OTHERCited in: History and Evolution of Treatment
[650]
Dastjerdi P, Tavakoli K, Narimani-Javid R et al.. “Functional mitral valve regurgitation outcomes by treatment modality: a systematic review and meta-analysis of reconstructed survival data.” BMC cardiovascular disorders (2026). PMID: 42321618 ↗
L1SR_OBSCited in: History and Evolution of Treatment
[651]
Bakhshwin A, Herlitz L, Hu S et al.. “Immunotactoid hepatopathy: A novel entity with histologically proven recurrence post liver transplantation.” American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons (2023). PMID: 38145784 ↗
L4CASE_REPORTCited in: History and Evolution of Treatment
[652]
Zhou Z, Luo B, Zhang X et al.. “Incidence, mortality and risk factors of invasive pulmonary aspergillosis in critically ill patients during the COVID-19 era: a global systematic review and meta-analysis.” Annals of clinical microbiology and antimicrobials (2026). PMID: 42432685 ↗
L2SR_OBSCited in: History and Evolution of Treatment
[653]
Kim HJ, Park CM, Cha DR et al.. “Spherical adsorptive carbon use and risks of dialysis initiation and mortality in advanced chronic kidney disease: a real-world cohort study.” Kidney research and clinical practice (2026). PMID: 42388072 ↗
L2COHORTCited in: History and Evolution of Treatment
[654]
Santana JC, Doppalapudi H, Ives CW et al.. “Prognostic value of silent myocardial infarction in patients with chronic kidney disease after kidney transplantation.” American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons (2022). PMID: 34967107 ↗
L2OTHERCited in: History and Evolution of Treatment, Complications (Chronic Systemic Sequelae)
[655]
Hellemons ME, Agarwal PK, van der Bij W et al.. “Former smoking is a risk factor for chronic kidney disease after lung transplantation.” American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons (2011). PMID: 21883906 ↗
L2OTHERCited in: History and Evolution of Treatment
[656]
Stratta RJ, Farney AC, Fridell JA. “To be, or not to be, on insulin for simultaneous kidney-pancreas transplant: Is that the question?” American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons (2026). PMID: 42190915 ↗
L5OTHERCited in: History and Evolution of Treatment
[657]
Naqvi SA, Rizvi SA, Zafar MN et al.. “Health status and renal function evaluation of kidney vendors: a report from Pakistan.” American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons (2008). PMID: 18510640 ↗
L3OTHERCited in: History and Evolution of Treatment
[658]
Kapogiannis C, Dimakopoulos G, Kapogiannis A et al.. “Comparison of genetic profile and kidney outcomes between very early-onset and non-very-early-onset autosomal dominant polycystic kidney disease in children: a systematic review and meta-analysis.” BMC nephrology (2026). PMID: 42401882 ↗
L4SR_OBSCited in: History and Evolution of Treatment
[659]
Badeli H, Motiei M, Nejad AT et al.. “Chronic kidney disease following pediatric cardiac surgery: a systematic review and meta-analysis.” BMC pediatrics (2026). PMID: 42332609 ↗
L4SR_OBSCited in: History and Evolution of Treatment
[660]
Tantisattamo E, Ku E. “Hypertension in Advanced Chronic Kidney Disease: Saving the Kidneys or the Heart?” Advances in kidney disease and health (2026). PMID: 42397326 ↗
L5REVIEW_NARRATIVECited in: History and Evolution of Treatment
[661]
Vaziri ND, Wong J, Pahl M et al.. “Chronic kidney disease alters intestinal microbial flora.” Kidney international (2012). PMID: 22992469 ↗
L3OTHERCited in: Complications (Chronic Systemic Sequelae), Special Populations & Pregnancy
[662]
Vakili K, Fullington NM, Turner CG et al.. “Aorto-mesenteric and renal allograft transplant: a novel treatment for midaortic syndrome.” American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons (2013). PMID: 23433449 ↗
L4CASE_REPORTCited in: Complications (Chronic Systemic Sequelae)
[663]
Macdougall IC. “Anaemia in CKD-treatment standard.” Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association (2024). PMID: 38012124 ↗
L5REVIEW_NARRATIVECited in: Complications (Chronic Systemic Sequelae)
[664]
Stoumpos S, Crowe K, Sarafidis P et al.. “Hypoxia-inducible factor prolyl hydroxylase inhibitors for anaemia in chronic kidney disease: a clinical practice document by the European Renal Best Practice board of the European Renal Association.” Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association (2024). PMID: 38573822 ↗
L1REVIEW_NARRATIVECited in: Complications (Chronic Systemic Sequelae)
[665]
Lutz J, Menke J, Sollinger D et al.. “Haemostasis in chronic kidney disease.” Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association (2013). PMID: 24132242 ↗
L5REVIEW_NARRATIVECited in: Complications (Chronic Systemic Sequelae)
[666]
Arreola Guerra JM, Martinez-Martinez JI. “Multifactorial chronic kidney disease.” Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association (2026). PMID: 40613565 ↗
L5REVIEW_NARRATIVECited in: Complications (Chronic Systemic Sequelae)
[667]
Bui HT, Apriliyasari RW, Bui QHQ et al.. “Association Between Frailty and Cognitive Impairment in Chronic Kidney Disease: A Systematic Review and Meta-Analysis.” Journal of nursing scholarship : an official publication of Sigma Theta Tau International Honor Society of Nursing (2026). PMID: 42375109 ↗
L2SR_OBSCited in: Complications (Chronic Systemic Sequelae)
[668]
Kitimbo J, Buregyeya E, Mutole G et al.. “Inpatient mortality and associated clinical factors among people living with HIV with cryptococcal meningitis in Uganda: A retrospective cohort study.” PloS one (2026). PMID: 42361014 ↗
L2COHORTCited in: Complications (Chronic Systemic Sequelae)
[669]
Bover J, Cozzolino M. “Mineral and bone disorders in chronic kidney disease and end-stage renal disease patients: new insights into vitamin D receptor activation.” Kidney international supplements (2011). PMID: 25018911 ↗
L5REVIEW_NARRATIVECited in: Prognosis and Natural History
[670]
Arogundade FA. “Kidney transplantation in a low-resource setting: Nigeria experience.” Kidney international supplements (2013). PMID: 25018990 ↗
L5OTHERCited in: Prognosis and Natural History
[671]
Ballermann BJ, Obeidat M. “Tipping the balance from angiogenesis to fibrosis in CKD.” Kidney international supplements (2014). PMID: 26312149 ↗
L5REVIEW_NARRATIVECited in: Prognosis and Natural History
[672]
Barsoum RS. “Burden of chronic kidney disease: North Africa.” Kidney international supplements (2013). PMID: 25018981 ↗
L5OTHERCited in: Prognosis and Natural History
[673]
Awuah KT, Finkelstein SH, Finkelstein FO. “Quality of life of chronic kidney disease patients in developing countries.” Kidney international supplements (2013). PMID: 25018987 ↗
L5OTHERCited in: Prognosis and Natural History
[674]
Zhang X, Li Y, Li Q et al.. “Postoperative cerebral infarction after major thoracic and abdominopelvic surgery: a retrospective single-centre cohort study of incidence, risk factors, and outcomes.” BMC anesthesiology (2026). PMID: 42374193 ↗
L2COHORTCited in: Prognosis and Natural History
[675]
Corona S, Sarshoghi A, Bouhout I et al.. “Extending the age cutoff: Outcomes of the Ross procedure in patients older than 60 years. A two-center retrospective study from the Canadian Ross Registry.” The Journal of thoracic and cardiovascular surgery (2026). PMID: 42362011 ↗
L2COHORTCited in: Prognosis and Natural History
[676]
de Menezes Neves PDM, Mansur J, Moyses-Neto M et al.. “Post-transplantat recurrence of lipoprotein glomerulopathy: report of 4 cases and literature review.” American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons (2025). PMID: 40306438 ↗
L4CASE_REPORTCited in: Prognosis and Natural History
[677]
Dong Y, Wang Z, Guo W et al.. “Association between urinary C4d levels and disease progression in IgA nephropathy.” Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association (2024). PMID: 38178632 ↗
L2OTHERCited in: Prognosis and Natural History
[678]
Zhao S, Wang X, Bai Q et al.. “Bile acids as a predictor for all-cause mortality in peritoneal dialysis patients: a retrospective cohort study.” BMC nephrology (2026). PMID: 42432533 ↗
L2COHORTCited in: Prognosis and Natural History
[679]
Ben Mahmoud N, Hamouda M, Ben Salem M et al.. “Risk factors of mortality in patients with acute kidney injury: Retrospective cohort study with longitudinal follow-up.” World journal of nephrology (2026). PMID: 42395687 ↗
L2COHORTCited in: Prognosis and Natural History
[680]
Meng XM, Wang L, Nikolic-Paterson DJ et al.. “Innate immune cells in acute and chronic kidney disease.” Nature reviews. Nephrology (2025). PMID: 40263532 ↗
L5REVIEW_NARRATIVECited in: Prognosis and Natural History
[681]
Thomas MC, Cooper ME, Zimmet P. “Changing epidemiology of type 2 diabetes mellitus and associated chronic kidney disease.” Nature reviews. Nephrology (2015). PMID: 26553517 ↗
L5REVIEW_NARRATIVECited in: Prognosis and Natural History
[682]
O'Leary JG, Levitsky J, Wong F et al.. “Protecting the Kidney in Liver Transplant Candidates: Practice-Based Recommendations From the American Society of Transplantation Liver and Intestine Community of Practice.” American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons (2016). PMID: 26990924 ↗
L1REVIEW_NARRATIVECited in: Prognosis and Natural History
[683]
Komenda P, Ferguson TW, Macdonald K et al.. “Cost-effectiveness of primary screening for CKD: a systematic review.” American journal of kidney diseases : the official journal of the National Kidney Foundation (2014). PMID: 24529536 ↗
L2SR_OBSCited in: Prevention, Screening & Surveillance
[684]
Rogerson TE, Chen S, Kok J et al.. “Tests for latent tuberculosis in people with ESRD: a systematic review.” American journal of kidney diseases : the official journal of the National Kidney Foundation (2012). PMID: 23068425 ↗
L2SR_OBSCited in: Prevention, Screening & Surveillance
[685]
Patel HD, Pierorazio PM, Johnson MH et al.. “Renal Functional Outcomes after Surgery, Ablation, and Active Surveillance of Localized Renal Tumors: A Systematic Review and Meta-Analysis.” Clinical journal of the American Society of Nephrology : CJASN (2017). PMID: 28483780 ↗
L1SR_OBSCited in: Prevention, Screening & Surveillance
[686]
Sakaguchi Y, Hamano T, Obi Y et al.. “A Randomized Trial of Magnesium Oxide and Oral Carbon Adsorbent for Coronary Artery Calcification in Predialysis CKD.” Journal of the American Society of Nephrology : JASN (2019). PMID: 31036759 ↗
L1RCTCited in: Prevention, Screening & Surveillance
[687]
Robinson CH, Ogome BJ, Selvathesan N et al.. “Kidney function and mortality in childhood nephrotic syndrome.” Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association (2025). PMID: 40600975 ↗
L2SR_OBSCited in: Prevention, Screening & Surveillance
[688]
Soomro QH, Anand ST, Weisbord SD et al.. “The Relationship between Rate and Volume of Intravenous Fluid Administration and Kidney Outcomes after Angiography.” Clinical journal of the American Society of Nephrology : CJASN (2022). PMID: 36008352 ↗
L2RCTCited in: Prevention, Screening & Surveillance
[689]
Lichtenberger FB, Xu M, Erdoğan C et al.. “Activating soluble guanylyl cyclase attenuates ischemic kidney damage.” Kidney international (2024). PMID: 39571904 ↗
L5OTHERCited in: Prevention, Screening & Surveillance
[690]
Funahashi Y, Park SH, Hebert JF et al.. “Nanotherapeutic kidney cell-specific targeting to ameliorate acute kidney injury.” Kidney international (2024). PMID: 39067856 ↗
L5OTHERCited in: Prevention, Screening & Surveillance
[691]
Romanowski K, Clark EG, Levin A et al.. “Tuberculosis and chronic kidney disease: an emerging global syndemic.” Kidney international (2016). PMID: 27178832 ↗
L5REVIEW_NARRATIVECited in: Prevention, Screening & Surveillance
[692]
Kalantar-Zadeh K, Kam-Tao Li P, Tantisattamo E et al.. “Living well with kidney disease by patient and care-partner empowerment: kidney health for everyone everywhere.” Kidney international (2021). PMID: 33509344 ↗
L5OTHERCited in: Prevention, Screening & Surveillance
[693]
Vassalotti JA, Francis A, Soares Dos Santos AC et al.. “Are your kidneys Ok? Detect early to protect kidney health.” Kidney international (2025). PMID: 39984248 ↗
L5OTHERCited in: Prevention, Screening & Surveillance
[694]
Kurata Y, Nangaku M. “Use of antibiotics as a therapeutic approach to prevent AKI-to-CKD progression.” Kidney international (2023). PMID: 37599013 ↗
L5OTHERCited in: Prevention, Screening & Surveillance
[695]
Calice-Silva V, Neyra JA, Ferreiro Fuentes A et al.. “Capacity for the management of kidney failure in the International Society of Nephrology Latin America region: report from the 2023 ISN Global Kidney Health Atlas (ISN-GKHA).” Kidney international supplements (2024). PMID: 38618500 ↗
L2REVIEW_NARRATIVECited in: Prevention, Screening & Surveillance
[696]
Swanepoel CR, McCulloch MI, Abraham G et al.. “Challenges for sustainable end-stage kidney disease care in low-middle-income countries: the problem of the workforce.” Kidney international supplements (2020). PMID: 32149008 ↗
L5REVIEW_NARRATIVECited in: Prevention, Screening & Surveillance
[697]
Bello AK, Alrukhaimi M, Ashuntantang GE et al.. “Global overview of health systems oversight and financing for kidney care.” Kidney international supplements (2018). PMID: 30675438 ↗
L2REVIEW_NARRATIVECited in: Prevention, Screening & Surveillance
[698]
Wainstein M, Bello AK, Jha V et al.. “International Society of Nephrology Global Kidney Health Atlas: structures, organization, and services for the management of kidney failure in Latin America.” Kidney international supplements (2021). PMID: 33981469 ↗
L2REVIEW_NARRATIVECited in: Prevention, Screening & Surveillance
[699]
Pippias M, Alfano G, Kelly DM et al.. “Capacity for the management of kidney failure in the International Society of Nephrology Western Europe region: report from the 2023 ISN Global Kidney Health Atlas (ISN-GKHA).” Kidney international supplements (2024). PMID: 38618502 ↗
L2REVIEW_NARRATIVECited in: Prevention, Screening & Surveillance
[700]
Tannor EK, Davidson B, Nlandu Y et al.. “Capacity for the management of kidney failure in the International Society of Nephrology Africa region: report from the 2023 ISN Global Kidney Atlas (ISN-GKHA).” Kidney international supplements (2024). PMID: 38618494 ↗
L2REVIEW_NARRATIVECited in: Prevention, Screening & Surveillance
[701]
Karam S, Amouzegar A, Alshamsi IR et al.. “Capacity for the management of kidney failure in the International Society of Nephrology Middle East region: report from the 2023 ISN Global Kidney Health Atlas (ISN-GKHA).” Kidney international supplements (2024). PMID: 38618498 ↗
L2REVIEW_NARRATIVECited in: Prevention, Screening & Surveillance
[702]
Hoy WE, Kincaid-Smith P, Hughson MD et al.. “CKD in Aboriginal Australians.” American journal of kidney diseases : the official journal of the National Kidney Foundation (2010). PMID: 20728257 ↗
L5REVIEW_NARRATIVECited in: Prevention, Screening & Surveillance
[703]
Targher G, Chonchol MB, Byrne CD. “CKD and nonalcoholic fatty liver disease.” American journal of kidney diseases : the official journal of the National Kidney Foundation (2014). PMID: 25085644 ↗
L5REVIEW_NARRATIVECited in: Prevention, Screening & Surveillance
[704]
Rudnick MR, Leonberg-Yoo AK, Litt HI et al.. “The Controversy of Contrast-Induced Nephropathy With Intravenous Contrast: What Is the Risk?” American journal of kidney diseases : the official journal of the National Kidney Foundation (2019). PMID: 31473019 ↗
L5REVIEW_NARRATIVECited in: Prevention, Screening & Surveillance
[705]
Diamantidis CJ, Zepel L, Smith VA et al.. “Epidemiology of Community-Acquired Acute Kidney Injury Among US Veterans.” American journal of kidney diseases : the official journal of the National Kidney Foundation (2023). PMID: 36963745 ↗
L2OTHERCited in: Prevention, Screening & Surveillance
[706]
Koppula S, Patel K, Unruh M. “The Delivery of Kidney Care in Rural or Sparsely Populated Settings.” American journal of kidney diseases : the official journal of the National Kidney Foundation (2025). PMID: 40311667 ↗
L5REVIEW_NARRATIVECited in: Prevention, Screening & Surveillance
[707]
Tonelli M, Dickinson JA. “Early Detection of CKD: Implications for Low-Income, Middle-Income, and High-Income Countries.” Journal of the American Society of Nephrology : JASN (2020). PMID: 32839279 ↗
L5REVIEW_NARRATIVECited in: Prevention, Screening & Surveillance
[708]
Thomas B, Matsushita K, Abate KH et al.. “Global Cardiovascular and Renal Outcomes of Reduced GFR.” Journal of the American Society of Nephrology : JASN (2017). PMID: 28408440 ↗
L2OTHERCited in: Prevention, Screening & Surveillance
[709]
Park M, Yoon E, Lim YH et al.. “Renal hyperfiltration as a novel marker of all-cause mortality.” Journal of the American Society of Nephrology : JASN (2014). PMID: 25343954 ↗
L2OTHERCited in: Prevention, Screening & Surveillance
[710]
Ferguson R, Leatherman S, Fiore M et al.. “Prevalence and Risk Factors for CKD in the General Population of Southwestern Nicaragua.” Journal of the American Society of Nephrology : JASN (2020). PMID: 32471819 ↗
L2OTHERCited in: Prevention, Screening & Surveillance
[711]
Wong G, Hope RL, Howard K et al.. “One-Time Fecal Immunochemical Screening for Advanced Colorectal Neoplasia in Patients with CKD (DETECT Study).” Journal of the American Society of Nephrology : JASN (2019). PMID: 31040191 ↗
L2OTHERCited in: Prevention, Screening & Surveillance
[712]
Wattanakit K, Folsom AR, Selvin E et al.. “Kidney function and risk of peripheral arterial disease: results from the Atherosclerosis Risk in Communities (ARIC) Study.” Journal of the American Society of Nephrology : JASN (2007). PMID: 17215445 ↗
L2OTHERCited in: Prevention, Screening & Surveillance
[713]
Moran AE, Odden MC, Thanataveerat A et al.. “Cost-effectiveness of hypertension therapy according to 2014 guidelines.” The New England journal of medicine (2015). PMID: 25629742 ↗
L2OTHERCited in: Prevention, Screening & Surveillance
[714]
de Jong PE, van der Velde M, Gansevoort RT et al.. “Screening for chronic kidney disease: where does Europe go?” Clinical journal of the American Society of Nephrology : CJASN (2008). PMID: 18287253 ↗
L5REVIEW_NARRATIVECited in: Prevention, Screening & Surveillance
[715]
Cusumano AM, González Bedat MC. “Chronic kidney disease in Latin America: time to improve screening and detection.” Clinical journal of the American Society of Nephrology : CJASN (2008). PMID: 18272831 ↗
L5REVIEW_NARRATIVECited in: Prevention, Screening & Surveillance
[716]
Dalrymple LS, Go AS. “Epidemiology of acute infections among patients with chronic kidney disease.” Clinical journal of the American Society of Nephrology : CJASN (2008). PMID: 18650409 ↗
L5REVIEW_NARRATIVECited in: Prevention, Screening & Surveillance
[717]
Lozano R, Naghavi M, Foreman K et al.. “Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010.” Lancet (London, England) (2012). PMID: 23245604 ↗
L2OTHERCited in: Prevention, Screening & Surveillance
[718]
Lees JS, Zhang L, Anandh U et al.. “Advances in the diagnosis and detection of chronic kidney disease.” Lancet (London, England) (2026). PMID: 42235558 ↗
L5REVIEW_NARRATIVECited in: Prevention, Screening & Surveillance
[719]
Lees JS, Škoberne A, Zhang L et al.. “Chronic kidney disease, complex conditions, and advancing therapeutics: new hope and challenges.” Lancet (London, England) (2026). PMID: 42235560 ↗
L5REVIEW_NARRATIVECited in: Prevention, Screening & Surveillance
[720]
Levin A, Tonelli M, Bonventre J et al.. “Global kidney health 2017 and beyond: a roadmap for closing gaps in care, research, and policy.” Lancet (London, England) (2017). PMID: 28434650 ↗
L5REVIEW_NARRATIVECited in: Prevention, Screening & Surveillance
[721]
Agrawal U, Bedston S, McCowan C et al.. “Severe COVID-19 outcomes after full vaccination of primary schedule and initial boosters: pooled analysis of national prospective cohort studies of 30 million individuals in England, Northern Ireland, Scotland, and Wales.” Lancet (London, England) (2022). PMID: 36244382 ↗
L2OTHERCited in: Prevention, Screening & Surveillance
[722]
Wiles K, Webster P, Seed PT et al.. “The impact of chronic kidney disease Stages 3-5 on pregnancy outcomes.” Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association (2021). PMID: 33313680 ↗
L2OTHERCited in: Prevention, Screening & Surveillance
[723]
Herzog CA. “Kidney disease in cardiology.” Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association (2007). PMID: 18079149 ↗
L5REVIEW_NARRATIVECited in: Prevention, Screening & Surveillance
[724]
Zoccali C, Valdivielso JM, Vogt L et al.. “Kidney-Heart Crosstalk: The Extracellular Vesicles Connection.” Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association (2026). PMID: 41661143 ↗
L5OTHERCited in: Prevention, Screening & Surveillance
[725]
Tang C, Cai J, Yin XM et al.. “Mitochondrial quality control in kidney injury and repair.” Nature reviews. Nephrology (2020). PMID: 33235391 ↗
L5REVIEW_NARRATIVECited in: Prevention, Screening & Surveillance
[726]
Chesnaye NC, Ortiz A, Zoccali C et al.. “The impact of population ageing on the burden of chronic kidney disease.” Nature reviews. Nephrology (2024). PMID: 39025992 ↗
L5REVIEW_NARRATIVECited in: Prevention, Screening & Surveillance
[727]
Zeder K, Siew ED, Kovacs G et al.. “Pulmonary hypertension and chronic kidney disease: prevalence, pathophysiology and outcomes.” Nature reviews. Nephrology (2024). PMID: 38890546 ↗
L5REVIEW_NARRATIVECited in: Prevention, Screening & Surveillance
[728]
Hinze C, Lovric S, Halloran PF et al.. “Epithelial cell states associated with kidney and allograft injury.” Nature reviews. Nephrology (2024). PMID: 38632381 ↗
L5REVIEW_NARRATIVECited in: Prevention, Screening & Surveillance
[729]
Bronder S, Abu-Omar A, Lennartz S et al.. “Cellular and humoral immunogenicity of respiratory syncytial virus vaccination in solid organ transplant recipients.” American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons (2025). PMID: 41062073 ↗
L2OTHERCited in: Prevention, Screening & Surveillance
[730]
Amelunxen E, Kokot A, Kolbrink B et al.. “APOSCREEN-1 - a prospective, single-arm clinical trial for the implementation of a pharmacy-based screening for cardiovascular-kidney-metabolic risk factors in Schleswig-Holstein.” BMC nephrology (2026). PMID: 42249426 ↗
L4TRIAL_NONRANDOMCited in: Prevention, Screening & Surveillance
[731]
Madaki PD, Frazzoli C, Ibibama JO et al.. “Environmental Burden of Lead and Public Health Issues in Nigeria: A Systematic Review of Emerging Evidence.” Biological trace element research (2026). PMID: 42295705 ↗
L2SR_OBSCited in: Prevention, Screening & Surveillance
[732]
Shah A, Romagnoli R, Dhingra N et al.. “Mediastinitis after cardiac surgery, from microbes to management: a systematic review.” Mediastinum (Hong Kong, China) (2026). PMID: 42427474 ↗
L2SR_OBSCited in: Prevention, Screening & Surveillance
[733]
Coleman WA, Dasu P, Ravichandran R et al.. “Acute Interstitial Nephritis Is a Potential Adverse Effect in Inflammatory Bowel Disease Patients Treated With Vedolizumab: A Case Report and Review of the Literature.” Kidney medicine (2026). PMID: 42199823 ↗
L4CASE_REPORTCited in: Prevention, Screening & Surveillance
[734]
Yoo D, Nguyen VK, Maggiore U et al.. “MERWACS: Development and external validation of a non-invasive machine learning tool for identifying subjects to be screened for CKD.” PLOS digital health (2026). PMID: 42424235 ↗
L2OTHERCited in: Prevention, Screening & Surveillance
[735]
Thadhani R, Karumanchi SA. “Transforming Preeclampsia Care: Molecular Diagnostics and Therapeutic Innovations.” Journal of the American Society of Nephrology : JASN (2026). PMID: 42418275 ↗
L5OTHERCited in: Prevention, Screening & Surveillance

Quick Reference

Overview and Recommendations

Background

Evaluation

Management

Board Review — High Yield

Deep Dive — Evidence Details

Definition, Classification and Nomenclature

Staging Framework

Classification by Cause

Clinical Significance

Controversies and Guideline Disagreement

Pathophysiology and Mechanism

Final Common Pathway of Kidney Fibrosis

Hemodynamic and Metabolic Drivers

Inflammatory and Cellular Injury Mechanisms

Tubular Injury and Cellular Senescence

Vascular and Endothelial Dysfunction

Controversies and Guideline Disagreement

Epidemiology, Etiology and Risk Factors

Demographic Patterns

Temporal Trends

Risk Factors

Special Populations and Emerging Risk Factors

Clinical Presentation

Presenting Symptoms

Physical Examination Findings

Cardiovascular and Pulmonary Findings

Gastrointestinal and Metabolic Findings

Red Flags

Atypical Presentations

Phenotypic Variants at Presentation

Diagnosis and Workup

History and Physical

Gold‑Standard Test

Laboratory Studies

Imaging

Biopsy / Histology

Diagnostic Algorithm

Controversies and Guideline Disagreement

Staging and Risk Stratification (KDIGO)

The KDIGO Heat-Map: GFR and Albuminuria

Confirmatory Testing with Cystatin C

Risk Prediction and Prognostic Tools

Acute Kidney Disease (AKD) and the AKI-CKD Continuum

Controversies and Guideline Disagreement

Acute Management

Step 1: Initial Assessment and Severity Classification

Step 2: First-Line Interventions by Emergency Type

Step 3: Escalation to Renal Replacement Therapy, the AEIOU Criteria

Step 4: Monitoring and Titration

Step 5: Resolution and Transition to Definitive Management

What NOT to Do

Drug Comparison Table: Potassium Binders

Dosing Table: Acute Interventions

Treatment Failure Protocol

Controversies and Guideline Disagreement

Long-term and Definitive Management

Step 1: Renin-Angiotensin System Blockade

Step 2: SGLT2 Inhibitors

Step 3: Nonsteroidal Mineralocorticoid Receptor Antagonist

Step 4: GLP-1 Receptor Agonists

Step 5: Disease-Specific Therapies

Lifestyle and Blood Pressure Control

Anemia and Metabolic Acidosis

What NOT to Do

Controversies and Guideline Disagreement

Dosing Table

Fluid, Electrolyte & Acid-Base Disorders

Managing Hyperkalemia to Preserve RAASi

Finerenone and Hyperkalemia

Metabolic Acidosis

Calcium, Phosphate, and Magnesium

Controversies and Guideline Disagreement

Renal Replacement Therapy, Dialysis Access & Transplantation

Modality Selection

Dialysis Access

Kidney Transplantation

Monitoring Dialysis Adequacy

and Metabolic Findings